Endocrinology

Found in most species of the animal kingdom, the endocrine system consists of glands that secrete hormones, and receptors that detect and react to the hormones. In response to environmental stimuli, the endocrine system secretes hormones and uses them as chemical messengers to orchestrate physiological, developmental and reproductive changes that affect the entire body for a long period of time. In order to maintain the proper functioning of the body through its entire life cycle, the endocrine system utilizes a complex feedback mechanism to fine-tune the balance of hormones in the bloodstream. Even a slight disruption to endocrine system's function can throw off the delicate balance of hormones in the human body and lead to an endocrine disorder, or endocrine disease, such as diabetes, adrenal insufficiency, hyper- or hypothyroidism, and polycystic ovary syndrome (PCOS).

(+)-Cloprostenol

(D-Cloprostenol) Cat. No.: HY-107381

(+)-Cloprostenol is a prostaglandin F2α (PGF2α) analogue, and shows selective agonistic activity at the **prostaglandin receptor**.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

(+)-Penbutolol

((R)-Penbutolol; (+)-Isopenbutolol) Cat. No.: HY-116790A

(+)-Penbutolol is a β-adrenoceptor antagonist, with an IC_{50} of 0.74 μM. (+)-Penbutolol is an optical isomer of l-penbutolol with Na^+ channel-blocking action.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(+)-Phenserine

Cat. No.: HY-16009

(+)-Phenserine is a novel selective **cholinesterase** noncompetitive inhibitor with an **IC_{50}** of 45.3 μM.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

(-)-Curine

Cat. No.: HY-N2569

(-)-Curine is an orally active bisbenzylisoquinoline alkaloid isolated from Chondrodendron platyphyllum. (-)-Curine presents anti-inflammatory and analgesic effects at nontoxic doses, at least in part, resulting from the inhibition of **prostaglandin E2** production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(20S)-Protopanaxatriol

(20(S)-APPT; g-PPT) Cat. No.: HY-N0835

(20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the **glucocorticoid receptor (GR)** and **oestrogen receptor (ER)**, and is also a **LXRα** inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(4E)-SUN9221

Cat. No.: HY-U00367

(4E)-SUN9221 is a potent antagonist of **α1-adrenergic receptor** and **5-HT2 receptor**, with antihypertensive and anti-platelet aggregation activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(9Z,11E)-Prodlure ((9Z,11E)-Tetradecadien-1-yl acetate; Ferodin SL; Litlure A)

Cat. No.: HY-101735

(9Z,11E)-Prodlure ((9Z,11E)-Tetradecadien-1-yl acetate) is the main component of the sex pheromone of female Spodoptera littoralis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

(R)-Elagolix

(NBI-56418) Cat. No.: HY-14789

Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).



Purity: 98.06%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

(R)-Propranolol hydrochloride

Cat. No.: HY-A0295

(R)-Propranolol hydrochloride is a less active enantiomer of the **β-adrenoceptor** antagonist propranolol (HY-B0573).



Purity: ≥97.0%
Clinical Data: Launched
Size: 100 mg

(R)-Terazosin

Cat. No.: HY-B0371B

(R)-Terazosin is an active R-enantiomer of Terazosin. (R)-Terazosin is a potent **α1-adrenoceptor** antagonist with K_i values of 6.51 nM, 1.01 nM and 1.97 nM for **α1a**, **α1b** and **α1d-adrenoceptor**, respectively.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(rac)-Dobutamine-d4 hydrochloride

Cat. No.: HY-15746S

(Rac)-Dobutamine-d4 hydrochloride is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on **α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors)**.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 10 mg, 25 mg

(rac)-Dobutamine-d6 hydrochloride

Cat. No.: HY-15746S1

(Rac)-Dobutamine-d6 hydrochloride is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on **α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(rac)-Nebivolol-d4

Cat. No.: HY-B0203BS1

(Rac)-Nebivolol-d4 ((Rac)-R 065824-d4) is a labelled racemic Nebivolol. Nebivolol selectively inhibits β1- adrenergic receptor with IC_{50} of 0.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(rac)-Nebivolol-d8

Cat. No.: HY-B0203BS

(Rac)-Nebivolol-d8 ((rac)-R 065824-d8) is a labelled racemic Nebivolol. Nebivolol selectively inhibits β1- adrenergic receptor with IC_{50} of 0.8 nM.



Purity: >98%
Clinical Data:
Size: 500 μg, 1 mg, 5 mg, 10 mg

(rac)-PF-998425

Cat. No.: HY-14250A

(rac)-PF-998425 is a potent, selective, nonsteroidal **androgen receptor (AR)** antagonist. (rac)-PF-998425 has **IC_{50}** values of 26 and 90 nM in the AR binding and cellular assays, respectively. (rac)-PF-998425 has the potential for the research of the androgenetic alopecia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(Rac)-Rotigotine hydrochloride

Cat. No.: HY-15394

(Rac)-Rotigotine hydrochloride is a racemate of Rotigotine.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(S)-Mapracorat

((S)-ZK-245186; (S)-BOL-303242X)

Cat. No.: HY-14864A

(S)-Mapracorat is a selective and less active glucocorticoid receptor agonist.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(S)-Terazosin

Cat. No.: HY-B0371D

(S)-Terazosin is an active S-enantiomer of Terazosin. (S)-Terazosin is a potent and high-affinity **α-adrenoceptor** antagonist with **K_i** values of 3.91 nM, 0.79 nM and 1.16 nM for **α1a**, **α1b** and **α1d-adrenoceptor**, respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(±)-Befunolol

Cat. No.: HY-101752

(±)-Befunolol is a **β-adrenoceptor** blocking agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(±)-Penbutolol-d9 hydrochloride ((Rac)-Penbutolol-d9 hydrochloride; (±)-Isopenbutolol-d9 hydrochloride)

Cat. No.: HY-116790BSA

(±)-Penbutolol-d9 ((Rac)-Penbutolol-d9) hydrochloride is a deuterium labeled (±)-Penbutolol hydrochloride. (+)-Penbutolol hydrochloride is a β-adrenoceptor antagonist, with an IC_{50} of 0.74 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

(±)-Tazifylline

Cat. No.: HY-U00018

(±)-Tazifylline is a potent, selective and long-acting **histamine H1 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,2-Didecanoylglycerol

Cat. No.: HY-115769

1,2-Didecanoylglycerol, a synthetic diacylglycerol, is metabolized by platelets to 1,2-didecanoylphosphatidic acid (PA_{10}) and activates **protein kinase C (PKC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,4-Diaminobutane dihydrochloride

(Putrescine dihydrochloride)

Cat. No.: HY-Y1781

1,4-Diaminobutane (Putrescine) dihydrochloride is an endogenous metabolite, acts as an indicator of pollution-induced stress in higher plants: barley and rape stressed with Cr(III) or Cr(VI).



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

1-Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone

Cat. No.: HY-N9520

Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is an antagonist of **angiotensin II receptor** (IC_{50}=48.2 μM).
Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is a quinolone alkaloid from Evodia rutaecarpa.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

11-Beta-hydroxyandrostenedione

(4-Androsten-11β-ol-3,17-dione)

Cat. No.: HY-114464

11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue).



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

11-Ketodihydrotestosterone

(11-KDHT; 5α-Dihydro-11-keto testosterone)

Cat. No.: HY-135794

11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

11-Oxo etiocholanolone

(11-Ketoetiocholanolone)

Cat. No.: HY-113457

11-Oxo etiocholanolone (11-Ketoetiocholanolone) is a metabolite of Etiocholanolone. Etiocholanolone is the excreted metabolite of testosterone and has anticonvulsant activity.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg

11β-Hydroxyandrosterone

Cat. No.: HY-113351

11β-Hydroxyandrosterone is a 11-oxygenated androgen metabolite of 11β-hydroxyandrostenedione.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

15-Keto latanoprost

Cat. No.: HY-130395

15-Keto latanoprost is a metabolite of Latanoprost, which is an ocular hypotensive agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

16-Dehydroprogesterone

Cat. No.: HY-128378

16-Dehydroprogesterone is a steroidal progestin.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

17,17-(Ethylenedioxy)androst-4-en-3-one

Cat. No.: HY-108952

17,17-(Ethylenedioxy)androst-4-en-3-one (4-androstene-3,17-dione-17-cyclic ethylene ketal) is an effective ingredient in cosmetics, which can be used for acne and promote hair growth research.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

17a-Hydroxypregnenolone

Cat. No.: HY-113263

17a-Hydroxypregnenolone is a pregnane steroid. 17a-Hydroxypregnenolone is a prohormone in the formation of dehydroepiandrosterone (DHEA).



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

17α-Hydroxyprogesterone acetate

Cat. No.: HY-N0347

17α-Hydroxyprogesterone acetate possesses progestational activity. 17α-Hydroxyprogesterone acetate has antiinflammatory effects at the murine maternal-fetal interface.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide

Cat. No.: HY-100287

2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide is a compound that inhibits stress-induced ulcer and low toxicity, and can maintain the content of phospholipase A2 and prostaglandin E2 in ulcerated rats induced by water immersed restrained stress.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Hydroxyestrone

(Catecholestrone)

Cat. No.: HY-113251

2-Hydroxyestrone (Catecholestrone) is a specific receptor-mediated antiestrogenic agent. 2-Hydroxyestrone is anticarcinogenic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Selenouracil

Cat. No.: HY-111959

2-Selenouracil is a useful specialized photosensitizer for photodynamical therapy.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

2-Thiouracil

(Thiouracil)

Cat. No.: HY-B0503

2-Thiouracil (Thiouracil) is an antithyroid compound. 2-Thiouracil can function as a highly specific melanoma seeker. 2-Thiouracil is a selective inhibitor of **neuronal nitric oxide synthase (nNOS)** with a K_i of 20 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

3,4-Dimethoxyphenol

Cat. No.: HY-N1780

3,4-Dimethoxyphenol is a plant-derived phenylpropanoid compound and can use as a whitening agent in cosmetics. 3,4-Dimethoxyphenol has **tyrosinase**-inhibiting activity. 3,4-Dimethoxyphenol has potent antioxidant effect isolated from the bacterial fermentation broth.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3,5-Diiodothyropropionic acid

Cat. No.: HY-126236

3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to **thyroid hormone receptor (TR)**, with K_a of 2.40 and 4.06 M^{-1} for TRα1 and TRβ1, respectively.



Purity: 99.20%
Clinical Data:
Size: 5 mg, 10 mg

3-Keto petromyzonol

Cat. No.: HY-119332

3-Keto petromyzonol, a main component of Sea lamprey male sex pheromones, modulates both synthesis and release of gonadotropin releasing hormone (GnRH), and subsequently, hypothalamic-pituitary-gonadal (HPG) output in immature sea lamprey.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

31-Norlanostenol

Cat. No.: HY-N7267

31-Norlanostenol is a triterpenic compound isolated from the latex of Euphorbia officinarum. 31-Norlanostenol can act as efficient insect growth regulator on S. frugiperda and Tenebrio molitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4',2-Dihydroxy-4,6-dimethoxydihydrochalcone

Cat. No.: HY-N8170

4',2-Dihydroxy-4,6-dimethoxydihydrochalcone, an **estrogen** agonist, shows binding affinity for bovine uterine estrogen receptor with an IC_{50}50 of 15 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4(3H)-Quinazolinone

Cat. No.: HY-W018800

4(3H)-Quinazolinone is a building block in chemical synthesis. Biologically active nitrogen heterocyclic compounds. Possesses a wide spectrum of biological properties like antibacterial, antifungal, anticonvulsant, anti-inflammatory, anti-HIV, anticancerous and analgesic activities.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

4,4'-Iminodiphenol

Cat. No.: HY-135324

4-Propionamidophenol (compound 4a) is an inactive estrogen receptor ligand based on the diphenylamine skeleton.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-HT2 antagonist 1

Cat. No.: HY-U00365

5-HT2 antagonist 1 is a potent antagonist of **5-HT2 receptor**, with weak **α1 adrenoceptor** blocking activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5a-Pregnane-3,20-dione

Cat. No.: HY-W006492

5a-Pregnane-3,20-dione is the endogenous progesterone metabolite.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 mg, 1 g, 5 g

6-Chloromelatonin

Cat. No.: HY-100940

6-Chloromelatonin is a potent **melatonin receptor** agonist with greater metabolic stability than melatonin. 6-Chloromelatonin compete for [^{3}H]-melatonin and 2-[^{125}I]-iodomelatonin binding to MT1 receptors (pK_i=8.9 and 9.1, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7,4'-Dihydroxyflavone

Cat. No.: HY-N2609

7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid isolated from Glycyrrhiza uralensis, the **eotaxin/CCL11** inhibitor, has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)paradoxical adverse effects on eotaxin...



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

7-α-Methylthio Spironolactone-D3

Cat. No.: HY-13284S



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

8-Demethyl Ivabradine

Cat. No.: HY-131283

8-Demethyl Ivabradine is a metabolite of Ivabradine. Ivabradine is an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A 779

Cat. No.: HY-P0216

A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an **Ang1-7 receptor** distinct from the classical AngII.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

A-192621

Cat. No.: HY-120295

A-192621 is a potent, nonpeptide, orally active and selective **endothelin B (ET_B) receptor** antagonist with an **IC_{50}** of 4.5 nM and a **K_i** of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ET_A (**IC_{50}** of 4280 nM and **K_i** of 5600 nM). A-192621 promotes **apoptosis** in PASMCs.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg

A81988

(Abbott81988)

Cat. No.: HY-U00188

A81988 is a potent, competitive, non-peptidic antagonist of **angiotensin AT_1** receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aaptamine

Cat. No.: HY-N4225

Aaptamine, a spongean alkaloid isolated from a sea sponge Aaptos aaptos, is a competitive antagonist of **α-adrenoceptor** and activates the p21 promoter in a p53-independent manner.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abaloparatide TFA

(BA 058 TFA; BIM 44058 TFA)

Cat. No.: HY-108742A

Abaloparatide TFA (BA 058 TFA) is a **parathyroid hormone receptor 1 (PTHR1)** analogue selected to be a potent and selective activator of the **PTHR1** signaling pathway.

Purity: 96.11%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Abarelix

(R3827; PPI 149)

Cat. No.: HY-13534

Abarelix (R3827; PPI 149) is a potent **gonadotrophin-releasing hormone (GnRH)** antagonist, used for prostate cancer treatment.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Abarelix Acetate

(PPI 149 Acetate; R 3827 Acetate)

Cat. No.: HY-13534A

Abarelix Acetate (PPI 149 Acetate; R 3827 Acetate) is a potent **gonadotrophin-releasing hormone (GnRH)** antagonist, used for prostate cancer research.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ABT-239

Cat. No.: HY-12195

ABT-239 is a novel, highly efficacious, non-imidazole class of **H3R** antagonist and a transient receptor potential vanilloid type 1 (**TRPV1**) antagonist. .



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ABT-546

(A-216546)

Cat. No.: HY-135283

ABT-546 (A-216546) is a potent, highly selective and active **endothelin ET_A receptor** antagonist with a **K_i** of 0.46 nM for [^{125}I]endothelin-1 binding to cloned **human endothelin ET_A**. ABT-546 is >25,000-fold more selective for the **ET_A receptor** than for the ET_B receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AC 187

Cat. No.: HY-P1393

AC 187 is a potent and orally active **amylin receptor** antagonist with an **IC_{50}** of 0.48 nM and a **K_i** of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AC 187 TFA

Cat. No.: HY-P1393A

AC 187 TFA is a potent and orally active **amylin receptor** antagonist with an IC_{50} of 0.48 nM and a K_i of 0.275 nM. AC 187 TFA shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 TFA has neuroprotective effects.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Acebutolol D7

Cat. No.: HY-17497S

Acebutolol D7 is a deuterium labeled Acebutolol. Acebutolol is a selective β1 adrenergic receptor antagonist used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Acebutolol hydrochloride

Cat. No.: HY-17497A

Acebutolol hydrochloride is a **β1 adrenergic receptor (β1AR)** antagonist. Acebutolol hydrochloride is used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 5 g, 10 g

Acoramidis

(AG10)

Cat. No.: HY-109165

Acoramidis (AG10) is an orally active and selective kinetic stabilizer of WT and V122I-**TTR (transthyretin)**. Acoramidis (AG10) is used in the study for transthyretin amyloidosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acoramidis hydrochloride

(AG10 hydrochloride)

Cat. No.: HY-109165A

Acoramidis (AG10) hydrochloride is an orally active and selective kinetic stabilizer of WT and V122I-**TTR (transthyretin)**. Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Acrivastine

(BW825C)

Cat. No.: HY-B1510

Acrivastine (BW825C) is a short acting **histamine 1** receptor antagonist for the treatment of allergic rhinitis.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Acrivastine D7

(BW825C D7)

Cat. No.: HY-B1510S

Acrivastine D7 (BW825C D7) is a deuterium labeled Acrivastine. Acrivastine is a short acting histamine 1 receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACT-373898

Cat. No.: HY-135500

ACT-373898 is an inactive carboxylic acid metabolite of Macitentan. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

ACTH (1-17)

(α1-17-ACTH)

Cat. No.: HY-P1545

ACTH (1-17), an adrenocorticotropin analogue, is a potent **human melanocortin 1 (MC1) receptor** agonist with a K_i of 0.21 nM.

SYSMEHFRWGKPVGKKR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ACTH (1-17) (TFA)

(α1-17-ACTH TFA)

Cat. No.: HY-P1545A

ACTH (1-17) TFA, an adrenocorticotropin analogue, is a potent **human melanocortin 1 (MC1) receptor** agonist with a K_i of 0.21 nM.

SYSMEHFRWGKPVGKKR (TFA salt)

Purity: 99.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Adenosine 5′-diphosphoribose sodium

(ADP ribose sodium) Cat. No.: HY-100973A

Adenosine 5′-diphosphoribose sodium (ADP ribose sodium) is a nicotinamide adenine nucleotide (NAD^+) metabolite. Adenosine 5′-diphosphoribose sodium is the most potent and primary intracellular Ca^{2+}-permeable cation **TRPM2 channel** activator.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mg

ADRA1D receptor antagonist 1

Cat. No.: HY-135270

ADRA1D receptor antagonist 1 is a potent, selective and orally active α_{1D} **adrenoceptor** antagonist, with a K_i of 1.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenocorticotropic Hormone (ACTH) (1-39), rat

(ACTH (1-39) (mouse, rat)) Cat. No.: HY-P1477

Adrenocorticotropic Hormone (ACTH) (1-39), rat is a potent **melanocortin 2 (MC2) receptor** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenocorticotropic Hormone (ACTH) (1-39), rat TFA

(ACTH (1-39) (mouse, rat) TFA) Cat. No.: HY-P1477A

Adrenocorticotropic Hormone (ACTH) (1-39), rat (TFA) is a potent **melanocortin 2 (MC2) receptor** agonist.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

Adrenosterone

((+)-Adrenosterone) Cat. No.: HY-17462

Adrenosterone ((+)-Adrenosterone) is a competitive **hydroxysteroid (11-beta) dehydrogenase 1 (HSD11β1)** inhibitor. Adrenosterone is a steroid hormone with weak androgenic effect. Adrenosterone is a dietary supplement that can decrease fat and increase muscle mass.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

Adriforant hydrochloride

(PF-3893787 hydrochloride) Cat. No.: HY-19705B

Adriforant hydrochloride (PF-3893787 hydrochloride) is a novel **histamine H4 receptor** antagonist binding affinity (K_i=2.4 nM) and is also a functional (K_i=1.56 nM) antagonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG1024

(Tyrphostin AG 1024) Cat. No.: HY-10253

AG1024 (Tyrphostin AG 1024) is a reversible, competitive and selective **IGF-1R** inhibitor with an IC_{50} of 7 μM. AG1024 inhibits phosphorylation of **IR** (IC_{50}=57 μM). AG1024 induces **apoptosis** and has anti-cancer activity.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aganepag isopropyl

(AGN-210961) Cat. No.: HY-19923

Aganepag isopropyl (AGN-210961) is an **EP2** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AGL-2263

Cat. No.: HY-112720

AGL-2263 is an **insulin receptor** and **insulin-like growth factor (IGF) receptor** inhibitor.



Purity: 97.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AGN 192836

Cat. No.: HY-100300

AGN 192836 is a potent and selective **α2 adrenergic** agonist with EC_{50}s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AGN 210676

(Simenepag)

Cat. No.: HY-14898

AGN 210676 is a selective prostaglandin **EP_2** agonist extracted from patent US20070203222A1, Compound example 23, has an **EC_{50}** of 5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Agnuside

(Agnoside)

Cat. No.: HY-N2518

Agnuside is a compound isolated from Vitex negundo, down-regulates pro-inflammatory mediators **PGE2** and **LTB4**, and reduces the expression of cytokines, with anti-arthritic activity.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AH 6809

Cat. No.: HY-10418

AH 6809 is an antagonist of **EP** and **DP receptor**, with **K_i**s of 1217, 1150, 1597, and 1415 nM for the cloned **human EP_1**, **EP_2**, **EP_3-III**, and **DP receptor** respectively. AH 6809 has a **K_i** of 350 nM for **mouse EP_2 receptor**.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AhR modulator-1

Cat. No.: HY-135671

AhR modulator-1 (compound 6-MCDF) is a selective and orally active **aryl hydrocarbon receptor (AhR)** modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting **prostatic VEGF** production prior to tumor formation. AhR modulator-1 also possess anti-**estrogenic** properties in rat uterus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ajmalicine

(Raubasine)

Cat. No.: HY-N1919

Ajmalicine (Raubasine) is found in herbs of Catharanthus roseus, is an antihypertensive drug used in the treatment of high blood pressure, decreases peripheral resistance and blood pressure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AL 082D06

(D06; D-06)

Cat. No.: HY-15709

AL 082D06 is a selective, nonsteroidal glucocorticoid receptor (**GR**) antagonist with **K_i** of 210 nM.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Alarelin Acetate

(Alarelin)

Cat. No.: HY-17405

Alarelin acetate is a synthetic **GnRH** agonist.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 100 mg

ALB-127158(a)

Cat. No.: HY-111398

ALB-127158(a) is a potent and selective melanin concentrating hormone 1 (**MCH_1**) receptor antagonist.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Alcaftadine

(R89674)

Cat. No.: HY-17039

Alcaftadine (R89674) is a **histamine H1 receptor** antagonist, which is used to prevent eye irritation brought on by allergic conjunctivitis.



Purity: 99.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Alcaftadine-D3

(R89674-D3)

Cat. No.: HY-17039S

Alcaftadine-D3 (R89674-D3) is a deuterium labeled Alcaftadine. Alcaftadine (HY-17039) is a H1 histamine receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALDH1A2-IN-1

Cat. No.: HY-139031

ALDH1A2-IN-1 is an active site-directed reversible **ALDH1A2** inhibitor (IC_{50}=0.91 μM; **Kd**=0.26 μM) with several hydrophobic interactions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alfuzosin

(SL 77499)

Cat. No.: HY-B0192

Alfuzosin is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Alfuzosin hydrochloride

(SL 77499-10)

Cat. No.: HY-B0192A

Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).



Purity: 98.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Alibendol

Cat. No.: HY-B0326

Alibendol is an antispasmodic,choleretic, and cholekinetic. Target: Others administration of alibendol in beagle dogs, observed retention times were approximately 5.0 min for alibendol. The within-run precision showed RSD values between 5.83 and 16.96 %.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Aligeron

Cat. No.: HY-101602

Aligeron is a non-selective **prostaglandin (PG)** antagonist, and has vasodilatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Allylestrenol

Cat. No.: HY-17375

Allylestrenol, a synthetic sexualsteroid, is used worldwide in case of endangered pregnancies.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Almorexant

(ACT 078573)

Cat. No.: HY-10805

Almorexant (ACT 078573) is a potent and competitive dual **orexin 1 receptor** (**OX1**)/**orexin 2 receptor** (**OX2**) antagonist with K_i values of 1.3 and 0.17 nM, respectively.



Purity: 99.01%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Almorexant hydrochloride

(ACT-078573 hydrochloride)

Cat. No.: HY-10805A

Almorexant hydrochloride (ACT 078573 hydrochloride) is a potent and competitive dual **orexin 1 receptor** (**OX1**)/**orexin 2 receptor** (**OX2**) antagonist with K_i values of 1.3 and 0.17 nM, respectively.



Purity: 99.88%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aloe-emodin-8-O-β-D-glucopyranoside

Cat. No.: HY-N2451

Aloe-emodin-8-O-β-D-glucopyranoside, a compound isolated from Saussrurea lappa, is a moderate inhibitor of **human protein tyrosine phosphatase 1B (hPTP1B)** with an IC_{50} of 26.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Alpha 1(I) Collagen (614-639), human

Cat. No.: HY-P1912

Alpha 1(I) Collagen (614-639), human is a peptide fragment of alpha-1 type I collagen.

SAGFDFSFLPQPPQEKAHDGGRYYRA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alrestatin

(AY-22284) Cat. No.: HY-B1202

Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

Alrestatin sodium

(AY-22284A) Cat. No.: HY-B1202A

Alrestatin sodium is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Altrenogest

(Allyltrenbolone; RU2267) Cat. No.: HY-B0521

Altrenogest (Allyltrenbolone) is a progestogen structurally related to veterinary steroid trenbolone.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

ALX 40-4C

Cat. No.: HY-P7061

ALX 40-4C is a small peptide inhibitor of the **chemokine receptor CXCR4**, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the **APJ receptor**, with an IC_{50} of 2.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALX 40-4C Trifluoroacetate

Cat. No.: HY-P7061A

ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the **chemokine receptor CXCR4**, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the **APJ receptor**, with an...



Purity: 95.90%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AM211

(AM211 free acid) Cat. No.: HY-13213

AM211 is a potent, selective and orally bioavailable **prostaglandin D2 (PGD2) receptor type 2 (DP2)** antagonist, with IC_{50}s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat DP2, respectively.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ambrisentan

(BSF 208075; LU 208075) Cat. No.: HY-13209

Ambrisentan is a selective ET type A receptor (**ETAR**) antagonist.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amcinonide

(CL-34699) Cat. No.: HY-B1197

Amcinonide inhibit NO release from activated microglia with IC50 3.38 nM. Amcinonide has affinity for the glucocorticoid receptor.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

AMD 3465

(GENZ-644494) Cat. No.: HY-15971A

AMD 3465 (GENZ-644494) is a potent antagonist of **CXCR4**, inhibits binding of 12G5 mAb and $CXCL12^{AF647}$ to **CXCR4**, with IC_{50}s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of **X4 HIV** strains (IC_{50}: 1-10 nM), but has no effect on CCR5-using...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMD 3465 hexahydrobromide

(GENZ-644494 hexahydrobromide) Cat. No.: HY-15971

AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of **CXCR4**, inhibits binding of 12G5 mAb and $CXCL12^{AF647}$ to **CXCR4**, with IC_{50}s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of **X4 HIV** strains...



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amebucort

Cat. No.: HY-U00298

Amebucort is a synthetic glucocorticoid corticosteroid, may used for the research of inflammatory disorders.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Amezinium methylsulfate

(Amezinium metilsulfate; Lu-1631)

Cat. No.: HY-A0275

Amezinium metilsulfate has multiple mechanisms, including stimulation of alpha and beta-1 receptors and inhibition ofnoradrenaline and tyramine uptake.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

AMG 487

Cat. No.: HY-15319

AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 **(CXCR3)** which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with **IC_{50}**s of 8.0 and 8.2 nM, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG-009

Cat. No.: HY-19499

AMG-009 is a potent antagonist of **prostaglandin D2**, with **IC_{50}** of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amibegron hydrochloride

(SR 58611A)

Cat. No.: HY-103207

Amibegron hydrochloride is a selective **β3-adrenoceptor** agonist, with an **EC_{50}** of 3.5 nM for **β-adrenoceptor** in rat colon; Amibegron hydrochloride has anxiolytic and antidepressant activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Aminaftone

(Aminaftone; Aminaphthone)

Cat. No.: HY-19890

Aminaftone, a derivative of 4-aminobenzoic acid, downregulates **endothelin-1** (**ET-1**) production in vitro by interfering with the transcription of the pre-pro-ET-1 gene.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminoguanidine hydrochloride

(Pimagedine hydrochloride; GER-11; Aminoguanidinium chloride)

Cat. No.: HY-B1041

Aminoguanidine hydrochloride is a diamine oxidase and NO synthase inhibitor, reduces levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, is an investigational drug for the treatment of diabetic nephropathy.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg

Amitraz

(BTS-27419)

Cat. No.: HY-B1111

Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Anamorelin

(RC-1291; ONO-7643)

Cat. No.: HY-14734

Anamorelin (RC-1291) is a potent **ghrelin receptor** agonist with **EC_{50}** value of 0.74 nM in the FLIPR assay.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Anamorelin Fumarate

(ONO-7643 Fumarate; RC1291 Fumarate)

Cat. No.: HY-14734B

Anamorelin Fumarate is a novel **ghrelin receptor** agonist with **EC_{50}** value of 0.74 nM in the FLIPR assay.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Anamorelin hydrochloride

(RC-1291 hydrochloride; ONO-7643 hydrochloride) Cat. No.: HY-14734A

Anamorelin (RC-1291) hydrochloride is a potent **ghrelin receptor** agonist with EC_{50} value of 0.74 nM in the FLIPR assay.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ancarolol

Cat. No.: HY-100141

Ancarolol is a **beta-adrenergic** blocking agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Androsta-1,4,6-triene-3,17-dione

Cat. No.: HY-136092

Androsta-1,4,6-triene-3,17-dione is a lipophilic and specific **aromatase** inhibitor with a K_i of 0.18 μM. Androsta-1,4,6-triene-3,17-dione inhibits estrogen biosynthesis and shows antifertility effects. Androsta-1,4,6-triene-3,17-dione induces impairment of spatial memory.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angiotensin (1-7)

(Ang-(1-7)) Cat. No.: HY-12403

Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine **ACE** activity (IC_{50}=0.65 μM).



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Angiotensin (1-7) (acetate)

(Ang-(1-7) (acetate)) Cat. No.: HY-12403A

Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Angiotensin II (1-4), human

Cat. No.: HY-P1792

Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Angiotensin II (1-4), human TFA

Cat. No.: HY-P1792A

Angiotensin II (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Angiotensin II (3-8), human

Cat. No.: HY-P1515

Angiotensin II (3-8), human is a less effective agonist at the **angiotensin AT_1 receptor**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Angiotensin II (3-8), human TFA

Cat. No.: HY-P1515A

Angiotensin II (3-8), human (TFA) is a less effective agonist at the **angiotensin AT_1 receptor**.



Purity: 99.14%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Angiotensin II (5-8), human

Cat. No.: HY-P1769

Angiotensin II (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II. Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca^{2+} levels.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Angiotensin II 5-valine

(Valine angiotensin II; 5-L-Valine angiotensin II) Cat. No.: HY-P0108

Angiotensin II 5-valine is an agonist of **angiotensin receptor**.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Angiotensin II human

(Angiotensin II; Ang II; DRVYIHPF) Cat. No.: HY-13948

Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mg, 50 mg

Angiotensin II human acetate

(Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate) Cat. No.: HY-13948A

Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system.



Purity: 99.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Angiotensin II human TFA

(Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA) Cat. No.: HY-13948B

Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Angiotensin III

Cat. No.: HY-113035

Angiotensin III is an **angiotensin 1 (AT1)** and **AT2** receptor agonist.

RVY-{Aaa}-HPF

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Angiotensin III TFA

Cat. No.: HY-113035A

Angiotensin III (TFA) is an **angiotensin 1 (AT1)** and **AT2** receptor agonist.

RVY-{Aaa}-HPF (TFA salt)

Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Angiotensin III, human, mouse

Cat. No.: HY-P1540

Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous **angiotensin type 2 receptor (AT_2R)** agonist, with **IC_{50}**s of 0.648 nM and 21.1 nM for AT_2R and AT_1R, respectively.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Antazoline hydrochloride

(Phenazoline hydrochloride) Cat. No.: HY-B1067

Antazoline hydrochloride is a 1st generation antihistamine with also anticholinergic properties used to relieve nasal congestion and in eye drops.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Antihistamine-1

Cat. No.: HY-100238

Antihistamine-1 is a **H1-antihistamine** (K_i=6.9 nM) with acceptable blood-brain barrier penetration and also an inhibitor of **CYP2D6** and **hERG channel** with **IC_{50}**s of 5.4 and 0.8 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aplaviroc

(AK 602; GSK 873140; GW 873140) Cat. No.: HY-17450

Aplaviroc (AK 602), a SDP derivative, is a **CCR5** antagonist, with **IC_{50}s** of 0.1-0.4 nM for HIV-1_{Ba-L}, HIV-1_{JRFL} and HIV-1_{MOKW}.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Aprepitant

(MK-0869; MK-869; L-754030) Cat. No.: HY-10052

Aprepitant (MK-0869) is a selective and high-affinity **neurokinin 1 receptor** antagonist with a K_d of 86 pM.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Aprocitentan

(ACT-132577) Cat. No.: HY-15895

Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of Macitentan. Aprocitentan is dual **ETA/ETB** antagonist with IC_{50}s of 3.4 nM and 987 nM, and pA_2 valus of 6.7 and 5.5, respectively.



Purity: 98.13%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aprocitentan D4

(ACT-132577 D4) Cat. No.: HY-15895S

Aprocitentan D4 (ACT-132577 D4) is a deuterium labeled Aprocitentan. Aprocitentan is a major and pharmacologically active metabolite of Macitentan. Aprocitentan is dual **ETA/ETB** antagonist with IC_{50}s of 3.4 nM and 987 nM, and pA_2 valus of 6.7 and 5.5, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APX-115 free base

(Ewha-18278 free base) Cat. No.: HY-120801A

APX-115 free base (Ewha-18278 free base) is a potent, orally active pan **NADPH oxidase (Nox)** inhibitor with K_i values of 1.08 μM, 0.57 μM, and 0.63 μM for **Nox1**, **Nox2** and **Nox4**, respectively. APX-115 free base effectively prevents kidney injury.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AR-08

Cat. No.: HY-U00371

AR-08 is an agonist of **α2-adrenergic receptor**, used for the treatment of attention deficit hyperactivety disorder (ADHD).



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Asapiprant

(S-555739) Cat. No.: HY-16763

Asapiprant is a potent and selective **DP_1 receptor** antagonist with a K_i of 0.44 nM.



Purity: 99.58%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Asenapine

(Org 5222) Cat. No.: HY-10121

Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of **serotonin receptors** (pK_i: 8.4-10.5), **adrenoceptors** (pK_i: 8.9-9.5), **dopamine receptors** (pK_i: 8.9-9.4) and **histamine receptors** (pK_i: 8.2-9.0).



Purity: 98.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Asoprisnil

(J867) Cat. No.: HY-119433

Asoprisnil (J867), a selective **progesterone receptor** modulator, exhibits mixed progesterone agonist and antagonist effects on various progesterone targeted tissues in animal and human.



Purity: 98.30%
Clinical Data:
Size: 1 mg

Astemizole

(R 43512) Cat. No.: HY-12532

Astemizole (R 43512), a second-generation antihistamine drug to diminish allergic symptoms with a long duration of action, is a **histamine H1-receptor** antagonist, with an IC_{50} of 4 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AT2 receptor agonist C21

Cat. No.: HY-100113

AT2 receptor agonist C21 is a druglike selective **angiotensin II AT2 receptor** agonist with K_i values of 0.4 nM and >10 μM for the AT2 receptor and AT1 receptor, respectively.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Atenolol

((RS)-Atenolol) Cat. No.: HY-17498

Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a K_i of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

ATI-2341

Cat. No.: HY-P0172

ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 **(CXCR4)**, which functions as a biased ligand, favoring Gαi activation over Gα13.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ATI-2341 TFA

Cat. No.: HY-P0172A

ATI-2341 is a potent and functionally selective allosteric agonist of **C-X-C chemokine receptor type 4 (CXCR4)**, which functions as a biased ligand, favoring Gαi activation over Gα13.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Atipamezole

(MPV 1248) Cat. No.: HY-12380A

Atipamezole (MPV 1248) is a potent **α_2-adrenoceptor antagonist** with a K_i of 1.6 nM.



Purity: 99.48%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

Atipamezole hydrochloride

(MPV-1248 hydrochloride) Cat. No.: HY-12380

Atipamezole (MPV-1248) hydrochloride is a potent **α_2-adrenoceptor antagonist** with a K_i of 1.6 nM.



Purity: 99.41%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

Atosiban

(RW22164; RWJ22164) Cat. No.: HY-17572

Atosiban (RW22164; RWJ22164) is a nonapeptide competitive **vasopressin/oxytocin receptor** antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.



Purity: 99.09%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Atosiban acetate

(RW22164 acetate; RWJ22164 acetate) Cat. No.: HY-17572A

Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive **vasopressin/oxytocin receptor** antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Atrasentan

(ABT-627; (+)-A 127722; A-147627) Cat. No.: HY-15403

Atrasentan (ABT-627) is an **endothelin receptor** antagonist with **IC_{50}** of 0.0551 nM for ET_A.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Atrasentan hydrochloride (ABT-627 hydrochloride; (+)-A 127722 hydrochloride; A-147627 hydrochloride)

Cat. No.: HY-15403A

Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective **endothelin A receptor** antagonist with an **IC_{50}** of 0.0551 nM for ET_A.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled

Cat. No.: HY-P2491

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, one of three mammalian natriuretic peptides (NPs), has endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide has the potential for cardiovascular diseases research.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate

Cat. No.: HY-P1235A

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. ANP (1-28) inhibits **endothelin-1** secretion in a dose-dependent way.



Purity: 96.81%
Clinical Data: Launched
Size: 500 μg, 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), rat

(Atrial natriuretic factor (1-28) (rat))

Cat. No.: HY-P1236

Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated **endothelin-1** secretion in a concentration-dependent manner.

Purity: 95.52%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Atrial Natriuretic Peptide (ANP) (1-28), rat TFA

(Atrial natriuretic factor (1-28) (rat) TFA)

Cat. No.: HY-P1236A

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated **endothelin-1** secretion in a concentration-dependent manner.

Purity: 98.74%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

AVE 0991

Cat. No.: HY-15778

AVE 0991 is a nonpeptide and orally active **angiotensin-(1-7) receptor** agonist with an IC_{50} of 21 nM.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AVE 0991 sodium salt

Cat. No.: HY-15778A

AVE 0991 sodium salt is a nonpeptide and orally active **Ang-(1-7) receptor Mas** agonist. AVE 0991 competes for high-affinity binding of [^{125}I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC_{50} of 21 nM.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avosentan

(Ro 67-0565; SPP-301)

Cat. No.: HY-15195

Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist. IC50 value: Target: ETA receptor.



Purity: 98.36%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZ-1355

Cat. No.: HY-101692

AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I_2/thromboxane A_2 ratio in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ084

Cat. No.: HY-119217

AZ084 is a potent, selective, allosteric and oral active **CCR8** antagonist, with a K_i of 0.9 nM. Has potential to treat asthma.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ7550

Cat. No.: HY-B0794

AZ7550 is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ7550 hydrochloride

Cat. No.: HY-B0794A

AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 98.66%
Clinical Data: Phase 1
Size: 5 mg, 10 mg

AZ7550 Mesylate

(AZ7550 trimesylate salt)

Cat. No.: HY-B0794B

AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 99.34%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

Azatadine

Cat. No.: HY-B0170

Azatadine is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. Target: Histamine Receptor Azatadine, a new antihistamine, was evaluated for its efficacy in 20 patients with chronic allergic rhinitis.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Azatadine dimaleate

(Azatadine maleate)

Cat. No.: HY-B0170A

Azatadine dimaleate is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. Target: Histamine Receptor Azatadine, a new antihistamine, was evaluated for its efficacy in 20 patients with chronic allergic rhinitis.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

AZD-3463

(ALK/IGF1R inhibitor)

Cat. No.: HY-15609

AZD-3463 (ALK/IGF1R inhibitor) is an orally active **ALK/IGF1R** inhibitor, with a K_i of 0.75 nM for ALK. AZD3463 induces **apoptosis** and **autophagy** in neuroblastoma cells.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD-4818

Cat. No.: HY-15545

AZD-4818 is a potent antagonist of chemokine **CCR1**. AZD-4818 can be used for the treatment of chronic obstructive pulmonary disease (COPD) .



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD-5069

Cat. No.: HY-19855

AZD-5069 is a potent **CXCR2 chemokine receptor** antagonist, used for caner treatment.



Purity: 99.63%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD1979

Cat. No.: HY-U00257

AZD1979 is a **Melanin-concentrating hormone receptor 1** (**MCHr1**) antagonist with an IC_{50} of ~12 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

AZD1981

Cat. No.: HY-15950

AZD1981 is a potent and selective CRTh2 antagonist; displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4).



Purity: 99.82%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

AZD2098

Cat. No.: HY-U00064

AZD2098 is a potent and selective **CC-chemokine receptor 4 (CCR4)** inhibitor with pIC_{50}s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD2906

Cat. No.: HY-113854

AZD2906 is a selective **glucocorticoid receptor (GR)** agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows IC_{50}s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD5423

Cat. No.: HY-108243

AZD5423 is an inhaled, potent, selective, and non-steroidal **glucocorticoid receptor (GR)** modulator (SGRM). AZD5423 effectively reduces allergen-induced responses in subjects with mild allergic asthma.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD8797

(KAND567)

Cat. No.: HY-13848

AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human **CX3CR1** receptor; antagonizes CX3CR1 and CXCR2 with K_is of 3.9 and 2800 nM, respectively.



Purity: 98.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD9567

Cat. No.: HY-120012

AZD9567 (compound 15) is a potent, oral active, non-steroidal and **selective glucocorticoid receptor modulator (SGRM)**, with an IC_{50} of 3.8 nM. Exhibits excellent efficacy in the streptococcal cell wall (SCW) reactivation model of joint inflammation.



Purity: ≥99.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg

Azelastine

Cat. No.: HY-B0462A

Azelastine, an antihistamine, is a potent and selective **histamine 1 (H_1)** antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Azelastine hydrochloride

Cat. No.: HY-B0462

Azelastine hydrochloridem, an antihistamine, is a potent and selective **histamine 1 (H_1)** antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Azepexole dihydrochloride

(B-HT 933 dihydrochloride; Oxazoloazepin dihydrochloride)

Cat. No.: HY-103212

Azepexole (B-HT 933) dihydrochloride is a potent and selective **alpha 2-adrenoceptor** agonist with **pK_i**s of 8.3, 7.6, and 7.5 for α2A-, α2B- and α2C-adrenoceptor subtypes, resepctively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azilsartan

(TAK-536)

Cat. No.: HY-14914

Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM.



Purity: 99.09%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Azilsartan medoxomil

(TAK-491)

Cat. No.: HY-14736

Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.



Purity: 99.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Azilsartan medoxomil monopotassium

(Azilsartan kamedoxomil; TAK 491 monopotassium)

Cat. No.: HY-17458

Azilsartan medoxomil monopotassium is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Azoramide

Cat. No.: HY-18705

Azoramide is a small-molecule modulator of the unfolded protein response with antidiabetic activity. in vitro: Azoramide is a dual-function endoplasmic reticulum (ER) modulator.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZP-531

Cat. No.: HY-P0231

AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.



Purity: 98.76%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg

Balovaptan

(RG7314)

Cat. No.: HY-109024

Balovaptan (RG7314) is a highly potent and selective brain-penetrant **vasopressin 1a (hV1a) receptor** antagonist, with K_is of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors, and is used for the research of autism.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bambuterol

((±)-Bambuterol; KWD-2183)

Cat. No.: HY-17501

Bambuterol ((±)-Bambuterol; KWD-2183) is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Bambuterol hydrochloride

((±)-Bambuterol hydrochloride; KWD-2183 hydrochloride)

Cat. No.: HY-17501A

Bambuterol hydrochloride ((±)-Bambuterol hydrochloride; KWD-2183 hydrochloride) is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bambuterol-d9 hydrochloride

((±)-Bambuterol-d9 hydrochloride; KWD-2183-d9 hydrochloride)

Cat. No.: HY-17501S

Bambuterol-D9 ((±)-Bambuterol-D9) hydrochloride is the deuterium labeled Bambuterol. Bambuterol ((±)-Bambuterol) hydrochloride is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bamirastine

(TAK-427)

Cat. No.: HY-101601

Bamirastine inhibits ligand binding to recombinant human histamine H_1 receptors (**rhH$_1$R**) with an **IC$_{50}$** value of 17.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bamocaftor

(VX-659)

Cat. No.: HY-126394

Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance regulator (**CFTR**) corrector designed to restore **F508del-CFTR** protein function. Bamocaftor can be used combine with Tezacaftor and Ivacaftor in cystic fibrosis research.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 200 mg

Baohuoside I

(Icariin-II; Icariside-II)

Cat. No.: HY-N0011

Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of **CXCR4**, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Batefenterol

(GSK961081; TD-5959)

Cat. No.: HY-12980

Batefenterol (GSK961081;TD-5959) is a novel **muscarinic** receptor antagonist and **β_2-adrenoceptor** agonist; displays high affinity for hM2, hM3 muscarinic and hβ_2-adrenoceptor with K_i values of 1.4, 1.3 and 3.7 nM, respectively.



Purity: 98.17%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bavisant

(JNJ-31001074)

Cat. No.: HY-14880

Bavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Bavisant dihydrochloride

Cat. No.: HY-14880A

Bavisant Hcl (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Bavisant dihydrochloride hydrate

(JNJ31001074AAC)

Cat. No.: HY-14880B

Bavisant dihydrochloride hydrate (JNJ31001074AAC) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.



Purity: 99.60%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Baxdrostat

Cat. No.: HY-132809

Baxdrostat is a **aldosterone synthase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAY-1316957

Cat. No.: HY-111539

BAY-1316957 is a potent, selective and orally active **prostaglandin E2 receptor subtype 4 (EP4-R)** antagonist with an **IC_{50}** of 15.3 nM for **human EP4-R**. BAY-1316957 has excellent drug metabolism and pharmacokinetics properties, and can be used for endometriosis research.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-298

Cat. No.: HY-130249

BAY-298 is an orally active and selective **luteinizing hormone receptor (LH-R)** antagonist with **IC_{50}**s of 96 nM, 23 nM and 78 nM for hLH (human LH) and rLH (rat LH) and cLH (cynomolgus monkey LH), respectively. BAY-298 can reduce sex hormone levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-899

Cat. No.: HY-130248

BAY-899 is an orally active and selective **luteinizing hormone receptor (LH-R)** antagonist with **IC_{50}**s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively. BAY-899 can reduce sex hormone levels.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BC11-38

Cat. No.: HY-108618

BC11-38 is a potent, selective, and biologically active **PDE11** inhibitor, with **IC_{50}**s of 0.28 μM and >100 μM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 5 mg

Beclometasone

(Beclomethasone)

Cat. No.: HY-B1540

Beclometasone (Beclomethasone) is a prototype **glucocorticoid receptor** agonist.



Purity: 95.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Beclometasone dipropionate

Cat. No.: HY-13571A

Betamethasone dipropionate, the prodrug of Betamethasone, is an orally active and potent **glucocorticoid** with anti-inflammatory and immunosuppressive activity. Betamethasone appears to be an effective inhibitor of LPS-induced inflammation and MMP release.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg

Befetupitant

(Ro67-5930)

Cat. No.: HY-19670

Befetupitant is a high-affinity, nonpeptide, competitive tachykinin 1 receptor (**NK1R**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benorilate

(Salipran)

Cat. No.: HY-107795

Benorylate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorylate has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit **prostaglandin (PG)** synthesis.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Bentiromide

Cat. No.: HY-B1493

Bentiromide is a peptide that is broken down in the pancreas by chymotrypsin. The bentiromide test is an excellent means of confirming the diagnosis of pancreatic exocrine insufficiency by outpatient test of chymotrypsin function.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Benzquinamide

(P2647; BZQ; Benzoquinamide)

Cat. No.: HY-U00244

Benzquinamide (P2647) is an antiemetic which can bind to the α_{2A}, α_{2B}, and α_{2C} **adrenergic receptors** (α2-AR) with K_i values of 1,365, 691, and 545 nM, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Benzyl isothiocyanate

Cat. No.: HY-77813

Benzyl isothiocyanate is a member of natural isothiocyanates with antimicrobial activity. Benzyl isothiocyanate potent inhibits cell mobility, migration and invasion nature and matrix metalloproteinase-2 (MMP-2) activity of murine melanoma cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Bepotastine

Cat. No.: HY-I0021

Bepotastine is a selective and orally active second-generation **histamine H1 receptor** antagonist. Bepotastine has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research.



Purity: 98.12%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bepotastine besilate

Cat. No.: HY-A0015

Bepotastine besilate is a selective and orally active second-generation **histamine H1 receptor** antagonist. Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Beta-Cortol

Cat. No.: HY-113418

Beta-Cortol is an androgen metabolite present in adults.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Betahistine dihydrochloride

Cat. No.: HY-B0524A

Betahistine dihydrochloride is an orally active **histamine H1 receptor** agonist and a **H3 receptor** antagonist. Betahistine dihydrochloride is used for the study of rheumatoid arthritis (RA).



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Betamethasone

Cat. No.: HY-13570

Betamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activities. Betamethasone accelerates fetal lung maturation and induces gene expression and apoptosis.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Betamethasone acibutate

Cat. No.: HY-121062

Betamethasone acibutate, derives from Betamethasone, is an acetate ester. Betamethasone acibutate is a glucocorticoid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Betamethasone dipropionate

(Betamethasone 17,21-dipropionate)

Cat. No.: HY-13571

Betamethasone dipropionate is a **glucocorticoid** steroid with anti-inflammatory and immunosuppressive abilities.



Purity: 98.31%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg, 1 g

Betamethasone hydrochloride

Cat. No.: HY-13570A

Betamethasone hydrochloride is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activities. Betamethasone hydrochloride accelerates fetal lung maturation and induces gene expression and apoptosis.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Betaxolol

Cat. No.: HY-B0381

Betaxolol is a selective **beta1 adrenergic receptor** blocker that can be used for the research of hypertension and glaucoma.



Purity: 95.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Betaxolol hydrochloride

(SL75212)

Cat. No.: HY-B0381A

Betaxolol Hydrochloride is a selective **beta1 adrenergic receptor** blocker that can be used for the research of hypertension and glaucoma.



Purity: 98.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

BI 689648

Cat. No.: HY-101217

BI 689648 is a novel, highly selective **aldosterone synthase** inhibitor which can inhibit **CYP11B1** and **CYP11B2** with IC_{50}s of 310 and 2.1 nM, respectively.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-167107

Cat. No.: HY-121251

BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (**β2AR**) with a dissociation constant K_d of 84 pM.



Purity: 99.81%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-671800

Cat. No.: HY-114141

BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells **(DP2/CRTH2)**, with IC_{50} values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively.



Purity: 99.23%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIBS 39

Cat. No.: HY-19732

BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BIIE-0246

(AR-H 053591)

Cat. No.: HY-101986

BIIE-0246 is a potent and highly selective **non-peptide neuropeptide Y (NPY) Y_2** receptor antagonist, with an IC_{50} of 15 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Bilastine

Cat. No.: HY-14447

Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bilastine-d6

Cat. No.: HY-14447S

Bilastine-d6 is the deuterium labeled Bilastine. Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bimatoprost

(AGN 192024)

Cat. No.: HY-B0191

Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bimatoprost D5

(AGN 192024 D5)

Cat. No.: HY-B0191S

Bimatoprost D5 (AGN 192024 D5) is a deuterium labeled Bimatoprost. Bimatoprost is a prostaglandin analog and is a topical hypotensive agent frequently used for treating ocular hypertension and glaucoma. Bimatoprost also has an antiadipogenic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bindarit

(AF2838)

Cat. No.: HY-B0498

Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins **MCP-1/CCL2**, **MCP-3/CCL7**, and **MCP-2/CCL8**, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity.



Purity: 99.68%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bis-propargyl-PEG9

Cat. No.: HY-133189

Bis-propargyl-PEG9 is a **PEG**-based **PROTAC linker** used in the synthesis of PROTACs.
Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bisoprolol hemifumarate

Cat. No.: HY-B0076

Bisoprolol hemifumarate is a selective **type β1 adrenergic receptor** blocker.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Bisphenol A

Cat. No.: HY-18260

Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC).



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

BMS CCR2 22

Cat. No.: HY-101908

BMS CCR2 22 is a potent, specific and high affinity **CC-type chemokine receptor 2 (CCR2)** antagonist with excellent binding affinity (binding **IC_{50}** of 5.1 nM) and potent functional antagonism (calcium flux **IC_{50}** of 18 nM and chemotaxis **IC_{50}** of 1 nM).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

BMS-193885

Cat. No.: HY-120619

BMS-193885 is a potent, selective, competitive, and brain penetrant **neuropeptide Y_1 receptor** antagonist with a **K_i** of 3.3 nM, and has an **IC_{50}** of 5.9 nM for hY_1, which displays > 100, > 160, > 160 and > 160-fold selectivity over α_1, hY_2, hY_4 and hY_5 receptors, respectively .



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

BMS-536924

Cat. No.: HY-10262

BMS-536924 is an orally active, competitive and selective **insulin-like growth factor receptor (IGF-1R)** kinase and **insulin receptor (IR)** inhibitor with **IC_{50}**s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BMS-564929

Cat. No.: HY-12111

BMS-564929 is an **androgen receptor** (AR) agonist, binds to androgen receptor (AR) with a K_i of 2.11±0.16 nM.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BMS-754807

Cat. No.: HY-10200

BMS-754807 is a potent and reversible **IGF-1R/IR** inhibitor (IC_{50}=1.8 and 1.7 nM, respectively; K_i=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC_{50} values of 6, 44, 7, 4, 9, and 25 nM, respectively.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-813160

Cat. No.: HY-109593

BMS-813160 is the first dual **CCR2/CCR5** antagonist, has the potential for cardiovascular treatment.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-819881

Cat. No.: HY-12433

BMS-819881 is a melaninconcentrating hormone receptor 1 (**MCHR1**) antagonist, which binds rat MCHR1 with a K_i of 7 nM. BMS-819881 also is selective and potent for **CYP3A4** activity with an EC_{50} of 13 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMY-25271

Cat. No.: HY-100191

BMY-25271 is a **histamine H2 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-Leu-Gly-Arg-AMC

Cat. No.: HY-P2237

Boc-Leu-Gly-Arg-AMC is a fluorogenic AMC substrate for the convertases. Boc-Leu-Gly-Arg-AMC can be used in enzymatic assays.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bombykol

(Isobombycol)

Cat. No.: HY-N7145

Bombykol, the first insect sex pheromone, is identified as the female-produced sex attractant of the silkworm moth Bombyx mori.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Bometolol Hydrochloride

Cat. No.: HY-U00386

Bometolol Hydrochloride is a **beta-adrenergic** blocking agent, used for the research of cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bosentan

Cat. No.: HY-A0013

Bosentan is a competitive and dual antagonist of **endothelin-1 (ET)** for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Bosentan (hydrate)

Cat. No.: HY-A0013A

Bosentan hydrate is a competitive and dual antagonist of **endothelin-1 (ET)** for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Bosentan-d4

Cat. No.: HY-115417

Bosentan-d4 is the deuterium labeled Bosentan. Bosentan is a competitive and dual antagonist of **endothelin-1 (ET)** for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

BQ-3020 TFA

Cat. No.: HY-P1016A

BQ-3020 (TFA) is a selective agonist of **ET_B receptor**, inhibits [^{125}I]ET-1 binding to ET_B receptor with an **IC_{50}** of 0.2 nM in cerebellum, and causes vasoconstriction.

Purity: 95.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BQ-788

Cat. No.: HY-15894A

BQ-788 is a potent, selective **ETB receptor** antagonist with **IC_{50}** of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with **IC_{50}** of 1300 nM.



Purity: 98.28%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg

BQ-788 sodium salt

Cat. No.: HY-15894

BQ-788 sodium salt is a potent and selective **ETB receptor** antagonist, inhibiting ET-1 binding to ETB receptors with an **IC_{50}** of 1.2 nM in human Girrardi heart cells.



Purity: 98.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Bradykinin

Cat. No.: HY-P0206

Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.



Purity: 99.92%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bradykinin (1-3)

Cat. No.: HY-P1497

Bradykinin (1-3) is a 3-amino acid residue peptide. Bradykinin (1-3) is an amino-truncated Bradykinin peptide, cleaved by Prolyl endopeptidase.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Bradykinin (1-5)

Cat. No.: HY-P1488

Bradykinin (1-5) is a major stable metabolite of Bradykinin, formed by the proteolytic action of angiotensin-converting enzyme (ACE).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bradykinin (1-6)

Cat. No.: HY-P1469

Bradykinin (1-6) is an amino-truncated Bradykinin peptide. Bradykinin (1-6) is a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY).



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Bradykinin (1-7)

(Bradykinin Fragment 1-7)

Cat. No.: HY-P1484

Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Bradykinin (2-9)

(Des-Arg1-bradykinin)

Cat. No.: HY-P1490

Bradykinin (2-9) is an amino-truncated Bradykinin peptide. Bradykinin (2-9) is a metabolite of Bradykinin, cleaved by Aminopeptidase P.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

BRD7552

Cat. No.: HY-19694

BRD7552, a potent **PDX1** transcription factor inducer, upregulates PDX1 expression in both primary human islets and ductal cells, and induces epigenetic changes in the PDX1 promoter consistent with transcriptional activation. BRD7552 increases insulin expression.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bremelanotide Acetate

(PT-141 Acetate)

Cat. No.: HY-18678A

Bremelanotide Acetate (PT-141 Acetate), a synthetic peptide analogue of α-MSH, is an agonist at **melanocortin receptors** including the MC3R and MC4R for the treatment of sexual dysfunction.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Brimonidine

(UK 14304; AGN190342)

Cat. No.: HY-B0659

Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brimonidine tartrate

(UK 14304 tartrate; AGN190342 tartrate)

Cat. No.: HY-B0659A

Brimonidine tartrate (UK 14304 tartrate) is a full α2-adrenergic receptor (α2-AR) agonist.

Purity: 99.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Brimonidine-d4 D-tartrate

Cat. No.: HY-B0659AS

Brimonidine-d4 (UK 14304-d4) D-tartrate is the deuterium labeled Brimonidine D-tartrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRL 37344 sodium

(BRL 37344A)

Cat. No.: HY-101325

BRL 37344 sodium (BRL 37344A) is a specific **β3-adrenergic receptor** agonist. BRL 37344 sodium treatment significantly lowers the body weight of obese mice.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Bromopropylate

Cat. No.: HY-B2044

Bromopropylate is a pesticide with moderate **anti-androgenic** activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brompheniramine maleate

((±)-Brompheniramine maleate)

Cat. No.: HY-B0480

Brompheniramine ((±)-Brompheniramine) maleate is a potent and orally active antihistamine of the propylamine class. Brompheniramine maleate is a selective **histamine H1 receptor** antagonist with a K_d of 6.06 nM.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Bucindolol

Cat. No.: HY-103214

Bucindolol is a **β1-adrenergic receptor** blocker, with intrinsic sympathomimetic activity, used in the research of heart failure.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg

Bufuralol hydrochloride

(Ro 3-4787 hydrochloride)

Cat. No.: HY-105124A

Bufuralol hydrochloride (Ro 3-4787 hydrochloride) is a potent non-selective, orally active **β-adrenoreceptor** antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Bunaprolast

(U66858) Cat. No.: HY-U00170

Bunaprolast (U66858) is a potent inhibitor of **LTB_4** production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of **lipoxygenase** and **TXB_2** release.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Burixafor hydrobromide

(TG-0054 hydrobromide) Cat. No.: HY-19867A

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of **CXCR4** and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Butaprost

Cat. No.: HY-100448A

Butaprost is a selective **prostaglandin E receptor (EP2)** agonist with an **EC_{50}** of 33 nM and a **K_i** of 2.4 μM for **murine EP2 receptor**. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost attenuates fibrosis by hampering **TGF-β/Smad2** signalling.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg (12.24 mM * 1 mL in Methyl acetate),

BW 245C

Cat. No.: HY-101987

BW 245C is a **prostanoid DP-receptor (DP1)** agonist, used to treat stroke.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

BX471

(ZK-811752) Cat. No.: HY-12080

BX471 (ZK-811752) is an orally active, potent and selective non-peptide **CCR1** antagonist with a **K_i** of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

BX471 hydrochloride

(ZK-811752 hydrochloride) Cat. No.: HY-12080A

BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide **CCR1** antagonist with **K_i** of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

C-Type Natriuretic Peptide (1-53), human

Cat. No.: HY-P1815

C-Type Natriuretic Peptide (1-53), human is the 1-53 fragment of C-Type Natriuretic Peptide. C-Type Natriuretic Peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C2 Ceramide

(Ceramide 2) Cat. No.: HY-101180

C2 Ceramide (Ceramide 2) is the main lipid of the stratum corneum and a **protein phosphatase 1 (PP1)** activator. C2 Ceramide activates **PP2A** and **ceramide-activated protein phosphatase (CAPP)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Cabergoline

(FCE-21336) Cat. No.: HY-15296

Cabergoline is an ergot derived-dopamine D_2-like receptor agonist that has high affinity for **D_2**, **D_3**, and **5-HT_{2B}** receptors (K_i=0.7, 1.5, and 1.2, respectively).



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Calcitonin, eel

(Thyrocalcitonin eel) Cat. No.: HY-P1463

Calcitonin, eel is the thyroid hormone peptide that contributes to the regulation of calcium homeostasis, widely used in the research of postmenopausal osteoporosis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Candesartan

(CV 11974) Cat. No.: HY-B0205

Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM. Target: Angiotensin II Receptor candesartan is indicated for the treatment of hypertension.



Purity: 98.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Candesartan Cilexetil

(TCV-116) Cat. No.: HY-17505

Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Capromorelin Tartrate

(CP 424391-18) Cat. No.: HY-15243

Capromorelin Tartrate is an orally active, potent **growth hormone secretagogue receptor (GHSR)** agonist, with K_i of 7 nM for hGHS-R1a.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Carbacyclin

(Carbaprostacyclin; Carba-PGI2) Cat. No.: HY-112322

Carbacyclin is a PGI2 analogue, acts as a **prostacyclin (PGI2) receptor** agonist and vasodilator, and potently inhibits platelet aggregation.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Carbazole derivative 1

(2-Fluoro-7-[(3-pyridinyl)methyl]-9H-carbazole) Cat. No.: HY-U00323

Carbazole derivative 1 is a carbazole derivative which can be used to reduce androgen or oestrogen levels in mammals, including humans.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carbetocin

Cat. No.: HY-17573

Carbetocin, an oxytocin (OT) analogue, is an **oxytocin receptor** agonist with a K_i of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research.



Purity: ≥98.0%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Carbetocin acetate

Cat. No.: HY-17573A

Carbetocin acetate, an oxytocin (OT) analogue, is an **oxytocin receptor** agonist with a K_i of 7.1 nM. Carbetocin acetate has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin acetate has the potential for postpartum hemorrhage research.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Carbimazole

Cat. No.: HY-B0558

Carbimazole is an imidazole **antithyroid agent** and can be used for the research of Graves' disease. Carbimazole plays its role due to its rapid conversion to methylmercapto imidazole (MMI) in vivo and can be converted to methimazole in vitro.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Carbinoxamine maleate salt

Cat. No.: HY-B1589A

Carbinoxamine maleate salt is a **histamine H1 receptor** antagonist.



Purity: 99.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Carboprost

(15(S)-15-Methyl Prostaglandin F2α; 15-Methyl-PGF2α) Cat. No.: HY-128428

Carboprost (15(S)-15-Methyl Prostaglandin F2α) is a metabolically stable synthetic analog of prostaglandin F2α. Carboprost stimulates uterine contractions and induces abortion.



Purity: 98.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Carboprost tromethamine

Cat. No.: HY-A0195

Carboprost tromethamine is the synthetic 15-methyl analogue of prostaglandin $F_{2\alpha}$. Carboprost tromethamine can effectively promote law contraction of the uterus and significantly reduce the amount of bleeding during and after delivery.



Purity: 98.28%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Carebastine

Cat. No.: HY-121356

Carebastine is the active metabolite of Ebastine. Carebastine is a **histamine H1 receptor** antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Carperitide

(Atrial Natriuretic Peptide (ANP) (1-28), human, porcine)

Cat. No.: HY-P1235

Carperitide (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine) is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch.

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Carteolol hydrochloride

(OPC-1085 hydrochloride)

Cat. No.: HY-17495A

Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

CAY10471 Racemate

(TM30089 Racemate)

Cat. No.: HY-13706

CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective **prostaglandin D2 receptor CRTH2** antagonist, with a K_i of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (K_i, >10000 nM) or PGD2 receptor DP (K_i, 1200 nM).



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

CAY10595

Cat. No.: HY-118180

CAY10595 is a potent **CRTH2/DP2** receptor antagonist that binds to the human receptor with a K_i of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCK-A receptor inhibitor 1

Cat. No.: HY-U00387

CCK-A receptor inhibitor 1 is a **cholecystokinin A (CCK-A) receptor** inhibitor with a binging IC_{50} of 340 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR1 antagonist 6

Cat. No.: HY-114193

CCR1 antagonist 6 (compound 16q) is a **chemokine receptor 1 (CCR1)** antagonist, with an IC_{50} of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR1 antagonist 7

Cat. No.: HY-114194

CCR1 antagonist 7 (compound 16r) is a **chemokine receptor 1 (CCR1)** antagonist, with an IC_{50} of 4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR1 antagonist 8

Cat. No.: HY-120588

CCR1 antagonist 8 (compound 19n), a third azaindazole series compound, is a **CCR1** antagonist, with an IC_{50} of 1.8 nM in Ca^{2+} flux assay.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CCR2 antagonist 1

Cat. No.: HY-112792

CCR2 antagonist 1 is a high-affinity and long-residence-time **CCR2** antagonist, with a K_i of 2.4 nM.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CCR2 antagonist 3

Cat. No.: HY-101264

CCR2 antagonist 3 is a chemokine receptor 2 **(CCR2)** antagonist.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCR2-RA-[R]

Cat. No.: HY-50081

CCR2-RA-[R] is an allosteric antagonist of the **C-C chemokine receptor type 2 (CCR2)** with an IC_{50} of 103 nM.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCR3 antagonist 1

Cat. No.: HY-U00331

CCR3 antagonist 1 is a potent antagonist of **CCR3**, used for the research of immunologic and inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR4 antagonist 2

Cat. No.: HY-125836

CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (**CCR4**) that inhibits T_{reg} trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR5 antagonist 1

Cat. No.: HY-100261

CCR5 antagonist 1 is a **CCR5** antagonist which can inhibit **HIV** replication extracted from WO 2004054974 A2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR6 inhibitor 1

Cat. No.: HY-112701

CCR6 inhibitor 1 is a potent and selective **CCR6** inhibitor, with IC_{50}s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC_{50}, > 30000 nM), and CCR7 (IC_{50}, 9400 nM). CCR6 inhibitor 1 markedly blocks ERK phosphorylation.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCX354

Cat. No.: HY-U00350

CCX354 is an antagonist of **CCR1**, with anti-inflammatory activity.



Purity: ≥99.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg

Cefminox sodium

(MT-141)

Cat. No.: HY-128932

Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits a broad spectrum of **antibacterial** activity.



Purity: 99.83%
Clinical Data: Launched
Size: 25 mg

Cenicriviroc

(TAK-652; TBR-652)

Cat. No.: HY-14882

Cenicriviroc (TAK-652) is an orally active, dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.



Purity: 98.07%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cenicriviroc Mesylate

(TAK-652 Mesylate; TBR-652 Mesylate) Cat. No.: HY-14882A

Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.



Purity: 98.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Centanafadine

(EB-1020) Cat. No.: HY-16736

Centanafadine is dual **norepinephrine (NE)/dopamine (DA)** transporter inhibitor, also inhibits serotonin transporter, with **IC_{50}s** of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Centanafadine hydrochloride

(EB-1020 hydrochloride) Cat. No.: HY-16736A

Centanafadine (hydrochloride) is dual **norepinephrine (NE)/dopamine (DA)** transporter inhibitor, also inhibits serotonin transporter, with **IC_{50}s** of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ceramides Mixture

Cat. No.: HY-113679

Ceramides Mixture is an endogenous ceramide and consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides Mixture is a main lipid component of the permeability barrier in epidermis.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Ceritinib

(LDK378) Cat. No.: HY-15656

Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive **ALK** tyrosine kinase inhibitor with an **IC_{50}** of 200 pM. Ceritinib (LDK378) also inhibits **IGF-1R**, **InsR**, and **STK22D** with **IC_{50}** values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ceritinib D7

(LDK378 D7) Cat. No.: HY-15656S

Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ceritinib dihydrochloride

(LDK378 dihydrochloride) Cat. No.: HY-15656A

Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive **ALK** tyrosine kinase inhibitor with an **IC_{50}** of 200 pM.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ceruletide

(Caerulein; Cerulein; FI-6934) Cat. No.: HY-A0190

Ceruletide is a decapeptide and a potent **cholecystokinin receptor** agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg x 2, 500 μg

Cetirizine

Cat. No.: HY-17042

Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Cetirizine dihydrochloride

(P071) Cat. No.: HY-17042A

Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist.



Purity: 99.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Cetirizine Impurity C

Cat. No.: HY-131256

Cetirizine Impurity C is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting **histamine H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Cetirizine Impurity D

Cat. No.: HY-100661

Cetirizine Impurity D is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cetrorelix Acetate

(SB-75 acetate)

Cat. No.: HY-P0009A

Cetrorelix Acetate (SB-75 acetate) is a potent gonadotropin-releasing hormone **(GnRH)** receptor antagonist with an IC_{50} of 1.21 nM.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Cetrorelix diacetate

(SB-75 diacetate)

Cat. No.: HY-P0009B

Cetrorelix diacetate (SB-075 diacetate) is a potent gonadotropin-releasing hormone **(GnRH)** receptor antagonist with an IC_{50} of 1.21 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGP-42112

(CGP42112A)

Cat. No.: HY-12405

CGP-42112 (CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

CGP-53153

Cat. No.: HY-U00125

CGP-53153 is a steroidal inhibitor of **5 alpha reductase** with IC_{50}s of 36 and 262 nM in rat and human prostatic tissue, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGP48369

Cat. No.: HY-101706

CGP48369 is a nonpeptidic **angiotensin II receptor** antagonist, used for anti-hypertensive research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGP71683 hydrochloride

(CGP71683A)

Cat. No.: HY-107723

CGP71683 hydrochloride is a competitive **neuropeptide Y5 receptor** antagonist with a K_i of 1.3 nM, and shows no obvious activity at Y1 receptor (K_i, >4000 nM) and Y2 receptor (K_i, 200 nM) in cell membranes.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CGS 15435

Cat. No.: HY-100283

CGS 15435, a potent thromboxane (TxA_2) synthetase inhibitor with an IC_{50} of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI_2 synthetase and lipoxygenase enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHEMBL333994

(FK-480)

Cat. No.: HY-U00363

CHEMBL333994 is a potent and orally effective Cholecystokinin A **(CCK-A)** antagonist, with an IC_{50} of 0.67 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chlormadinone acetate

Cat. No.: HY-B1095

Chlormadinone acetate is a steroidal progestin, with antiandrogen and antiestrogenic effects.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Chloropyramine hydrochloride

Cat. No.: HY-B1305

Chloropyramine hydrochloride is a **histamine receptor H1** antagonist which can also inhibit the biochemical function of **VEGFR-3** and **FAK**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Chlorotrianisene

Cat. No.: HY-B2158

Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active **estrogen receptor** modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme **COX-1** and inhibits platelet aggregation in whole blood.



Purity: 99.24%
Clinical Data: Launched
Size: 5 mg, 10 mg

Chlorpheniramine maleate

(Chlorphenamine maleate)

Cat. No.: HY-B0286A

Chlorpheniramine maleate is an histamine H1 receptor antagonist with IC50 of 12 nM.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Chlorphenoxamine

Cat. No.: HY-B1607

Chlorphenoxamine is an antihistamine and anticholinergic used as an antipruritic and antiparkinsonian agent. Target: Histamine Receptor.



Purity: 95.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Chlorpropamide

Cat. No.: HY-B1429

Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Target: Chlorpropamide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

CI-949

Cat. No.: HY-U00364

CI-949 is an allergic mediator release inhibitor, which inhibits **histamine**, **leukotriene C_4/D_4 (LTC_4/LTD_4)**, and **thromboxane B_2 (TXB_2)** release with **IC_{50}**s of 11.4 μM, 0.5 μM and 0.1 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ciclesonide

(RPR251526)

Cat. No.: HY-B0625

Ciclesonide (RPR251526) is a glucocorticoid with an potent anti-inflammatory activity. Ciclesonide can be used for asthma research.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Cicloprolol hydrochloride

Cat. No.: HY-U00066

Cicloprolol is a partial **β 1-adrenoceptor** agonist .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cimetidine

(SKF-92334)

Cat. No.: HY-14289

Cimetidine (SKF-92334) is an orally active and inverse histamine H2 receptor antagonist with a K_i of 0.6 μM. Cimetidine is an inverse agonist. Cimetidine has anti-cancer and anti-inflammatory activity.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g, 10 g

Cinnarizine

Cat. No.: HY-B1090

Cinnarizine is an antihistamine and a calcium channel blocker, promote cerebral blood flow, used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Cinnarizine D8

Cat. No.: HY-B1090S

Cinnarizine D8 is a deuterium labeled Cinnarizine. Cinnarizine is an antihistamine and a calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Cipralisant

(GT-2331)

Cat. No.: HY-106993

Cipralisant (GT-2331) is an orally active, low-toxicity, potent, selective, high affinity **histamine H3 receptor** full antagonist in vivo, and an agonist in vitro, with a **pK_i** of 9.9 for **histamine H3 receptor** and a **K_i** of 0.47 nM for rat **histamine H3 receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ciproxifan

(FUB-359)

Cat. No.: HY-14567

Ciproxifan (FUB 359) is a potent, selective, orally bioavailable and competitive antagonist of **histamine H_3-receptor**, with an **IC_{50}** of 9.2 nM. Ciproxifan displays low apparent affinity at other receptor subtypes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ciproxifan maleate

(FUB 359 maleate)

Cat. No.: HY-15289

Ciproxifan maleate (FUB 359 maleate) is a potent, selective, orally bioavailable and competitive antagonist of **histamine H_3-receptor**, with an **IC_{50}** of 9.2 nM. Ciproxifan maleate displays low apparent affinity at other receptor subtypes.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CJ-42794

(CJ-042794)

Cat. No.: HY-10797

CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist, inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5, a binding affinity that was at least 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1,...



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Clascoterone (Cortexolone 17 alpha-propionate; Cortexolone 17α-propionate; CB-03-01)

Cat. No.: HY-13331

Clascoterone (Cortexolone 17 alpha-propionate;Cortexolone 17α-propionate;CB-03-01) is a new topical and peripherally selective androgen antagonist.



Purity: 98.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg, 500 mg

Clemastine fumarate

(HS-592 fumarate; Meclastine fumarate)

Cat. No.: HY-B0298A

Clemastine (fumarate) (HS-592 (fumarate)) is a selective histamine H1 receptor antagonist with IC_{50} of 3 nM.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Clemizole

Cat. No.: HY-30234

Clemizole is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. Clemizole is an inhibitor of **TRPC5 channel**. The **IC_{50}** of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its **EC_{50}** for viral replication is 8 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Clemizole hydrochloride

Cat. No.: HY-30234A

Clemizole hydrochloride is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. Clemizole hydrochloride is an inhibitor of **TRPC5 channel**.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Clenproperol

Cat. No.: HY-100699

Clenproperol is a **β2-adrenergic** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clenproperol-D7

Cat. No.: HY-100699S

Clenproperol-D7 is the deuterium labeled Clenproperol. Clenproperol is a β2-adrenergic agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Clobetasol propionate

Cat. No.: HY-13600

Clobetasol propionate is a potent and selective **CYP3A5** inhibitor with an IC_{50} of 0.206 μM. Clobetasol propionate has no inhibiting on CYP3A4 or other major CYPs. Clobetasol propionate is a corticosteroid and has the potential for psoriasis and other dermatoses research.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Clomiphene citrate

(Clomifene citrate)

Cat. No.: HY-B0463

Clomiphene citrate (Clomifene citrate) is a selective estrogen receptor modulator. Target: Estrogen Receptor/ERR Clomifene citrate (CC) acted as an estrogen antagonist regardless of the concentration of E2 added together.



Purity: 99.28%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Clonidine hydrochloride

Cat. No.: HY-B0409A

Clonidine hydrochloride is an agonist of **α2-adrenoceptor** and potent antihypertensive agent.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Cloprostenol sodium salt

(ICI 80996 sodium salt)

Cat. No.: HY-108415

Cloprostenol sodium salt (ICI 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent, and is a **PGF2α receptor** agonist.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Clorprenaline D7

Cat. No.: HY-131106S

Clorprenaline D7 is a deuterium labeled Clorprenaline. Clorprenaline is a **β2-adrenergic receptor** agonist that is implicated in bronchial expansion. Clorprenaline has the potential for asthma research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clorprenaline hydrochloride

Cat. No.: HY-B1347

Clorprenaline hydrochloride is a **β_2-adrenergic receptor** agonist that is implicated in bronchial expansion. Clorprenaline has the potential for asthma research.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

CO23

Cat. No.: HY-130012

CO23 is a selective **thyroid hormone receptor (TR) α** agonist and used for growth and development regulation. CO23 was able to be transported through the blood-brain barrier.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Conivaptan hydrochloride

(YM 087)

Cat. No.: HY-18347A

Conivaptan (hydrochloride) is a non-peptide antagonist of **vasopressin receptor**, with K_i values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 kidney receptor respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Conophylline

Cat. No.: HY-N3619

Conophylline is a vinca alkaloid extracted from leaves of a tropical plant Ervatamia microphylla. Conophylline is a differentiation inducer of for pancreatic cells. Conophylline suppresses HSC and induces apoptosis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Corticosterone (17-Deoxycortisol; 11β,21-Dihydroxyprogesterone; Kendall's compound B)

Cat. No.: HY-B1618

Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.



Purity: 99.70%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg

Cortisol sulfate (Cortisol 21-sulfate)

Cat. No.: HY-N8460

Cortisol sulfate (Cortisol 21-sulfate) is a metabolite of Cortisol (HY-N0583). Cortisol sulfate is a specific ligand for intracellular transcortin.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cortisone (17-Hydroxy-11-dehydrocorticosterone; Kendall's compound E)

Cat. No.: HY-17461

Cortisone (17-Hydroxy-11-dehydrocorticosterone), an oxidized metabolite of Cortisol (a Glucocorticoid). Cortisone acts as an immunosuppressant and anti-inflammatory agent.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Cortisone acetate (Cortisone 21-acetate)

Cat. No.: HY-17461A

Cortisone acetate (Cortisone 21-acetate), an oxidized metabolite of Cortisol (a Glucocorticoid). Cortisone acetate acts as an immunosuppressant and anti-inflammatory agent.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Cortistatin-14

Cat. No.: HY-P1932

Cortistatin-14, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties.

Purity: 99.93%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Cortistatin-14 TFA

Cat. No.: HY-P1932A

Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Cortodoxone (11-Deoxycortisol; cortexolone; Reichstein's substance S)

Cat. No.: HY-77839

Cortodoxone is a glucocorticoid steroid hormone that can be oxygenated to cortisol (Hydrocortisone).



Purity: 98.74%
Clinical Data: No Development Reported
Size: 100 mg

Cotosudil

Cat. No.: HY-137436

Cotosudil is a ROCK kinase inhibitor, which can be used for glaucoma or ocular hypertension research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP 316311

Cat. No.: HY-14129

CP 316311 is a potent and selective **CRF1 receptor** antagonist with an IC_{50} value of 6.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP 376395

Cat. No.: HY-14130

CP 376395 is a potent and selective **Corticotropin releasing factor 1 (CRF1)** receptor antagonist.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-66948

Cat. No.: HY-19048

CP-66948 is a **histamine H2-receptor** antagonist with gastric antisecretory activity and mucosal protective properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRF, bovine

(Corticotropin Releasing Factor bovine)

Cat. No.: HY-P1533

CRF, bovine is a potent agonist of **CRF receptor**, and displaces [^{125}I-Tyr]ovine CRF with a K_i of 3.52 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRF, bovine TFA

(Corticotropin Releasing Factor bovine TFA)

Cat. No.: HY-P1533A

CRF, bovine (TFA) is a potent agonist of **CRF receptor**, and displaces [^{125}I-Tyr]ovine CRF with a K_i of 3.52 nM.

Purity: 96.50%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

CRTh2 antagonist 1

Cat. No.: HY-112265

CRTh2 antagonist 1 is a **CRTh2** antagonist with an IC_{50} of 89 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRTh2 antagonist 2

Cat. No.: HY-125970

CRTh2 antagonist 2 is selective and potent **CRTH2** antagonist extracted from patent US20140148470A1, compound Example 1, has an IC_{50} of ≤10 nM. CRTh2 antagonist 2 can be used in research of androgenic alopecia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRTH2-IN-1

(Ramatroban analog)

Cat. No.: HY-U00423

CRTH2-IN-1 (Ramatroban analog) is a selective **prostaglandin D2 receptor DP2** (**CRTH2**) antagonist with an IC_{50} of 6 nM in a human DP2 binding assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CS-003 Free base

Cat. No.: HY-19633

CS-003 Free base (CS-003), a triple tachykinin receptor antagonist, shows high affinities for human (**Neurokinin**) NK1, NK2 and NK3 receptors with K_i values of 2.3 nM, 0.54 nM and 0.74 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CXCR2-IN-1

Cat. No.: HY-101022

CXCR2-IN-1 is a central nervous system penetrant **CXCR2** antagonists with a **pIC$_{50}$** of 9.3.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CXCR7 modulator 1

Cat. No.: HY-107987

CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid **CXCR7** modulator, with a K_i of 9 nM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

CXCR7 modulator 2

Cat. No.: HY-112154

CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (**CXCR7**), with a K_i of 13 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cyclic ADP-ribose

(cADPR)

Cat. No.: HY-N7395

Cyclic ADP-ribose (cADPR) is a potent second messenger for **calcium mobilization** that is synthesized from NAD^+ by an ADP-ribosyl cyclase.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 500 µg

Cyclic ADP-ribose ammonium

(cADPR ammonium)

Cat. No.: HY-N7395A

Cyclic ADP-ribose ammonium (cADPR ammonium) is a potent second messenger for **calcium mobilization** that is synthesized from NAD^+ by an ADP-ribosyl cyclase.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 500 µg

Cyclofenil

Cat. No.: HY-W011100

Cyclofenil is a selective **estrogen receptor** modulator and an ovulation-inducing agent. Cyclofenil shows an inhibitory effect on **dengue virus** replication in Vero cells with an EC_{50} of 1.62 µM. Cyclofenil has anti-dengue-virus activity.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

CYN 154806

Cat. No.: HY-P1202

CYN 154806, a cyclic octapeptide, is a potent and selective **somatostatin sst2 receptor** antagonist, with **pIC$_{50}$** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CYN 154806 TFA

Cat. No.: HY-P1202A

CYN 154806 TFA, a cyclic octapeptide, is a potent and selective **somatostatin sst2** receptor antagonist, with **pIC$_{50}$** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cyprodinil

Cat. No.: HY-116214

Cyprodinil is an anilinopyrimidine broad-spectrum **fungicide** that inhibits the biosynthesis of methionine in phytopathogenic fungi.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Cyproheptadine hydrochloride sesquihydrate

Cat. No.: HY-B1165

Cyproheptadine hydrochloride sesquihydrate is an antihistamine and is an antagonist of serotonin and histamine2.



Purity: 99.00%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Cyproterone acetate

Cat. No.: HY-13604

Cyproterone acetate is an **anti-androgen** (**IC$_{50}$**=7.1 nM) and progestogen synthetic steroid. Cyproterone acetate has affinity with progesteron and with glucocorticoidal receptors.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg, 500 mg

D2343

Cat. No.: HY-U00206

D2343 is a **β2-adrenoceptor** agonist and also is an **α1- adrenoceptor** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D3-βArr

Cat. No.: HY-124867

D3-βArr is a positive allosteric modulator for **thyrotropin receptor (TSHR)**, which initiates translocation of β-Arr 1 by direct TSHR activation and potentiates TSH-mediated preosteoblast differentiation in vitro.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Dabuzalgron

(Ro 115-1240)

Cat. No.: HY-117071

Dabuzalgron (Ro 115-1240) is an orally active and selective **α-1A adrenergic receptor** agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dagrocorat

(PF-00251802)

Cat. No.: HY-16718

Dagrocorat (PF-00251802) is an orally active and selective high-affinity partial agonist of the **glucocorticoid receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dagrocorat hydrochloride

(PF-00251802 hydrochloride)

Cat. No.: HY-16718A

Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the **glucocorticoid receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daidzein

Cat. No.: HY-N0019

Daidzein is a soy isoflavone, which acts as a **PPAR** activator.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Danirixin

(GSK1325756)

Cat. No.: HY-19768

Danirixin is a selective, and reversible **CXCR2** antagonist, with IC_{50}of12.5 nM for CXCL8.



Purity: 98.21%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Dapiprazole hydrochloride

Cat. No.: HY-A0142A

Dapiprazole hydrochloride is a potent α-adrenergic blocking drug, which is used to reverse mydriasis after eye examination.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DAPTA

(D-Ala-peptide T-amide; Adaptavir)

Cat. No.: HY-P1034

DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively **CCR5**, and shows potent anti-HIV activities.



Purity: 95.16%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg

Darbufelone

(CI-1004)

Cat. No.: HY-101438

Darbufelone is a dual inhibitor of cellular $PGF_{2\alpha}$ and LTB_4 production. Darbufelone potently inhibits **PGHS-2** (IC_{50}= 0.19 μM) but is much less potent with **PGHS-1** (IC_{50}=20 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Darbufelone mesylate

(CI-1004 mesylate)

Cat. No.: HY-101438A

Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular $PGF_{2\alpha}$ and LTB_4 production. Darbufelone potently inhibits **PGHS-2** (IC_{50} = 0.19 μM) but is much less potent with **PGHS-1** (IC_{50}= 20 μM).



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Darusentan

(Lu-135252) Cat. No.: HY-15404

Darusentan (Lu-135252) is a selective **endothelin receptor A (ET-A) receptor** antagonist, which binds with a K_i of 1.4 nM to the ET-A receptor and a K_i of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors.



Purity: 98.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Decloxizine

(UCB-1402; NSC289116) Cat. No.: HY-17582

Decloxizine(UCB-1402; NSC289116) is a histamine 1 receptor antagonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Decloxizine dihydrochloride

(UCB 1402 dihydrochloride) Cat. No.: HY-A0075

Decloxizine dihydrochloride(UCB-1402; NSC289116) is a histamine 1 receptor antagonist.



Purity: 98.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Deflazacort

Cat. No.: HY-13609

Deflazacort, a glucocorticoid, is an inactive prodrug and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Deflazacort-D5

Cat. No.: HY-13609S

Deflazacort-D5 is the deuterium labeled Deflazacort. Deflazacort, a glucocorticoid, is an inactive prodrug and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Deflazacort-D7

Cat. No.: HY-13609S1

Deflazacort-D7 is the deuterium labeled Deflazacort. Deflazacort, a glucocorticoid, is an inactive prodrug and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Degarelix

Cat. No.: HY-16168A

Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (**GnRHR**) antagonist.



Purity: 99.92%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Dehydrocholic acid

Cat. No.: HY-B1393

Dehydrocholic acid is a synthetic bile acid, manufactured by the oxidation of cholic acid. Dehydrocholic acid acts as a hydrocholeretic, increasing bile output to clear increased bile acid load.



Purity: 98.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Dehydroisoandrosterone 3-acetate

(Dehydroepiandrosterone 3-acetate; DHEA acetate) Cat. No.: HY-B1405

Dehydroepiandrosterone 3-acetate is a testosterone/estrogen precursor and known modulator of vertebrate aggression.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Deoxycorticosterone acetate (11-Deoxycorticosterone acetate;

DOC acetate; Cortexone acetate) Cat. No.: HY-B1472

Deoxycorticosterone acetate is a steroid hormone produced by the adrenal gland that possesses mineralocorticoid activity and acts as a precursor to aldosterone.



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Deriglidole

(SL 86-0715) Cat. No.: HY-101683

Deriglidole is a peripheral **adrenoceptor** antagonist with a high affinity for α_2-adrenoceptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desisobutyryl-ciclesonide

(CIC-AP; Ciclesonide active principle) Cat. No.: HY-111490

Desisobutyryl-ciclesonide is the active metabolite of Ciclesonide. Desisobutyryl-ciclesonide has affinity for the **glucocorticoid receptor**.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Desloratadine

(Sch34117) Cat. No.: HY-B0539

Desloratadine (Sch34117) is the orally active major metabolite of the nonsedating **H1-antihistamine** Loratadine. Desloratadine is a selective **H1-receptor** antagonist that has anti-allergic and anti-inflammatory activities.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Desonide

Cat. No.: HY-B0248

Desonide is a nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. Target: Glucocorticoid Receptor Desonide is a low-potency topical corticosteroid that has been used for decades in the treatment of steroid-responsive dermatoses .



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Desoxycorticosterone pivalate

(DOCP) Cat. No.: HY-107917

Desoxycorticosterone pivalate (DOCP) is a mineralocorticoid hormone and an analog of Desoxycorticosterone. Desoxycorticosterone pivalate is used for the management of canine hypoadrenocorticism.



Purity: 98.23%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Detomidine

Cat. No.: HY-B0163

Detomidine, an imidazole derivative, is a potent **α2-adrenergic** agonist. Detomidine produces dose-dependent sedative and analgesic effects.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Detomidine carboxylic acid

Cat. No.: HY-135895

Detomidine carboxylic acid is the major urinary metabolite of Detomidine. Detomidine is a synthetic **α2-adrenergic** agonist. Detomidine also has cardiac and respiratory effects and an antidiuretic action.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Detomidine hydrochloride

Cat. No.: HY-B0163A

Detomidine hydrochloride, an imidazole derivative, is a potent **α2-adrenergic** agonist. Detomidine hydrochloride produces dose-dependent sedative and analgesic effects.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Dexamethasone

(Hexadecadrol; Prednisolone F) Cat. No.: HY-14648

Dexamethasone (Hexadecadrol) is a **glucocorticoid receptor** agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Dexamethasone acetate

(Dexamethasone 21-acetate; Hexadecadrol acetate) Cat. No.: HY-14648A

Dexamethasone acetate (Dexamethasone 21-acetate) is a **glucocorticoid receptor** agonist. Dexamethasone acetate has the potential for ophthalmic infections treatment.



Purity: 98.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Dexamethasone palmitate

(DXP) Cat. No.: HY-128922

Dexamethasone palmitate (DXP) is a prodrug of Dexamethasone, which is a glucocorticoid receptor agonist. Dexamethasone palmitate (DXP) has a 47-fold lower affinity for the glucocorticoid receptor than Dexamethasone. Anti-inflammatory agent.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dexamethasone phosphate disodium

(Dexamethasone 21-phosphate disodium salt) Cat. No.: HY-B1829A

Dexamethasone phosphate disodium is a **glucocorticoid receptor** agonist.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Dexchlorpheniramine maleate

(S-(+)-Chlorpheniramine maleate salt) Cat. No.: HY-B1062

Dexchlorpheniramine maleate is an antihistamine, with anticholinergic properties, used to treat allergic conditions.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg

Dexloxiglumide

Cat. No.: HY-128878

Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8).



Purity: 98.25%
Clinical Data:
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride)

Cat. No.: HY-17034A

Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of **α2-adrenoceptor**, with a K_i of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor.



Purity: 99.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Diacetolol D7

Cat. No.: HY-100635S

Diacetolol D7 is a deuterium labeled Diacetolol. Diacetolol is the major metabolite of Acebutolol. Diacetolol is a **β-adrenoceptor** blocking and anti-arrhythmic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Dicentrine

Cat. No.: HY-N6969

Dicentrine is a natural product isolated from the plant Lindera megaphylla with antihypertensive effect. Dicentrine is an **α_1-adrenoceptor** antagonist which has effective against human hyperplastic prostates.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dicloralurea

(DCU; Dichlorolurea) Cat. No.: HY-B0922

Dicloralurea is a veterinary food additive that inhibits methane production in herbicide ruminants, acts as a growth stimulant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dicyclohexyl phthalate-3,4,5,6-d4

Cat. No.: HY-W009142S



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Dienestrol

Cat. No.: HY-B1403

Dienestrol is a synthetic, non-steroidal estrogen, is an estrogen receptor agonist, for the treatment of menopausal and postmenopausal symptoms.



Purity: 96.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Dienogest

(STS 557)

Cat. No.: HY-B0084

Dienogest(STS-557) is a specific progesterone receptor agonist with potent oral endometrial activity and is used in the treatment of endometriosis. Target: progesterone receptor agonist Dienogest is an orally active synthetic progesterone (or progestin).



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Diethylstilbestrol

(Stilbestrol)

Cat. No.: HY-14598

Diethylstilbestrol (Stilbestrol), a synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders.



Purity: 98.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 1 g, 5 g

Dimaprit dihydrochloride

Cat. No.: HY-B1478

Dimaprit dihydrochloride is a selective **histamine H2 receptor** agonist, it also inhibits **nNOS** with an IC_{50} of 49 μM. Dimaprit dihydrochloride can stimulate gastric acid secretion.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Dimenhydrinate

Cat. No.: HY-B1215

Dimenhydrinate is an anti-emetic and anti-histamine commonly available over-the-counter as a motion sickness remedy.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Dinoprost

(Prostaglandin F2α; PGF2α)

Cat. No.: HY-12956

Dinoprost (Prostaglandin F2α) is an orally active, potent **prostaglandin F (PGF) receptor (FP receptor)** agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL).



Purity: 99.06%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt; PGF2α THAM; Prostaglandin F2α THAM)

Cat. No.: HY-12956A

Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent **prostaglandin F (PGF) receptor (FP receptor)** agonist.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Diphenhydramine hydrochloride

Cat. No.: HY-B0303A

Diphenhydramine hydrochloride is a first-generation histamine H1-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can across the ovine blood-brain barrier (BBB).



Purity: 99.04%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg, 500 mg, 5 g

Diphenmanil methylsulfate

(Diphemanil mesylate)

Cat. No.: HY-16171

Diphemanil methylsulfate is a quaternary ammonium anticholinergic. It binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids as well as saliva and sweat.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Diphenylpyraline hydrochloride

(4-Diphenylmethoxy-1-methylpiperidine hydrochloride)

Cat. No.: HY-B0970

Diphenylpyraline hydrochloride is a potent **histamine H_1 receptor** antagonist. Diphenylpyraline hydrochloride acts as an orally active antihistamine agent with antimuscarinic and antiallergic effects.



Purity: 99.25%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

DL-Norepinephrine hydrochloride

Cat. No.: HY-N7142

DL-Norepinephrine hydrochloride is a synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrineDL-Norepinephrine hydrochloride is a neurotransmitter targets **α1 and β1 adrenoceptors**, has an increasing effect...



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

DMP 696

Cat. No.: HY-12131

DMP 696 is a selective corticotropin-releasing hormone receptor 1 (CRHR1) antagonist, used for the treatment of anxiety and depression.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Dobutamine hydrochloride

Cat. No.: HY-15746

Dobutamine hydrochloride is a synthetic catecholamine that acts on **α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors)**. Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR.



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Dopexamine hydrochloride

(FPL60278AR)

Cat. No.: HY-U00205

Dopexamine hydrochloride is a **β2 adrenergic receptor** agonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Doxazosin

(UK 33274)

Cat. No.: HY-B0098

Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic **α1-adrenergic receptors**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Doxazosin D8

(UK 33274 D8)

Cat. No.: HY-B0098S

Doxazosin D8 (UK 33274 D8) is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1 adrenergic receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Doxazosin mesylate

(UK 33274 mesylate)

Cat. No.: HY-B0098A

Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic **α1-adrenergic receptors**.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Doxylamine D5 succinate

Cat. No.: HY-A0069S

Doxylamine D5 succinate is deuterium labeled Doxylamine, which is a first generation antihistamine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Doxylamine succinate

Cat. No.: HY-A0069

Doxylamine (succinate) is a first generation antihistamine; can be used by itself as a short-term sedative and in combination with other drugs to provide night-time allergy and cold relief.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Doxylamine-d5

Cat. No.: HY-A0069AS

Doxylamine D5 is deuterium labeled Doxylamine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DPC-AJ1951

Cat. No.: HY-P1418

DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (**PTH**)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 in ex vivo and in vivo assays of bone resorption.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DPC-AJ1951 TFA

Cat. No.: HY-P1418A

DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (**PTH**)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 TFA in ex vivo and in vivo assays of bone resorption.

{Aib}V{Aib}EIQL{Nle}HQRAKY-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Drospirenone

(Dihydrospirorenone)

Cat. No.: HY-B0111

Drospirenone(Dihydrospirorenone) is a synthetic progestin that is an analog to spironolactone.



Purity: 98.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Drospirenone-d4

Cat. No.: HY-B0111S

Drospirenone-d4 (Dihydrospirorenone-d4) is the deuterium labeled Drospirenone. Drospirenone (Dihydrospirorenone) is a synthetic progestin that is an analog to spironolactone.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

DS08210767

Cat. No.: HY-125879

DS08210767 is a highly potent, orally bioavailable **PTHR1** antagonist with IC_{50} of 90 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DY131

(GSK 9089)

Cat. No.: HY-15483

DY131 (GSK 9089) is a potent and selective **ERRγ** and **ERRβ** agonist. DY131displays inactive against ERRα, ERα and ERβ. DY131 also inhibits **Smo** signaling.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Dydrogesterone

Cat. No.: HY-B0257A

Dydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Dydrogesterone-D6

Cat. No.: HY-B0257AS

Dydrogesterone-D6 is the deuterium labeled Dydrogesterone. Dydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

d[Cha4]-AVP

Cat. No.: HY-P1390

d[Cha4]-AVP is a potent and selective **vasopressin (AVP) V1b receptor** agonist with a K_i of 1.2 nM for **human V1b receptor**. d[Cha4]-AVP shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors.

{Mpa}YF{Cha}NCPRG-NH_2
(Disulfide bridge:Mpa_1-Cys_6)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

d[Cha4]-AVP TFA

Cat. No.: HY-P1390A

d[Cha4]-AVP TFA is a potent and selective **vasopressin (AVP) V1b receptor** agonist with a K_i of 1.2 nM for **human V1b receptor**. d[Cha4]-AVP TFA shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors.

{Mpa}YF{Cha}NCPRG-NH_2
(Disulfide bridge:Mpa_1-Cys_6) (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E6130

Cat. No.: HY-107456

E6130 is an orally active and highly selective **CX3CR1** modulator, that may be effective for treatment of inflammatory bowel disease.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

E7046

Cat. No.: HY-103088

E7046 is an orally bioavailable and specific **EP4** antagonist, with IC_{50} of 13.5 nM and K_i of 23.14 nM. E7046 exhibits anti-tumor activities.



Purity: 99.68%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Ebastine

(LAS-W 090; RP64305)

Cat. No.: HY-B0674

Ebastine (LAS-W 090) is an orally active, second-generation **histamine H1 receptor** antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ebastine-d5

Cat. No.: HY-B0674S

Ebastine-d5 (LAS-W 090-d5) is the deuterium labeled Ebastine. Ebastine (LAS-W 090) is an orally active, second-generation **histamine H1 receptor** antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Ebopiprant

(OBE022)

Cat. No.: HY-112284

Ebopiprant (OBE022) is an oral and selective prostaglandin $F_{2\alpha}$ (**$PGF_{2\alpha}$**) receptor antagonist, with K_is of 1 nM, 26 nM for human and rat FP receptors, respectively.



Purity: 98.73%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ebrotidine

(FI3542)

Cat. No.: HY-15538

Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ecastolol

Cat. No.: HY-101691

Ecastolol is a **beta adrenergic receptor** antagonist, with antianginal activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Elagolix sodium

(NBI-56418 sodium)

Cat. No.: HY-14369

Elagolix sodium is a human **GnRH receptor** (**GnRHR**) antagonist with an IC_{50} and K_i of 0.25 and 3.7 nM, respectively.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Elisartan

(HN 65021)

Cat. No.: HY-19214

Elisartan is an orally active non-peptide pro-drug of **angiotensin II AT1 receptor** antagonist HN-12206, and shows anti-hypertension activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ELN-441958

Cat. No.: HY-15043

ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Emicerfont

(GW876008)

Cat. No.: HY-14367

Emicerfont is a corticotropin-releasing factor type 1 (**CRF_1**) receptor antagonist with an IC_{50} of 66 nM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Endothelin 1 (swine, human)

Cat. No.: HY-P0202

Endothelin 1 (swine, human) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 acts through two types of receptors ET_A and ET_B.



Purity: 96.35%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

EP1-antagonist-1

Cat. No.: HY-101695

EP1-antagonist-1 is a **EP1** antagonist with a pK_i of 7.54 and an pIC_{50} of 8.5.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epanolol

(Visacor; ICI141292)

Cat. No.: HY-U00183

Epanolol (Visacor; ICI141292) is a potent **β-adrenoceptor** partial agonist with a greater affinity for **β1**- than β2-adrenoceptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epanolol-d5

Cat. No.: HY-U00183S

Epanolol-d5 (Visacor-d5) is the deuterium labeled Epanolol. Epanolol (Visacor) is a potent **β-adrenoceptor** partial agonist with a greater affinity for **β1**- than β2-adrenoceptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Epelsiban

(GSK 557296)

Cat. No.: HY-105018

Epelsiban (GSK 557296) is a potent, selective and orally bioavailable **oxytocin receptor** antagonist, with a pK_i of 9.9 for human oxytocin receptor.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Epibetulinic acid

Cat. No.: HY-N0223

Epibetulinic acid exhibits potent inhibitory effects on **NO** and prostaglandin E2 (**PGE2**) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with IC_{50}s of 0.7 and 0.6 μM, respectively. Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epinastine

(WAL801)

Cat. No.: HY-B0640

Epinastine (WAL801) is an antihistamine and mast cell stabilizer. Epinastine is a potent, selective and orally-active **histamine H1 receptor** antagonist. Epinastine also inhibits IL-8 release and has an antiallergic action.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Epinastine hydrochloride

(WAL801 hydrochloride)

Cat. No.: HY-B0640A

Epinastine hydrochloride (WAL801 hydrochloride) is an antihistamine and mast cell stabilizer. Epinastine hydrochloride is a potent, selective and orally-active **histamine H1 receptor** antagonist. Epinastine hydrochloride also inhibits IL-8 release and has an antiallergic action.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Eprosartan mesylate

(SKF-108566J)

Cat. No.: HY-15834A

Eprosartan mesylate (SKF-108566J) is a selective, competitive, nonpeptid and orally active **angiotensin II receptor** antagonist, used as an antihypertensive.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Eprotirome

(KB2115)

Cat. No.: HY-10473

Eprotirome (KB2115) is a liver-selective **thyroid hormone receptor (TR)** agonist. KB2115 has modestly higher affinity for **TRβ** than for **TRα**. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research.



Purity: 99.77%
Clinical Data: Phase 3
Size: 1 mg

Equilin

(7-Dehydroestrone) Cat. No.: HY-B1176

Equilin (7-Dehydroestrone) is an important member of the large group of oestrogenic substances and is chemically related to menformon (oestrone). Equilin increases the growth of cortical neurons via an NMDA receptor-dependent mechanism.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Esmolol hydrochloride

Cat. No.: HY-B1392

Esmolol hydrochloride is a beta adrenergic receptor blocker.



Purity: 99.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Esmolol-d7 hydrochloride

Cat. No.: HY-B1392S

Esmolol-d7 hydrochloride is the deuterium labeled Esmolol hydrochloride. Esmolol hydrochloride is a beta adrenergic receptor blocker.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Esomeprazole magnesium

((S)-Omeprazole magnesium; (-)-Omeprazole magnesium) Cat. No.: HY-B1446

Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active **H⁺, K⁺-ATPase** inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

Cat. No.: HY-17021A

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the **H⁺, K⁺-ATPase** in gastric parietal cells.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate)

Cat. No.: HY-17022

Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active **H⁺, K⁺-ATPase** inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research.



Purity: ≥95.0%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg

Esomeprazole potassium salt ((S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

Cat. No.: HY-17021B

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the **H⁺, K⁺-ATPase** in gastric parietal cells.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Esomeprazole sodium

((S)-Omeprazole sodium; (-)-Omeprazole sodium) Cat. No.: HY-17023

Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active **proton pump** inhibitor. Esomeprazole reduces acid secretion through inhibition of the **H⁺, K⁺-ATPase** in gastric parietal cells.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 250 mg

Estradiol

(β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol) Cat. No.: HY-B0141

Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Estradiol (cypionate)

Cat. No.: HY-B1100

Estradiol cypionate is a 17 β-cyclopentylpropinate ester of estradiol, inhibits ET-1 synthesis via estrogen receptor IC50 value: Target: estrogen receptor Estradiol cypionate is a synthetic ester, is a estrogen.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Estradiol benzoate

(β-Estradiol 3-benzoate; 17β-Estradiol 3-benzoate) Cat. No.: HY-B1192

Estradiol Benzoate (β-Estradiol 3-benzoate), a prodrug of estradiol, acts as a steroid sex hormone. It exhibits mild anabolic and metabolic properties, and increases blood coagulability.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Estradiol dipropionate

Cat. No.: HY-B2245

Estradiol dipropionate is a combined estrogen-progesterone, acts as an **estrogen** and **progesterone** agonist.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Estradiol valerianate

(β-Estradiol 17-valerate) Cat. No.: HY-B0672

Estradiol valerianate (β-estradiol 17-valerate) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy drugs.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Estradiol-d4

(β-Estradiol-d4; 17β-Estradiol-d4; 17β-Oestradiol-d4) Cat. No.: HY-B0141S1

Estradiol-D4 (β-Estradiol-D4) is the deuterium labeled Estradiol. Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Estramustine phosphate sodium

Cat. No.: HY-13627

Estramustine phosphate sodium, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate sodium depolymerises **microtubules** by binding to microtubule associated proteins (MAPs) and/or to tubulin.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Estrogen receptor modulator 6

Cat. No.: HY-138690

Estrogen receptor modulator 6 (compound 3a) is a selective **estrogen receptor (ER) β** agonist (K_i=0.44 nM). Estrogen receptor modulator 6 displays 19-fold selectivity for ERβ over ERα(K_i=8.4 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Estrone

(E1; Oestrone) Cat. No.: HY-B0234

Estrone (E1) is a natural estrogenic hormone. Estrone is the main representative of the endogenous estrogens and is produced by several tissues, especially adipose tissue. Estrone is the result of the process of aromatization of androstenedione that occurs in fat cells.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Estrone sulfate potassium

Cat. No.: HY-113293A

Estrone sulfate potassium is a natural endogenous steroid and is an estrogen ester and conjugate.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Estropipate (Piperazine estrone sulfate; Estrone sulfate piperazine salt)

Cat. No.: HY-B1361

Estropipate is a form of estrogen, used to treat symptoms of menopause, also used to prevent osteoporosis.



Purity: 99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Etelcalcetide

(AMG 416; KAI-4169) Cat. No.: HY-P1955

Etelcalcetide (AMG 416) is a synthetic peptide as an activator of the **calcium sensing receptor (CaSR)**. Etelcalcetide is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Etelcalcetide hydrochloride

(AMG 416 hydrochloride; KAI-4169 hydrochloride) Cat. No.: HY-P1955A

Etelcalcetide hydrochloride (AMG 416 hydrochloride) is a synthetic peptide as an activator of the **calcium sensing receptor (CaSR)**.



Purity: 99.31%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Etersalate

(Eterylate; Etherylate) Cat. No.: HY-101606

Etersalate inhibits platelet function and decreases **thromboxane A2** (**TXA2**) levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethamsylate

Cat. No.: HY-B1074

Ethamsylate is a haemostatic drug, also inhibits biosynthesis and action of those prostaglandins.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ethynodiol diacetate

(Ethynodiol acetate) Cat. No.: HY-B1089

Ethynodiol diacetate (Ethynodiol acetate) is a steroidal progestin which is used as a hormonal contraceptive, it has relatively little or no potency as an androgen,has significant estrogenic effects.



Purity: 98.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Ethynyl Estradiol

(17α-Ethynylestradiol; Ethynylestradiol) Cat. No.: HY-B0216

Ethynyl Estradiol (17α-Ethynylestradiol;Ethynylestradiol) is an orally bio-active estrogen used in almost all modern formulations of combined oral contraceptive pills.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Eurycomanone

(Pasakbumin A) Cat. No.: HY-N5012

Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Evatanepag

(CP-533536 free acid) Cat. No.: HY-14839

Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. IC50 value: 0.3 nM (EC50) Target PGE2 in vitro: CP-533536 is a potent and selective EP2agonist.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Exemestane

(FCE 24304; EXE) Cat. No.: HY-13632

Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal **aromatase** inhibitor with IC_{50}s of 30 nM and 40 nM for **human placenta**l and **rat ovarian aromatase**, respectively. Exemestane can be used for hormone-dependent breast cancer research.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Exemestane-D2

(FCE 24304-D2; EXE-D2) Cat. No.: HY-13632S

Exemestane-D2 (FCE 24304-D2) is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal **aromatase** inhibitor with IC_{50}s of 30 nM and 40 nM for **human placenta**l and **rat ovarian aromatase**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Falintolol, (Z)-

Cat. No.: HY-U00283

Falintolol, (Z)-, a new **β-adrenergic** antagonist, is characterized by the presence of an oxime function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Famotidine

(MK-208) Cat. No.: HY-B0377

Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Fenipentol

(1-Phenyl-1-pentanol) Cat. No.: HY-B1273

Fenipentol (1-Phenyl-1-pentanol), a synthetic derivative of an ingredient of Curcuma longa that is used as a condiment and dye.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

Fenmetozole Tosylate

Cat. No.: HY-U00402

Fenmetozole Tosylate is an antagonist of the actions of ethanol, also antagonizes **α2-adrenergic receptor**, and acts as an antidepressant drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fenoterol

(Th-1165; Phenoterol) Cat. No.: HY-B0976

Fenoterol (Th-1165), a sympathomimetic agent, is a selective and orally active **β2-adrenoceptor** agonist. Fenoterol is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fenoterol hydrobromide

(Th-1165a; Phenoterol hydrobromide) Cat. No.: HY-B0976A

Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active **β2-adrenoceptor** agonist.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fenoterol-d6 hydrobromide

Cat. No.: HY-B0976AS

Fenoterol-d6 hydrobromide (Th-1165a-d6) is the deuterium labeled Fenoterol hydrobromide. Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active **β2-adrenoceptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Fenspiride hydrochloride

Cat. No.: HY-A0027

Fenspiride hydrochloride is an α adrenergic and H1 histamine receptor antagonist. IC50 value: Target: Adrenergic receptor; H1 receptor Fenspiride hydrochloride is a bronchodilator with anti-inflammatory properties.



Purity: 99.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fenspiride-d5 hydrochloride

Cat. No.: HY-A0027S

Fenspiride-d5 hydrochloride is the deuterium labeled Fenspiride hydrochloride. Fenspiride hydrochloride is an α adrenergic and H1 histamine receptor antagonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Fevipiprant

(QAW039; NVP-QAW039) Cat. No.: HY-16768

Fevipiprant (QAW039; NVP-QAW039) is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood.



Purity: 99.63%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Fexofenadine hydrochloride (MDL-16455 hydrochloride; Terfenadine carboxylate hydrochloride)

Cat. No.: HY-B0801A

Fexofenadine hydrochloride (MDL-16455 hydrochloride), a **H1R** antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial (person aged ≥16 years).



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Fexofenadine-d6

(MDL-16455-d6; Terfenadine carboxylate-d6) Cat. No.: HY-B0801S

Fexofenadine D6 (MDL-16455 D6) is deuterium labeled is Fexofenadine, which is an antihistamine pharmaceutical agent.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fezolinetant

(ESN-364) Cat. No.: HY-19632

Fezolinetant is an antagonist of the **neurokinin 3 receptor (NK3R)**, used for the treatment of menopausal hot flushes.



Purity: 98.16%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fiduxosin

Cat. No.: HY-U00399

Fiduxosin is a potent **α1-adrenoceptor** antagonist, with K_i of 0.160 nM, 24.9 nM, and 0.920 nM for α1a-, α1b-, and α1d-adrenoceptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Filorexant

(MK-6096) Cat. No.: HY-15653

Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding).



Purity: 99.35%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fimasartan

(BR-A-657) Cat. No.: HY-B0780

Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.



Purity: 98.04%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Flemiphilippinin A

Cat. No.: HY-N4316

Flemiphilippinin A is a prenylated isoflavone isolated from Flemingia philippinensis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Flunisolide

Cat. No.: HY-B1121

Flunisolide is a corticosteroid often used to treat allergic rhinitis.The principal mechanism of action of Flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action.



Purity: 99.92%
Clinical Data: Launched
Size: 100 mg

Fluocinolone (Acetonide)

Cat. No.: HY-B0415

Fluocinolone Acetonide is a glucocorticoid derivative used topically in the treatment of various skin disorders. Target: Glucocorticoid Receptor Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching.



Purity: 99.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Fluocinonide

Cat. No.: HY-B0485

Fluocinonide (Vanos) is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Fluticasone (propionate)

Cat. No.: HY-B0154

Fluticasone propionate, a potent topical anti-inflammatory corticosteroid, is a selective **glucocorticoid receptor** agonist, with an absolute affinity (K_D) of 0.5 nM. Fluticasone propionate shows little or no activity at other steroid receptors. Anti-viral activity.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Forskolin

(Coleonol; Colforsin) Cat. No.: HY-15371

Forskolin (Coleonol) is a potent **adenylate cyclase** activator with an IC_{50} of 41 nM and an EC_{50} of 0.5 μM for **type I adenylyl cyclase**. Forskolin is also an inducer of intracellular **cAMP** formation.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Fosaprepitant

(L-758298) Cat. No.: HY-14407

Fosaprepitant (L-785298) is a prodrug of Aprepitant (HY-10052). Fosaprepitant is a **neurokinin-1 receptor** antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fosaprepitant dimeglumine

(MK-0517; L785298) Cat. No.: HY-14407A

Fosaprepitant dimeglumine (MK-0517) is a prodrug of Aprepitant (HY-10052). Fosaprepitant dimeglumine is a **neurokinin-1 receptor** antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV).



Purity: 98.05%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Fosdagrocorat

(PF-04171327) Cat. No.: HY-16722

Fosdagrocorat (PF-04171327) is a dissociated **glucocorticoid receptor** agonist.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FR 167653

(FR 167653 sulfate) Cat. No.: HY-18754A

FR 167653 (FR 167653 sulfate), an orally active and selective **p38 MAPK** inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FR 167653 free base

Cat. No.: HY-18754

FR 167653 free base, an orally active and selective **p38 MAPK** inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FR167344 free base

Cat. No.: HY-100301

FR167344 free base is an orally active, nonpeptide **bradykinin receptor B2** antagonist. FR167344 free base shows a high affinity binding to the B2 receptor with an IC_{50} value of 65 nM and no binding affinity for the B1 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FR252384

Cat. No.: HY-U00335

FR252384 is a **neuropeptide Y-Y5 receptor** antagonist, with an IC_{50} of 2.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FRG8701

Cat. No.: HY-U00238

FRG-8701 is a new **Histamine H_2-receptor** antagonist with an IC_{50} of ranging from 0.25 to 0.43 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Furprofen

Cat. No.: HY-106907

Furprofen is an non-steroidal anti-inflammatory drug (NSAID) with analgesic properties. Furprofen acts via the inhibition of **prostaglandin (PGE) synthesis**. Furprofen can be treated orally for the relief of pain.



Purity: 99.85%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fuscoside
(OPC-21268)

Cat. No.: HY-15009

Fuscoside (OPC-21268) is an orally effective, nonpeptide, **vasopressin V1** receptor antagonist with an IC_{50} of 0.4 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

G-Protein antagonist peptide

Cat. No.: HY-P1376

G-Protein antagonist peptide is the substance P-related peptide that inhibits binding of G proteins to their receptors. G-Protein antagonist peptide competitively and reversibly inhibits **M2 muscarinic receptor** activation of G_i or G_o and inhibits G_s activation by β-adrenoceptors.

{Glp}QWFWWM-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G-Protein antagonist peptide TFA

Cat. No.: HY-P1376A

G-Protein antagonist peptide TFA is a truncated substance P-related peptide, competes with receptor for G protein binding.

{Glp}QWFWWM-NH_2 (TFA salt)

Purity: 97.35%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Galanin (1-16), mouse, porcine, rat

Cat. No.: HY-P1578

Galanin (1-16), mouse, porcine, rat is an agonist of the hippocampal **galanin receptor**, with a K_d of 3 nM.

GWTLNSAGYLLGPHAI

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Galanin (1-16), mouse, porcine, rat TFA

Cat. No.: HY-P1578A

Galanin (1-16), mouse, porcine, rat (TFA) is an agonist of the hippocampal **galanin receptor**, with a K_d of 3 nM.

GWTLNSAGYLLGPHAI (TFA salt)

Purity: 99.39%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Galanin (1-30), human

Cat. No.: HY-P1127

Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of **GalR1 and GalR2 receptors**, with K_is of both 1 nM.

GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS

Purity: 99.11%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Galanin Receptor Ligand M35

Cat. No.: HY-P1840

Galanin Receptor Ligand M35 is a high-affinity ligand and antagonist of **galanin receptor** (K_d=0.1 nM). Galanin Receptor Ligand M35 exerts a K_i values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.

GWTLNSAGYLLGPPPGFSPFR-NH_2

Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Galanin Receptor Ligand M35 TFA

Cat. No.: HY-P1840A

Galanin Receptor Ligand M35 TFA is a high-affinity ligand and antagonist of **galanin receptor** (K_d=0.1 nM). Galanin Receptor Ligand M35 TFA exerts a K_i values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.

GWTLNSAGYLLGPPPGFSPFR-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Galantide

Cat. No.: HY-P0262

Galantide, a non-specific **galanin receptor** antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus.

GWTLNSAGYLLGPQQFFGLM-NH_2

Purity: 99.27%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Ganoderlactone D

Cat. No.: HY-N3503

Ganoderlactone D shows inhibitory effects of yeast α-Glucosidase with IC_{50} values of 41.7 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gastrin I (1-14), human

Cat. No.: HY-P1806

Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion.

{Glp}-GPWLEEEEEAYGW

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gastrin I (1-14), human TFA

Cat. No.: HY-P1806A

Gastrin I (1-14), human TFA is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion.

{Glp}-GPWLEEEEEAYGW (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gastrin I, human

Cat. No.: HY-P1097

Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via **cholecystokinin 2 (CCK2)** receptor.

pE-GPWLEEEEEAYGWMDF-NH_2

Purity: 99.93%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gastrin I, rat

(Rat Gastrin-17)

Cat. No.: HY-P2416

Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently.

Pyr-RPPMEEEEEAYGWMDF-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gastrin/CCK antagonist 1

Cat. No.: HY-U00375

Gastrin/CCK antagonist 1 is an antagonist of **gastrin/CCK**, used for the research of gastrointestinal disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Genistein 7,4'-di-O-β-D-glucoside

Cat. No.: HY-N5103

Genistein 7,4'-di-O-β-D-glucoside is a natural product with significantly estrogenic proliferative effect in MCF-7 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gestodene

(SHB 331; WL 70)

Cat. No.: HY-B0110

Gestodene(SHB 331;WL 70) is a progestogen hormonal contraceptive. Target: Estrogen Receptor/ERR Gestodene is androgenically neutral, meaning that contraceptive pills containing gestodene do not exhibit the androgenic side effects (e.g.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Gestodene-d6

(SHB 331-d6; WL 70-d6)

Cat. No.: HY-B0110S

Gestodene-d6 (SHB 331-d6) is the deuterium labeled Gestodene. Gestodene(SHB 331) is a progestogen hormonal contraceptive.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GI 181771

Cat. No.: HY-11076

GI 181771 is a **cholecystokinin 1** receptor agonist investigated for the treatment of obesity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rg5

Cat. No.: HY-N0908

Ginsenoside Rg5 is the main component of Red ginseng. Ginsenoside blocks binding of **IGF-1** to its receptor with an **IC_{50}** of ~90 nM. Ginsenoside Rg5 also inhibits the mRNA expression of **COX-2** via suppression of the DNA binding activities of **NF-κB p65**.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V)

Cat. No.: HY-N0607

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a **Ca^{2+}**-antagonistic antiplatelet effect with an IC_{50} of 155 μM. Ginsenoside Ro reduces the production of **TXA_2** more than it reduces the activities of COX-1 and TXAS.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glucocorticoid receptor agonist

Cat. No.: HY-14234

Glucocorticoid receptor agonist is a potent Glucocorticoid receptor agonist. IC50 value: Target:.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GnRH antagonist 2

Cat. No.: HY-134864

GnRH antagonist 2 (formula I) is a **GnRH receptor** antagonist that can be used for endometriosis research.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GnRH-I

Cat. No.: HY-P0292

GnRH-I is a small 10 amino acid long peptide (decapeptide) from the hypothalamus, acts at the hypophysis to cause an increase in release of biologically active Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in the blood.

Pyr-HWSYGLRPG-NH_2

Purity: 99.93%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Goserelin (ICI 118630)

Cat. No.: HY-13673

Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a **GnRH** agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Goserelin acetate (ICI-118630 acetate)

Cat. No.: HY-13673A

Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a **GnRH** agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GPR30 agonist-1

Cat. No.: HY-138686

GPR30 agonist-1 is a **G protein-coupled receptor 30 (GPR30)** agonist. GPR30 agonist-1 exerts vasorelaxant effects.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GPR35 agonist 1

Cat. No.: HY-101033

GPR35 agonist 1 (compound 50) is a potent and specific **G protein-coupled receptor-35 (GPR35)/CXCR8** agonist with an EC_{50} of 5.8 nM, displays good druggability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GR 159897

Cat. No.: HY-107691

GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide **neurokinin 2 (NK_2) receptor** antagonist. GR 159897 has little or no affinity for NK_1 and NK_3 receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GR-73632

Cat. No.: HY-P1192

GR-73632 is a novel tachykinin neurokinin 1 (**NK-1**) receptor agonist. GR-73632 acts directly on the peripheral terminals of primary sensory neurons through NK1 receptor which convey itch signals.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gramine

(Donaxine) Cat. No.: HY-N0166

Gramine (Donaxine) is a natural alkaloid isolated from giant reed, acts as an active **adiponectin receptor (AdipoR)** agonist, with **IC_{50}**s of 3.2 and 4.2 μM for AdipoR2 and AdipoR1, respectively. Gramine is also a human and mouse **β2-Adrenergic receptor (β2-AR)** agonist.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Grapiprant

(CJ-023423; RQ-00000007; AAT-007) Cat. No.: HY-16781

Grapiprant (CJ-023423) is a selective **EP4 receptor** antagonist whose physiological ligand is prostaglandin E_2 (PGE_2). Grapiprant displaces [^{3}H]-PGE_2 (1 nM) binding to dog recombinant **EP4 receptor** with **IC_{50}** value of 35 nM and **K_i** value of 24 nM.



Purity: 99.45%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GSK-269984A

Cat. No.: HY-14467

GSK-269984A is a **Prostaglandin E2 Receptor 1 (EP1)** antagonist with a **pIC_{50}** of 7.9.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK1059865

Cat. No.: HY-101534

GSK1059865 is a potent **orexin 1 receptor** antagonist.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK1838705A

Cat. No.: HY-13020

GSK1838705A is a potent and reversible **IGF-IR** and the **insulin receptor** inhibitor with **IC_{50}**s of 2.0 and 1.6 nM, respectively. It also inhibits **ALK** with an **IC_{50}** of 0.5 nM.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK189254A

(GSK189254) Cat. No.: HY-14111

GSK189254A (GSK189254) is a novel, potent and selective histamine **H3** receptor antagonist with **pK_i** values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK1904529A

Cat. No.: HY-10524

GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of **insulin-like growth factor-1 receptor (IGF-1R)** and **insulin receptor (IR)**, with **IC_{50}**s of 27 and 25 nM, respectively.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GSK2239633A

Cat. No.: HY-100183

GSK2239633A is a CC-chemokine receptor 4 (**CCR4**) antagonist, which inhibits the binding of [^{125}I]-TARC to human CCR4 with a **pIC_{50}** of 7.96±0.11.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

GSK583

Cat. No.: HY-100339

GSK583 is a highly potent, orally active and selective inhibitor of **RIP2 Kinase**, with **IC_{50}** of 5 nM. GSK583 inhibits both TNF-α and IL-6 production with an IC_{50} value of 200 nM.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK726701A

Cat. No.: HY-112152

GSK726701A is a novel **prostaglandin E2 receptor 4 (EP4)** partial agonist with a **pEC_{50}** of 7.4.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK9027

Cat. No.: HY-103548

GSK9027, as a non-steroidal glucocorticoid receptor (**GR**) agonist, behaves as a partial agonist on the 2×glucocorticoid response element (GRE) reporter system, and achieves intrinsic activities relative to dexamethasone.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guanabenz Acetate

(BR-750; Wy8678 acetate)

Cat. No.: HY-B0566

Guanabenz (Acetate) (BR-750) is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.



Purity: 98.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Guanfacine

Cat. No.: HY-17416A

Guanfacine is a selective α2A receptor agonist. Target: α2A Receptor Guanfacine is a sympatholytic. It is a selective α2A receptor agonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Guanfacine hydrochloride

Cat. No.: HY-17416

Guanfacine hydrochloride, an anti-hypertensive agent, is a selective α2A-adrenoceptor agonist with Kd of 31 nM and displays 60-fold selectivity over α2B-adrenoceptors. IC50 Value: 31 nM(Kd) Target: Adrenergic Receptor Guanfacine is a sympatholytic.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Guanoxabenz

(Hydroxyguanabenz)

Cat. No.: HY-U00123

Guanoxabenz is an **α2 adrenergic receptor** agonist, with a K_i of 4000 nM and the fully activated form 40 nM for an α2A adrenoceptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guanylin(human)

Cat. No.: HY-P1179

Guanylin(human), a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW 766994

(GW 994)

Cat. No.: HY-107051

GW 766994 (GW 994) is an orally active and specific **chemokine receptor-3 (CCR3)** antagonist. GW 766994 has the potential for asthma and eosinophilic bronchitis research.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW-870086

Cat. No.: HY-103662

GW-870086 is a potent anti-inflammatory agent, acting as a **glucocorticoid receptor** agonist, with a **pIC_{50}** of 10.1 in A549 cells expressing NF-κB.



Purity: 98.00%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW627368

Cat. No.: HY-16963

GW627368 (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid **EP4** receptor with additional human **TP** receptor affinity, with **pK_i** values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

H-Val-Pro-Pro-OH

Cat. No.: HY-114161

H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme **(ACE)**, with an **IC_{50}** of 9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

H-Val-Pro-Pro-OH TFA

Cat. No.: HY-114161A

H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (**ACE**), with an IC_{50} of 9 μM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

H3 receptor-MO-1

Cat. No.: HY-U00339

H3 receptor-MO-1 is a modulator of **histamine H3 receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

H3R-IN-1 Hydrochloride

Cat. No.: HY-112219A

H3R-IN-1 Hydrochloride is a **histamine receptor 3** (**H3R**) inverse agonist extracted from patent WO2013107336A1, compound example 2.



Purity: 95.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

H4 Receptor antagonist 1

Cat. No.: HY-114025

H4 Receptor antagonist 1 is a potent and selective **histamine H4 receptor** inverse agonist, with an IC_{50} of 19 nM.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

H4R antagonist 1

Cat. No.: HY-111501

H4R antagonist 1 is a potent and highly selective **histamine H4 receptor** (**H4R**) antagonist with an IC_{50} of 27 nM. H4R antagonist 1 does not show any noticeable binding affinity to other subtypes of histamine receptors, H1R, H2R, and H3R.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hemokinin 1 (mouse)

Cat. No.: HY-P1030

Hemokinin 1 (mouse) is a selective agonist of **neurokinin-1 receptor**, with K_i of 0.175 nM and 560 nM for human NK1 receptor and human NK2 receptor, respectively.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Hexestrol

Cat. No.: HY-B1662

Hexestrol is a nonsteroidal synthetic estrogen, with a K_i of 0.06 and 0.06 nM for **estrogen receptor alpha (ERα)** and **ERβ**. Hexestrol can be used for the research of the diseases caused by estrogen deficiencym, and it also can increase the weight of cattle.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Higenamine

(Norcoclaurine)

Cat. No.: HY-N2037

Higenamine (Norcoclaurine), a β2-AR agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine (Norcoclaurine) has anti-apoptotic effects.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 20 mg

Higenamine hydrochloride

(Norcoclaurine hydrochloride)

Cat. No.: HY-N2037A

Higenamine hydrochloride (Norcoclaurine hydrochloride), a **β2-AR** agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Histamine

(Ergamine)

Cat. No.: HY-B1204

Histamine is an organic nitrogenous compound involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Histamine phosphate

(Histamine diphosphate) **Cat. No.:** HY-A0129

Histamine (phosphate) diphosphate is a potent agonist of histamine receptors and vasodilator. It can activate nitric oxide synthetase.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

HOKU-81

(4-Hydroxytulobuterol) **Cat. No.:** HY-50291

HOKU-81 (4-Hydroxytulobuterol) is one of the metabolites of Tulobuterol (HY-B1810). HOKU-81 is a potent and selective **β2-adrenoceptor** stimulant. HOKU-81 has bronchodilating effect.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 25 mg

Homo Sildenafil

Cat. No.: HY-131100

Homo Sildenafil, an analog of Sildenafil, acts as a **phosphodiesterase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Homo Sildenafil-d5

Cat. No.: HY-131100S

Homo Sildenafil-d5 is the deuterium labeled Homo Sildenafil. Homo Sildenafil, an analog of Sildenafil, acts as a **phosphodiesterase** inhibitor.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

HT-2157

(SNAP 37889) **Cat. No.:** HY-100717

HT-2157 (SNAP 37889) is a selective, high-affinity, competitive antagonists of **galanin-3 receptor** (**Gal_3**).



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Human growth hormone-releasing factor

(Growth Hormone Releasing Factor human) **Cat. No.:** HY-P0089

Human growth hormone-releasing factor (Growth Hormone Releasing Factor human) is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Human growth hormone-releasing factor TFA

(Growth Hormone Releasing Factor human TFA) **Cat. No.:** HY-P0089A

Human growth hormone-releasing factor TFA (Growth Hormone Releasing Factor human TFA) is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary.

Purity: 98.22%
Clinical Data: No Development Reported
Size: 5 mg

Hydrocortisone

(Cortisol) **Cat. No.:** HY-N0583

Hydrocortisone (Cortisol) is a steroid hormone or glucocorticoid secreted by the adrenal cortex.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Hydrocortisone 17-butyrate

(Cortisol 17-butyrate; Hydrocortisone butyrate) **Cat. No.:** HY-B0983

Hydrocortisone 17-butyrate is an adrenocortico hormone.



Purity: 99.93%
Clinical Data: Launched
Size: 100 mg

Hydrocortisone acetate

(Hydrocortisone 21-acetate; Cortisol 21-acetate) **Cat. No.:** HY-B1183

Hydrocortisone acetate is a corticosteroid, used to decrease swelling, itching, and pain that is caused by minor skin irritations or by hemorrhoids.



Purity: 99.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Hydrocortisone cypionate

Cat. No.: HY-U00089

Hydrocortisone cypionate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Hydrocortisone hemisuccinate

(Hydrocortisone 21-hemisuccinate)

Cat. No.: HY-B1402

Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid, is an orally active steroidal anti-inflammatory drug (SAID).



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Hydrocortisone phosphate

(Hydrocortisone 21-phosphate; Cortisol 21-phosphate)

Cat. No.: HY-B1155

Hydrocortisone phosphate (Hydrocortisone 21-phosphate), a physiological glucocorticoid, and is an orally active steroidal anti-inflammatory drug (SAID).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Hydroxyzine

Cat. No.: HY-B0548

Hydroxyzine, a benzodiazepine **antihistamine** agent, acts as an orally active **histamine H1-receptor** and serotonin antagonist. Hydroxyzine has anxiolytic effect and can be used for the research of generalised anxiety disorder.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Hydroxyzine D4

Cat. No.: HY-B0548S

Hydroxyzine D4 is deuterium labeled Hydroxyzine. Hydroxyzine is a heterocyclic **histamine H1-receptor** antagonist. Hydroxyzine has anticholinergic, anxiolytic and analgesic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxyzine D4 dihydrochloride

Cat. No.: HY-B0548AS

Hydroxyzine D4 dihydrochloride is deuterium labeled Hydroxyzine. Hydroxyzine is a heterocyclic **histamine H1-receptor** antagonist. Hydroxyzine has anticholinergic, anxiolytic and analgesic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxyzine D8

Cat. No.: HY-B0548S1

Hydroxyzine D8 is deuterium labeled Hydroxyzine. Hydroxyzine is a **histamine H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Hydroxyzine dihydrochloride

Cat. No.: HY-B0548A

Hydroxyzine dihydrochloride, a benzodiazepine **antihistamine** agent, acts as a orally active **histamine H1-receptor** and serotonin antagonist. Hydroxyzine dihydrochloride has anxiolytic effect and can be used forthe research of generalised anxiety disorder.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Hydroxyzine pamoate

Cat. No.: HY-B0895

Hydroxyzine pamoate is a histamine H1-receptor antagonist. Target: Histamine H1-Receptor Hydroxyzine inhibits carbachol (10 μM)-induced serotonin release by 34% at 10 μM, by 25% 1 μM and by 17% 0.1 μM in pretreated bladder slices for 60 min .



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Hydroxyzine-d8 Dihydrochloride

Cat. No.: HY-B0548AS2

Hydroxyzine-d8 Dihydrochloride is the deuterium labeled Hydroxyzine dihydrochloride. Hydroxyzine dihydrochloride, a benzodiazepine **antihistamine** agent, acts as a orally active **histamine H1-receptor** and serotonin antagonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Ibodutant

(MEN 15596) Cat. No.: HY-14770

Ibodutant (MEN 15596) is a potent and selective **tachykinin NK2 receptor** antagonist with a **pK_i** of 10.1.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Ibutamoren Mesylate

(MK-677; MK-0677) Cat. No.: HY-50844

Ibutamoren Mesylate (MK-677) is a potent, non-peptide **Growth hormone secretagogue receptor (GHSR)** agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue.



Purity: 98.42%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

Icatibant

(HOE 140) Cat. No.: HY-17446

Icatibant (HOE-140) is a potent and specific peptide antagonist of **bradykinin B2 receptor** with **IC_{50}** and **K_i** of 1.07 nM and 0.798 nM respectively.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

ICI 118,551 hydrochloride

(ICI 118551 hydrochloride) Cat. No.: HY-13951

ICI 118,551 (hydrochloride) is a highly selective **β2 adrenergic receptor** antagonist, with **K_i**s of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Idazoxan hydrochloride

(RX 781094 hydrochloride) Cat. No.: HY-14561A

Idazoxan hydrochloride (RX 781094 hydrochloride) is an **α_2-adrenoceptor** antagonist and is also a **imidazoline receptors (IRs)** antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like drugs (IMs).



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Iloprost

(Ciloprost; ZK 36374) Cat. No.: HY-A0096

Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2.



Purity: 99.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Iloprost-d4

Cat. No.: HY-A0096S

Iloprost-d4 (Ciloprost-d4) is the deuterium labeled Iloprost. Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 250 µg

Imnopitant

Cat. No.: HY-109147

Imnopitant is a NK1 receptor antagonist (WO2020132716, compound 1) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imoxiterol

(RP 58802B) Cat. No.: HY-101585

Imoxiterol (RP 58802B) is a **β-adrenergic** agonist.



Purity: 93.86%
Clinical Data: No Development Reported
Size: 1 mg

Impurity of Doxercalciferol

Cat. No.: HY-76937

Impurity of Doxercalciferol is an impurity of doxercalciferol, which is a synthetic analog of ergocalciferol (vitamin D2), used as a drug for secondary hyperparathyroidism and metabolic bone disease, and it suppresses parathyroid synthesis and secretion.



Purity: 96.08%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

INCB 3284

Cat. No.: HY-15450A

INCB 3284 is a potent, selective and orally bioavailable human **CCR2** antagonist, inhibiting monocyte chemoattractant protein-1 binding to **hCCR2**, with an IC_{50} of 3.7 nM. INCB 3284 can be used in the research of acute liver failure.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

INCB 3284 dimesylate

Cat. No.: HY-15450

INCB 3284 dimesylate is a potent, selective and orally bioavailable human **CCR2** antagonist, inhibiting monocyte chemoattractant protein-1 binding to **hCCR2**, with an IC_{50} of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

INCB3344

Cat. No.: HY-50674

INCB3344 is a potent, selective and orally bioavailable **CCR2** antagonist with IC_{50} values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Indacaterol

Cat. No.: HY-14299

Indacaterol(Onbrez; Arcapta) is an ultra-long-acting β-adrenoceptor agonist. IC50 value: Target: β-adrenoceptor Indacaterol inhibits cAMP production in Chinese hamster ovary cells stably transfected with human β2 adrenoceptors with pEC50 of 8.06.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Indacaterol maleate

(QAB149)

Cat. No.: HY-14299A

Indacaterol (QAB149) maleate is an ultra-long-acting β-adrenoceptor agonist.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Indanidine

Cat. No.: HY-101717

Indanidine is an **alpha-adrenergic** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indirubin Derivative E804

Cat. No.: HY-18785

Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor **(IGF1R)**, with an IC_{50} of 0.65 μM for IGF1R.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Insulin (human)

Cat. No.: HY-P0035

Insulin (human) is a polypeptide hormone that regulates the level of glucose.

Insulin (human)

Purity: 96.90%
Clinical Data: Launched
Size: 25 mg, 50 mg, 100 mg

Insulin levels modulator

Cat. No.: HY-112819

Insulin levels modulator could be used to treat diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Insulin(cattle)

(Insulin from bovine pancreas)

Cat. No.: HY-P1156

Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

Insulin(cattle)

Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

INT-777

(S-EMCA) Cat. No.: HY-15677

INT-777 is a potent **TGR5** agonist with an EC_{50} of 0.82 μM.



Purity: 100.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Iopanoic acid

Cat. No.: HY-B1664

Iopanoic acid is an inhibitor of **5'-Deiodinase** and also an iodinated contrast medium.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

IPSU

Cat. No.: HY-13796

IPSU is a selective, orally available and brain penetrant **OX2R** antagonist with a pK_i of 7.85.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Irbesartan

(SR-47436; BMS-186295) Cat. No.: HY-B0202

Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.



Purity: 98.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Irbesartan-d4

(SR-47436-d4; BMS-186295-d4) Cat. No.: HY-B0202S

Irbesartan D4 is the deuterium labeled Irbesartan, which is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 1 mg

IRL-1620

Cat. No.: HY-16465

IRL-1620 is a potent and selective **endothelin receptor type B (ETB)** agonist with a K_i of 16 pM.

{Suc}-DEEAVYFAHLDIIW

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IRL-1620 TFA

Cat. No.: HY-16465A

IRL-1620 (TFA) is a potent and selective **endothelin receptor type B (ETB)** agonist with a K_i of 16 pM.

{Suc}-DEEAVYFAHLDIIW (TFA salt)

Purity: 95.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 μg, 1 mg, 5 mg

Isoferulic acid

(3-Hydroxy-4-methoxycinnamic acid) Cat. No.: HY-N0761

Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is a cinnamic acid derivative that has antidiabetic activity. Isoferulic acid binds to and activates α1-adrenergic receptors (IC_{50}=1.4 μM) to enhance secretion of β-endorphin (EC_{50}=52.2 nM) and increase glucose use.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Isolithocholic acid (3β-Hydroxy-5β-cholanic acid; 3-Epilithocholic acid; β-Lithocholic acid)

Cat. No.: HY-B0172B

Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isoprenaline hydrochloride

(Isoproterenol hydrochloride) Cat. No.: HY-B0468

Isoprenaline hydrochloride is a non-selective **β-adrenergic receptor** agonist with potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 1 g

Isoxsuprine hydrochloride

Cat. No.: HY-B1270

Isoxsuprine hydrochloride is a **beta-adrenergic receptor** agonist with K_is of 13.65 μM and 3.48 μM for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a **NMDA receptor** antagonist.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg

IT1t

Cat. No.: HY-101458

IT1t is a potent **CXCR4** antagonist; inhibits CXCL12/CXCR4 interaction with an IC_{50} of 2.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IT1t dihydrochloride

Cat. No.: HY-101458A

IT1t dihydrochloride is a potent **CXCR4** antagonist; inhibits CXCL12/CXCR4 interaction with an IC_{50} of 2.1 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ivabradine hydrochloride

Cat. No.: HY-B0162A

Ivabradine hydrochloride is an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (**HCN**) channel blocker.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Ivabradine metabolite N-Demethyl Ivabradine hydrochloride

(N-Demethyl ivabradine hydrochloride)

Cat. No.: HY-12778

N-Demethyl Ivabradine Hcl is a metabolite of Ivabradine, which is a specific inhibitor of the funny channel.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ivabradine-d3 hydrochloride

Cat. No.: HY-B0162AS1

Ivabradine D3 Hydrochloride is the deuterium labeled Ivabradine hydrochloride. Ivabradine hydrochloride is a new I_f inhibitor with IC_{50} of 2.9 μM, and used as a pure heart rate lowering agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ivabradine-d6 hydrochloride

Cat. No.: HY-B0162AS

Ivabradine D6 hydrochloride is the deuterium labeled Ivabradine hydrochloride. Ivabradine hydrochloride is a new I_f inhibitor with IC_{50} of 2.9 μM, and used as a pure heart rate lowering agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ivacaftor

(VX-770)

Cat. No.: HY-13017

Ivacaftor (VX-770) is a potent and orally bioavailable **CFTR** potentiator, targeting G551D-CFTR and F508del-CFTR with EC_{50}s of 100 nM and 25 nM, respectively.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ivacaftor benzenesulfonate

(VX-770 benzenesulfonate)

Cat. No.: HY-13017A

Ivacaftor benzenesulfonate is an orally bioavailable **CFTR** potentiator, used for cystic fibrosis treatment.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ivacaftor hydrate

(VX-770 hydrate)

Cat. No.: HY-13017B

Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable **CFTR** potentiator, used for cystic fibrosis treatment.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ivaltinostat formic

(CG-200745 formic) Cat. No.: HY-16138A

Ivaltinostat (CG-200745) formic is an orally active, potent pan-**HDAC** inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

JMS-17-2

Cat. No.: HY-123918

JMS-17-2 is a potent and selective **CX3CR1** antagonist with an IC_{50} of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JMS-17-2 hydrochloride

Cat. No.: HY-123918A

JMS-17-2 hydrochloride is a potent and selective **CX3CR1** antagonist with an IC_{50} of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JMV 2959

Cat. No.: HY-U00433

JMV 2959 is a growth hormone secretagogue receptor type 1a (**GHS-R_{1a}**) antagonist with an IC_{50} of 32 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

JMV 2959 hydrochloride

Cat. No.: HY-U00433A

JMV 2959 hydrochloride is a growth hormone secretagogue receptor type 1a (**GHS-R_{1a}**) antagonist with an IC_{50} of 32±3 nM in LLC-PK_1 cells.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

JNJ-10229570

Cat. No.: HY-107139

JNJ-10229570 is an antagonist of **melanocortin receptor 1 (MC1R)** and **melanocortin receptor 5 (MC5R)**, which inhibits sebaceous gland differentiation and the production of sebum-specific lipids.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-31020028

Cat. No.: HY-14450

JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity (pIC50=8.07, human; pIC50=8.22 rat); >100-fold selective versus human Y1/Y4/Y5 receptors.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-39758979

Cat. No.: HY-101189

JNJ-39758979 is a selective, orally active, and high-affinity **histamine H_4 receptor** antagonist with K_is of 12.5, 5.3, and 25 nM for human, mouse, and monkey histamine H_4 receptor, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-5207852

Cat. No.: HY-12190

JNJ-5207852 is a selective and potent **histamine H_3** receptor (H_3R) antagonist, with **pK_is** of 8.9, 9.24 for rat and human H_3R, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-7777120

Cat. No.: HY-13508

JNJ-7777120 is a selective H4R antagonist with Ki of 4 ±1 nM, exhibits >1000-fold selectivity over the other histamin receptors.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JP1302 dihydrochloride

Cat. No.: HY-103213

JP1302 dihydrochloride is a selective, high affinity antagonist of the **alpha2C-adrenoceptor (α_{2C}-adrenoceptor)**, with a K_b value (antagonist activity) of 16 nM and a K_i (binding affinity) value of 28 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kaempferitrin

(Lespedin; Lespenephryl)

Cat. No.: HY-N0628

Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates **insulin** signaling pathway.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

KAG-308

Cat. No.: HY-128686

KAG-308 is a potent selective and orally active agonist of **EP4 receptor** (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Karacoline

Cat. No.: HY-N6812

Karacoline, a diterpene alkaloid found in the plant Aconitum kusnezoffii, reduces degradation of the extracellular matrix (ECM) in intervertebral disc degeneration (IDD) via the NF-κB signaling pathway.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Kassinin

Cat. No.: HY-P0250

Kassinin is a peptide derived from the Kassina frog. It belongs to tachykinin family of neuropeptides. It is secreted as a defense response, and is involved in neuropeptide signalling.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

KAT681

(T0681)

Cat. No.: HY-U00220

KAT681 is a liver-selective thyromimetic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketotifen fumarate

(HC 20511 fumarate)

Cat. No.: HY-B0157A

Ketotifen (HC 20511) fumarate is a second-generation noncompetitive **H1-antihistamine** and mast cell stabilizer, which is used to prevent asthma attacks.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Ketotifen-d3 fumarate

Cat. No.: HY-B0157AS

Ketotifen-d3 (HC 20511-d3) fumarate is the deuterium labeled Ketotifen fumarate. Ketotifen (HC 20511) fumarate is a second-generation noncompetitive **H1-antihistamine** and mast cell stabilizer, which is used to prevent asthma attacks.



Purity: >98%
Clinical Data:
Size: 5 mg, 50 mg

KF 13218

Cat. No.: HY-U00231

KF 13218 is a potent, selective and long lasting **thromboxane B2** (**TXB2**) synthase inhibitor with an IC_{50} value of 5.3±1.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kinetensin

(Kinetensin (human))

Cat. No.: HY-P1255

Kinetensin is a **neurotensin**-like peptide isolated from pepsin-treated human plasma.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Kisspeptin-54(human)

(Metastin(human))

Cat. No.: HY-P1022

Kisspeptin-54(human) (Metastin(human)) is an endogenous ligand for **kisspeptin receptor (KISS1, GPR54)**. Kisspeptin-54(human) binds to **rat** and **human GPR54 receptors** with K_i values of 1.81 nM and 1.45 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kisspeptin-54(human) TFA

(Metastin(human) TFA)

Cat. No.: HY-P1022A

Kisspeptin-54(human) TFA (Metastin(human) TFA) is an endogenous ligand for **kisspeptin receptor (KISS1, GPR54)**. Kisspeptin-54(human) TFA binds to **rat** and **human GPR54 receptors** with K_i values of 1.81 nM and 1.45 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KM11060

Cat. No.: HY-19970

KM11060 is a corrector of the F508 deletion (F508del)-cystic fibrosis transmembrane conductance regulator (CFTR) trafficking defect. KM11060 can be used for the research of F508del-CFTR processing defect and development of cystic fibrosis therapeutics.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Ko-3290

Cat. No.: HY-101721

Ko-3290 is an antagonist of **β-adrenoceptor**, with cardioselectivity and antilipolytic effects in animals.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KP136

(AL136)

Cat. No.: HY-U00168

KP136 (AL136) is an orally effective antiallergic agent. The IC_{50} is 76.1 μg/mL for **histamine release** and 63 ug/mL for **degranulation**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KP496

Cat. No.: HY-U00253

KP496 is a selective, dual antagonist for **Leukotriene D4 receptor** and **Thromboxane A2 receptor**.



Purity: 95.81%
Clinical Data: No Development Reported
Size: 5 mg

KT5720

Cat. No.: HY-N6789

KT5720 is a cell-permeable, potent, specific, reversible, ATP-competitive inhibitor of **protein kinase A (PKA)**, with a K_i of 60 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 50 μg, 100 μg

KU14R

Cat. No.: HY-15481

KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KUL-7211 racemate

Cat. No.: HY-19673A

KUL-7211 racemate is the racemate of KUL-7211. KUL-7211 is a selective **β-adrenoceptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KW-8232

Cat. No.: HY-100304A

KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of **PGE2**.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KW-8232 free base

Cat. No.: HY-100304

KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of **PGE2**.



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 1 mg

Kynurenic acid

(Quinurenic acid)

Cat. No.: HY-100806

Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting <b >NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of **GPR35/CXCR8**.



Purity: 99.03%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg, 500 mg

Kynurenic acid sodium

Cat. No.: HY-107512

Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting **NMDA, glutamate, α7 nicotinic acetylcholine receptor**. Kynurenic acid sodium is also an agonist of **GPR35/CXCR8**.



Purity: 99.76%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg

L 152804

Cat. No.: HY-107734

L 152804 is an orally active and selective **neuropeptide Y Y5 receptor (NPY5-R)** antagonist, with a K_i of 26 nM for **hY5**. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

L 888607

Cat. No.: HY-111271

L 888607 is a potent, and selective **CRTH2** (also known as DP_2) agonist with a K_i of 0.8 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L 888607 Racemate

Cat. No.: HY-111271A

L 888607 Racemate is a selective prostaglandin D_2 receptor subtype 1 **(DP1)** antagonist, with K_i**s** of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-159282

(MK 996)

Cat. No.: HY-19191

L-159282 is a highly potent, orally active, nonpeptide **angiotensin II receptor** antagonist, with anti-hypertensive activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-368,899 hydrochloride

Cat. No.: HY-108677

L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide **oxytocin receptor** antagonist, with **IC_{50}**s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-371,257

Cat. No.: HY-15010

L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of **oxytocin receptor** (pA2=8.4) with high affinity at both the oxytocin receptor (K_i=19 nM) and **vasopressin V1a receptor** (K_i=3.7 nM).



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-692585

Cat. No.: HY-50760

L-692585 is a potent and nonpeptidyl **growth hormone secretagogue receptor (GHS-R1a)** agonist, with a K_i of 0.8 nM. L-692585 acts directly on somatotropes causing GH release.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-765314

Cat. No.: HY-101385

L-765314 is a potent and selective **α1b adrenergic receptor** antagonist with K_is of 5.4 nM and 2.0 nM for rat and human α1b adrenergic receptor, respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-771688

Cat. No.: HY-U00237

L-771688 is a highly selective **α1A-Adrenoceptor** antagonist with a K_i of 0.43±0.02 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Fucitol

(1-Deoxy-D-galactitol)

Cat. No.: HY-N4112

L-Fucitol (1-Deoxy-D-galactitol) is a sugar alcohol isolated from Nutmeg.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

L-Lysine hydrochloride

Cat. No.: HY-N0470

L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

L-Thyroxine

(Levothyroxine; T4)

Cat. No.: HY-18341

L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4).



Purity: 96.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

L-Thyroxine sodium

(Levothyroxine sodium; T4 sodium)

Cat. No.: HY-18341B

L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4).



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

L-Thyroxine sodium salt pentahydrate

(Sodium levothyroxine pentahydrate)

Cat. No.: HY-18341A

L-Thyroxine sodium salt pentahydrate (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4).



Purity: 99.38%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

L162441

Cat. No.: HY-U00245

L162441 is an **Angiotensin type 1 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L755507

Cat. No.: HY-19334

L755507 is a potent, selective agonist of β_3-**AR** with an IC_{50} of 35 nM.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Labetalol hydrochloride

(AH-5158 hydrochloride; Sch-15719W)

Cat. No.: HY-B1108

Labetalol hydrochloride is a mixed alpha/beta adrenergic antagonist that is used to treat high blood pressure.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Lactitol

(D-Lactitol) Cat. No.: HY-N7104

Lactitol (D-Lactitol), a nonabsorbable disaccharide, has the potential for constipation research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Lacto-N-biose I

(Galβ1-3GlcNAc) Cat. No.: HY-141488

Lacto-N-biose I (Galβ1-3GlcNAc), as an endogenous metabolite, is an acceptor for the α1,2-fucosyltransferase enzyme from Helicobacter pylori.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lafutidine

(FRG-8813) Cat. No.: HY-B0160

Lafutidine (FRG-8813) is a **histamine H2-receptor** antagonist (H_2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease.



Purity: 98.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Landiolol hydrochloride

(ONO1101 hydrochloride) Cat. No.: HY-100607A

Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting **beta**-blocker (β1/β2 selectivity=255:1, a half-life of 4min) acts as an **adrenoceptor** antagonist.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Lanreotide acetate

(BIM 23014 acetate) Cat. No.: HY-P1959A

Lanreotide acetate (BIM 23014 acetate) is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for carcinoid syndrome.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Laropiprant

(MK-0524) Cat. No.: HY-50175

Laropiprant is a potent, selective **DP receptor** antagonist with K_i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.



Purity: 99.73%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lasofoxifene Tartrate

(CP-336156) Cat. No.: HY-A0038

Lasofoxifene Tartrate is a non-steroidal selective estrogen receptor modulator (SERM).



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lasofoxifene-d4

Cat. No.: HY-A0037S

Lasofoxifene-d4 is the deuterium labeled Lasofoxifene. Lasofoxifene is a non-steroidal selective estrogen receptor modulator (SERM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Latrepirdine dihydrochloride

(Dimebolin dihydrochloride) Cat. No.: HY-14537

Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and **amyloid-β** (**Aβ**) secretion.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Lecirelin

Cat. No.: HY-P0051

Lecirelin, a synthetic gonadotropin-releasing hormone (GnRH) analogue, acts as a **GnRH** agonist. Lecirelin is widely used for the research of bovine ovarian follicular cysts.

{Glp}-HWSYVLRP

Purity: 99.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Leelamine hydrochloride

Cat. No.: HY-110028

Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Levalbuterol tartrate

(Levosalbutamol tartrate)

Cat. No.: HY-17457

Levosalbutamol tartrate(levalbuterol) is the R-enantiomer of the short-acting β2-adrenergic receptor agonist salbutamol. IC50 Value: Target: β2-adrenergic receptor Levosalbutamol and salbutamol produced significantly better bronchodilator responses than placebo.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Levobetaxolol hydrochloride

((S)-Betaxolol hydrochloride; AL-1577A)

Cat. No.: HY-B0381B

Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye. Levobetaxolol hydrochloride can be used for the research of glaucoma.



Purity: 98.53%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Levocetirizine

((R)-Cetirizine)

Cat. No.: HY-B0814

Levocetirizine ((R)-Cetirizine) is a third-generation **peripheral H1-receptor** antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Levocetirizine dihydrochloride

((R)-Cetirizine dihydrochloride)

Cat. No.: HY-W010841

Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation **peripheral H1-receptor** antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Levodropropizine

((S)-(-)-Dropropizine; DF-526)

Cat. No.: HY-B1895

Levodropropizine (DF-526) is a histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive drug.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Levonorgestrel

(D-Norgestrel)

Cat. No.: HY-B0257

Levonorgestrel is a synthetic progestogen used as an active ingredient in some hormonal contraceptives.



Purity: 99.13%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Levonorgestrel-D8

(D-Norgestrel-D8)

Cat. No.: HY-B0257S

Levonorgestrel-D8 (D-Norgestrel-D8) is the deuterium labeled Levonorgestrel. Levonorgestrel is a synthetic progestogen used as an active ingredient in some hormonal contraceptives.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Lidanserin

(ZK-33839)

Cat. No.: HY-101815

Lidanserin (ZK-33839) acts as a **5-HT$_{2A}$** and **α_1-adrenergic receptor** antagonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Lindleyin

Cat. No.: HY-N2448

Lindleyin, isolated from Rhei rhizoma, mediates hormonal effects through estrogen receptors. Lindleyin binds to **ERα** with estrogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linsitinib

(OSI-906)

Cat. No.: HY-10191

Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the **IGF-1 receptor** and **insulin receptor (IR)** with IC_{50}s of 35 and 75 nM, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Linuron

Cat. No.: HY-B1866

Linuron is a phenylurea herbicide that is widely used to control the growth of grass and weeds in various agriculture crops and in orchards. Linuron is a **photosystem II** inhibitor. Linuron is also a competitive **androgen receptor (AR)** antagonist with a K_i of 100 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Liothyronine

(Triiodothyronine; 3,3',5-Triiodo-L-thyronine; T3)

Cat. No.: HY-A0070A

Liothyronine is an active form of thyroid hormone, which binds to **β1 thyroid hormone receptor** (**TRβ1**), and activates its activity.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Liothyronine sodium (Triiodothyronine sodium; 3,3',5-Triiodo-L-thyronine sodium; T3 sodium)

Cat. No.: HY-A0070

Liothyronine sodium is an active form of thyroid hormone, which binds to **β1 thyroid hormone receptor** (**TRβ1**), and activates its activity.



Purity: 99.17%
Clinical Data: Launched
Size: 100 mg, 500 mg

Lixivaptan

(VPA-985; WAY-VPA 985)

Cat. No.: HY-14185

Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective **vasopressin receptor** V2 antagonist, with IC_{50} values of 1.2 and 2.3 nM for human and rat V2, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LMD-009

Cat. No.: HY-121885

LMD-009 is a selective **CCR8** nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC_{50}s from 11 to 87 nM.



Purity: 99.85%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg

LML134

Cat. No.: HY-128656

LML134 (compound 18b) is an orally active and high selective **Histamine 3 receptor (H3R)** inverse agonist with K_is of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile.



Purity: 99.83%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Locustatachykinin I

Cat. No.: HY-P1183

Locustatachykinin I is a insect tachykinin-related peptide isolated from Locusta migratoria. Locustatachykinin I exhibits sequence homologies with the vertebrate tachykinins. In Lacanobia, Locustatachykinin I is also a substrate for a deamidase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Locustatachykinin I TFA

Cat. No.: HY-P1183A

Locustatachykinin I TFA is a insect tachykinin-related peptide isolated from Locusta migratoria. Locustatachykinin I TFA exhibits sequence homologies with the vertebrate tachykinins. In Lacanobia, Locustatachykinin I TFA is also a substrate for a deamidase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lodenafil

(Hydroxyhomosildenafil)

Cat. No.: HY-123210

Lodenafil is a potent **phosphodiesterase type 5 (PDE5)** inhibitor for the treatment of erectile dysfunction (ED).



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lodenafil carbonate

Cat. No.: HY-108045

Lodenafil carbonate, a dimer that acts as a prodrug delivering Lodenafil in vivo, is an orally active **phosphodiesterase type 5 (PDE5)** inhibitor for the treatment of erectile dysfunction (ED).



Purity: ≥98.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 1 mg, 5 mg

Lodoxamide

(U-42585E free acid)

Cat. No.: HY-14270

Lodoxamide (U-42585E free acid) is an antiallergic compound acting as a mast-cell stabilizer for the treatment of asthma and allergic conjunctivitis.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Lodoxamide tromethamine

(U-42585E)

Cat. No.: HY-16289

Lodoxamide tromethamine (U-42585E) is a medication for the treatment of prophylaxis of mast cell-mediated allergic disease.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lofexidine

Cat. No.: HY-B1052A

Lofexidine is a selective **α2-receptor** agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal.



Purity: 99.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Lofexidine hydrochloride

(Baq-168; MDL-14042)

Cat. No.: HY-B1052

Lofexidine (hydrochloride) is a selective **α2-receptor** agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Lofexidine-d4 hydrochloride

Cat. No.: HY-B1052S

Lofexidine-d4 hydrochloride (Baq-168-d4) is the deuterium labeled Lofexidine hydrochloride. Lofexidine hydrochloride is a selective **α2-receptor** agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Loratadine

(Loratidine; SCH 29851)

Cat. No.: HY-17043

Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity. Loratadine can inhibit immunologic release of inflammatory mediators.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Loratadine-d4

(Loratidine-d4; SCH 29851-d4)

Cat. No.: HY-17043S

Loratadine-d4 (Loratidine-d4) is the deuterium labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Loratadine-d5

(Loratidine-d5; SCH 29851-d5)

Cat. No.: HY-17043S1

Loratadine-d5 (Loratidine-d5) is the deuterium labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lorglumide sodium salt

(CR-1409 sodium salt)

Cat. No.: HY-B1439B

Lorglumide sodium salt (CR-1409 sodium salt) is a potent **cholecystokinin (CCK) receptor** antagonist.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Losartan

(DuP-753) Cat. No.: HY-17512

Losartan is an **angiotensin II receptor** antagonist, competing with the binding of angiotensin II to AT1 receptors with IC_{50} of 20 nM.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Losartan (D4 Carboxylic Acid)

(E-3174 D4; EXP-3174 D4) Cat. No.: HY-12765S

Losartan D4 Carboxylic Acid (E-3174 D4) is the deuterium labeled Losartan(EXP-3174), which is an angiotensin II receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Losartan D4

(DuP-753 D4) Cat. No.: HY-17512S

Losartan D4 (DuP-753 D4) is the deuterium labeled Losartan. Losartan is an **angiotensin II receptor** antagonist, competing with the binding of angiotensin II to AT1 receptors with IC_{50} of 20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Losartan potassium

(DuP-753 potassium) Cat. No.: HY-17512A

Losartan potassium (DuP-753 potassium) is an **angiotensin II receptor type 1 (AT1)** antagonist, competing with the binding of angiotensin II to AT1 with an IC_{50} of 20 nM.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Loteprednol Etabonate

Cat. No.: HY-17358

Loteprednol etabonate (LE) is an orally active "soft" steroid belonging to a unique class of glucocorticoids. Loteprednol etabonate (LE) exhibits anti-inflammatory activity and has been used in optometry and ophthalmology.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Loxiglumide

(CR-1505) Cat. No.: HY-B2154

Loxiglumide is a cholecystokinin (**CCK-1**) receptor antagonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ludaterone

Cat. No.: HY-137444

Ludaterone is an antiandrogen agent, with potent antiandrogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LUF5771

Cat. No.: HY-139303

LUF5771 is a potent allosteric recombinant luteinizing hormone (**recLH**) and **Org 43553** inhibitor. LUF5771 is able to partially activate the LH receptor with low efficacy.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lusaperidone

(R107474) Cat. No.: HY-U00117

Lusaperidone (R107474) is an α2 **adrenergic receptor** antagonist with K_is of 0.13 and 0.15 nM for α2A and α2C, respectively.



Purity: 97.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Luteinizing hormone (human)

Cat. No.: HY-P2293

Luteinizing hormone (human), a heterodimeric glycoprotein hormone produced by the pituitary gland (LH), plays key roles in human reproduction.

Luteinizing hormone (human)

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 μg

LY191704

Cat. No.: HY-118091

LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective **human type I 5α-reductase** inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503.



Relative stereochemistry

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY2510924

Cat. No.: HY-12488

LY2510924 is a potent and selective **CXCR4** antagonist that blocks SDF-1 binding to CXCR4 with an **IC_{50}** of 0.079 nM.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY285434

Cat. No.: HY-U00202

LY285434 is a suitable **angiotensin II receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY377604

Cat. No.: HY-13713

LY377604 is a **human β_3-adrenergic receptor** agonist with an **EC_{50}** of 2.4 nM and also a **β_1-** and **β_2-adrenergic receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY88074

Cat. No.: HY-135585

LY88074 (Compound 88074) is a Raloxifene analog lacking the basic side chain. Raloxifene is a selective estrogen receptor modulator, and reduces fracture risk at least in part by improving the mechanical properties of bone in a cell- and estrogen receptor-independent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY88074 analog 1

Cat. No.: HY-135593

LY88074 analog 1 is a **benzothiophene compound** with nitrogen-containing non-basic side chains, Compound 26, extracted from patent EP0747380A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY88074 Methyl ether

Cat. No.: HY-135592

LY88074 Methyl ether (Example 2) is useful for the inhibition of the various estrogen deficient conditions, which are associated with estrogendeprivation syndrome including osteoporosis and hyperlipidemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY88074 Trimethyl ether

Cat. No.: HY-135583

LY88074 Trimethyl ether (Example 1) is useful for the inhibition of the various estrogen deficient conditions, which are associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lys-γ3-MSH(human)

Cat. No.: HY-P1210

Lys-γ3-MSH(human) is a melanocortin peptide derived from the C-terminal of the fragment of pro-opiomelanocortin (POMC). Lys-γ3-MSH(human) potentiates the steroidogenic response of the rat adrenal to adrenocorticotrophin (ACTH).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lys-γ3-MSH(human) TFA

Cat. No.: HY-P1210A

Lys-γ3-MSH(human) TFA is a melanocortin peptide derived from the C-terminal of the fragment of pro-opiomelanocortin (POMC). Lys-γ3-MSH(human) TFA potentiates the steroidogenic response of the rat adrenal to adrenocorticotrophin (ACTH).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

M40

Cat. No.: HY-P1025

M40 is a potent, non-selective **galanin receptor** antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Macitentan

(ACT-064992)

Cat. No.: HY-14184

Macitentan (ACT-064992) is an orally active, non-peptide dual **ETA** and **ETB** (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Macitentan (n-butyl analogue)

Cat. No.: HY-14184A

Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin **ETA** and **ETB receptor** antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Mapenterol hydrochloride

Cat. No.: HY-136435

Mapenterol hydrochloride is a type of **β2-adrenoceptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mapenterol-d6 hydrochloride

Cat. No.: HY-136435S1

Mapenterol-d6 hydrochloride is the deuterium labeled Mapenterol hydrochloride. Mapenterol hydrochloride is a type of **β2-adrenoceptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 250 μg, 1 mg, 5 mg, 10 mg

Mapracorat

(ZK-245186; BOL-303242X)

Cat. No.: HY-14864

Mapracorat is a novel non-steroidal selective **glucocorticoid receptor** agonist.



Purity: 99.40%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Maraviroc

(UK-427857)

Cat. No.: HY-13004

Maraviroc (UK-427857) is a selective **CCR5** antagonist with activity against human **HIV**.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Maraviroc-d6

Cat. No.: HY-13004S

Maraviroc-d6 (UK-427857-d6) is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective **CCR5** antagonist with activity against human **HIV**.



Purity: >98%
Clinical Data:
Size: 500 μg, 1 mg, 5 mg, 10 mg, 50 mg

Maropitant

Cat. No.: HY-10053

Maropitant is a selective and orally active **neurokinin (NK1) receptor** antagonist. Maropitant acts by blocking the binding of substance P within the emetic center and the chemoreceptor trigger zone (CRTZ). Maropitant is highly effective in preventing vomiting.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Mavorixafor

(AMD-070)

Cat. No.: HY-50101

Mavorixafor (AMD-070) is a potent, selective and orally available **CXCR4** antagonist, with an IC_{50} value of 13 nM against CXCR4 ^{125}I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC_{50} of 1 and 9 nM, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Mavorixafor trihydrochloride

(AMD-070 trihydrochloride) Cat. No.: HY-50101A

Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available **CXCR4** antagonist, with an **IC_{50}** value of 13 nM against CXCR4 ^{125}I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with...



Purity: 98.69%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

MC-4R Agonist 1

Cat. No.: HY-U00396

MC-4R Agonist 1 is an agonist of **human melanocortin-4 receptor (MC-4R)**, used in the research of obesity, diabetes, and sexual dysfunction.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MCH-1 antagonist 1

Cat. No.: HY-100331

MCH-1 antagonist 1 is a potent melanin concentrating hormone (**MCH-1**) antagonist with a **K_i** of 2.6 nM. MCH-1 antagonist 1 also inhibits **CYP3A4** with an **IC_{50}** of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MCHR1 antagonist 1

Cat. No.: HY-U00353

MCHR1 antagonist 1 is a selective antagonist of **melanin concentrating hormone-1 (MCH1) receptor**, with a **K_b** of 1 nM and a **K_i** of 4 nM at human MCH1, and may be used to reduce the body mass.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MCHR1 antagonist 2

Cat. No.: HY-100321

MCHR1 antagonist 2 is an antagonist of **melanin concentrating hormone receptor 1**, with an **IC_{50}** of 65 nM; MCHR1 antagonist 2 also inhibits **hERG**, with an **IC_{50}** of 4.0 nM in IMR-32 cells.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCHR1 antagonist 3

Cat. No.: HY-136152

MCHR1 antagonist 3 is a potent the **melanin-concentrating hormone receptor-1 (MCHR1)** antagonist. MCHR1 antagonist 3 is used to regulate energy metabolism.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mebhydrolin

Cat. No.: HY-B1303A

Mebhydrolin is a specific **histamine H_1 receptor** antagonist.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Mebhydrolin napadisylate

(Mebhydroline 1,5-naphthalenedisulfonate salt) Cat. No.: HY-B1303

Mebhydrolin napadisylate is a specific **histamine H_1 receptor** antagonist.



Purity: 99.93%
Clinical Data: Launched
Size: 100 mg

Medetomidine

Cat. No.: HY-17034

Medetomidine(Domtor) is a potent, highly selective α2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively).



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Medetomidine hydrochloride

(MPV785) Cat. No.: HY-17034B

Medetomidine hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic and sedative properties.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Medroxyprogesterone

(17α-Hydroxy-6α-methylprogesterone; U8840)

Cat. No.: HY-B0648

Medroxyprogesterone is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist. Target: Progesterone Receptor Medroxyprogesterone (MP), is a steroidal progestin drug which was never marketed for use in humans.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Medroxyprogesterone acetate

(Medroxyprogesterone 17-acetate; Farlutin)

Cat. No.: HY-B0469

Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with **progesterone**, **androgen** and **glucocorticoid receptors**.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Medroxyprogesterone acetate-d3

(Medroxyprogesterone 17-acetate-d3; Farlutin-d3)

Cat. No.: HY-B0469S

Medroxyprogesterone acetate D3 is deuterium labeled Medroxyprogesterone acetate. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with **progesterone**, **androgen** and **glucocorticoid receptors**.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mg

Megestrol acetate

Cat. No.: HY-13676

Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol **androgen receptors** human BPH tissue.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Melanin Concentrating Hormone, salmon

(MCH (salmon))

Cat. No.: HY-P1525

Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Melanin Concentrating Hormone, salmon TFA

(MCH (salmon) (TFA))

Cat. No.: HY-P1525A

Melanin Concentrating Hormone, salmon TFA (MCH (salmon) TFA) is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system.

Purity: 95.03%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Men 10376

(Neurokinin-2 receptor antagonist)

Cat. No.: HY-P1276

Men 10376 is a selective **tachykinin NK-2 receptor** antagonist, with a K_i of 4.4 μM for rat small intestine NK-2 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Men 10376 TFA

(Neurokinin-2 receptor antagonist TFA)

Cat. No.: HY-P1276A

Men 10376 TFA is a selective **tachykinin NK-2 receptor** antagonist, with a K_i of 4.4 μM for rat small intestine NK-2 receptor.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MEN11467

Cat. No.: HY-U00207

MEN11467 is a selective and orally- effective peptidomimetic **tachykinin NK_1 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mepixanox

(Pimexone)

Cat. No.: HY-100150

Mepixanox (Pimexone) is an analeptic drug used in respiratory and cardiorespiratory insufficiency.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Meprednisone

Cat. No.: HY-B0243

Meprednisone is a glucocorticoid and a methylated derivative of prednisone. Target: Glucocorticoid Receptor Meprednisone is a glucocorticoid and a methylated derivative of prednisone.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mepyramine maleate

(Pyrilamine maleate)

Cat. No.: HY-B1281

Mepyramine maleate, a first generation antihistamine, is an antagonist of **histamine H1 receptor**, with K_ds of 0.8 nM, 5200 nM and >3000 nM for H1, H2, and H3 receptor, respectively, and a pK_d of 9.4 for H1 receptor.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Mequitazine

(LM-209)

Cat. No.: HY-B2168

Mequitazine is a potent, nonsedative and long-acting histamine H_1 antagonist.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mestranol

Cat. No.: HY-B0390

Mestranol is an inactive prodrug and becomes biologically active on conversion to ethinyl estradiol (EE). Mestranol acts as an **estrogen receptor** agonist.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Metaproterenol

(Orciprenaline)

Cat. No.: HY-B1276A

Metaproterenol (Orciprenaline) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM. Metaproterenol also has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Metaproterenol hemisulfate

(Orciprenaline hemisulfate)

Cat. No.: HY-B1276

Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Metaproterenol-d7 hemisulfate

Cat. No.: HY-B1276S

Metaproterenol-d7 (Orciprenaline-d7) hemisulfate is the deuterium labeled Metaproterenol hemisulfate. Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Methimazole

Cat. No.: HY-B0208

Methimazole is an antithyroid compound widely used for the research of hyperthyroidism. Methimazole has potent hepatotoxicity.



Purity: 98.14%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Methimazole D3

Cat. No.: HY-B0208S

Methimazole D3 is a deuterium labeled Methimazole. Methimazole is an antithyroid drug used for the treatment of the hyperthyroidism in humans and animals.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Methyldopa

(L-(-)-α-Methyldopa; MK-351)

Cat. No.: HY-B0225

Methyldopa (L-(-)-α-Methyldopa), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for **α2-adrenergic receptors**). Methyldopa is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Methyldopa hydrate

(L-(-)-α-Methyldopa hydrate; MK-351 hydrate) Cat. No.: HY-B0225B

Methyldopa hydrate (L-(-)-α-Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for **α2-adrenergic receptors**). Methyldopa hydrate is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Methyldopa hydrochloride

(L-(-)-α-Methyldopa hydrochloride; MK-351 hydrochloride) Cat. No.: HY-B0225A

Methyldopa hydrochloride (L-(-)-α-Methyldopa hydrochloride) hydrochloride, a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for **α2-adrenergic receptors**).



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Methylprednisolone

(U 7532) Cat. No.: HY-B0260

Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical **COVID-19** by activating **ACE2** and reducing IL-6 levels.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Methylprednisolone succinate

(Methylprednisolone hydrogen succinate) Cat. No.: HY-B1900

Methylprednisolone succinate is a synthetic glucocorticoid and widely used as an anti-inflammatory agent.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Metiamide

(SK&F 92058) Cat. No.: HY-15540

Metiamide (SK&F 92058) is a histamine H2-receptor antagonist developed from another H2 antagonist, burimamide.



Purity: 97.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Metipranolol hydrochloride

Cat. No.: HY-16316

Metipranolol hydrochloride is a non-selective **β adrenergic receptor** blocking agent.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Metoprolol

Cat. No.: HY-17503

Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. IC50 value: Target: β1 receptor.



Purity: 99.89%
Clinical Data: Launched
Size: 25 mg, 50 mg, 100 mg

Metoprolol Succinate

Cat. No.: HY-17503A

Metoprolol Succinate (Toprol XL) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. IC50 value: Target: β1 receptor.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Metoprolol Tartrate

Cat. No.: HY-17503B

Metoprolol is a cardioselective β1-adrenergic blocking agent. Target: β1- adrenergic Receptor Patients took 50 mg metoprolol twice daily with weekly titration to response or 200 mg twice daily.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

MF498

Cat. No.: HY-10794

MF498 is a novel and selective E prostanoid receptor 4 (EP4 receptor) antagonist, displayed strong binding affinity for the EP4 receptor with Ki of 0.7 nM.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MG 1

Cat. No.: HY-U00110

MG 1 is an α1 **adrenergic receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mianserin

(Mianserine)

Cat. No.: HY-B0188

Mianserin is a H1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant. Target: H1 receptor Mianserin is a psychoactive drug of the tetracyclic antidepressant (TeCA) therapeutic family.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Mianserin hydrochloride

(Org GB 94)

Cat. No.: HY-B0188A

Mianserin hydrochloride (Org GB 94) is a H1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Midaglizole hydrochloride

((±)-DG5128; DG5128)

Cat. No.: HY-U00165

Midaglizole hydrochloride (DG5128) is a preferential **α2-adrenoceptor** antagonist. Midaglizole hydrochloride (DG5128) exhibits 7.4 times higher affinity (**pK_i**=6.28) toward α2-adrenoceptor than α1-adrenoceptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mifepristone

(RU486; RU 38486)

Cat. No.: HY-13683

Mifepristone (RU486) is a **progesterone receptor** (**PR**) and **glucocorticoid receptor** (**GR**) antagonist with **IC_{50}**s of 0.2 nM and 2.6 nM in in vitro assay.



Purity: 98.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Mini Gastrin I, human

Cat. No.: HY-P1593

Mini Gastrin I, human is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

LEEEEEAYGWMDF-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mini Gastrin I, human TFA

Cat. No.: HY-P1593A

Mini Gastrin I, human (TFA) is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

LEEEEEAYGWMDF-NH_2 (TFA salt)

Purity: 98.08%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mirabegron

(YM178)

Cat. No.: HY-14773

Mirabegron is a selective **β_3-adrenoceptor** agonist with **EC_{50}** of 22.4 nM.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mirificin

(Puerarin apioside)

Cat. No.: HY-N2134

Mirificin (Puerarin apioside) is a isoflavone in Puerariae Lobatae Radix. Mirificin inhibits **tyrosinase (TYR)** with an **IC_{50}** of 12.66 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Mirodenafil

(SK3530)

Cat. No.: HY-14930

Mirodenafil(SK3530) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction. Target: PDE5 Mirodenafil is a newly developed oral phosphodiesterase type 5 inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Misoprostol

(SC-29333)

Cat. No.: HY-B0610

Misoprostol (SC-29333) is an orally active synthetic **prostaglandin E1 (PGE1)** analog that is used for gastric ulcers research.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Mizolastine

Cat. No.: HY-B0164

Mizolastine is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Mizolastine dihydrochloride

Cat. No.: HY-B0164A

Mizolastine dihydrochloride is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

MK-0249

Cat. No.: HY-U00076

MK-0249 is a potent **histamine H3 receptor** antagonist, with K_i of 1.7 nM for human H3.



Purity: 99.53%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

MK-0493

Cat. No.: HY-118930

MK-0493 is a potent, orally active and selective agonist of the **melanocortin receptor 4 (MC4R)**, demonstrating significant reductions in energy intake.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-0557

Cat. No.: HY-15411

MK-0557 is a highly selective, orally available neuropeptide **Y5** receptor antagonist with a K_i of 1.6 nM.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

MK-0773

(PF-05314882)

Cat. No.: HY-11027

MK-0773 is a **selective androgen receptor modulators (SARMs)** that binds to AR with an IC_{50} of 6.6 nM.



Purity: 98.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-0812

Cat. No.: HY-50669

MK-0812 is a potent and selective **CCR2** antagonist with low nM affinity for CCR2.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-0812 Succinate

Cat. No.: HY-50669A

MK-0812 Succinate is a potent and selective **CCR2** antagonist with high affinity at CCR2.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-1064

Cat. No.: HY-19914

MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-2894

Cat. No.: HY-10413

MK-2894 is a potent, selective, orally active and high affinity (K_i=0.56 nM) full antagonist against **E prostanoid receptor 4 (EP4 receptor)** (IC_{50}=2.5 nM). MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-2894 sodium salt

Cat. No.: HY-10414

MK-2894 sodium salt is a potent, selective, orally active and high affinity (K_i=0.56 nM) full antagonist against **E prostanoid receptor 4 (EP4 receptor)** (IC_{50}=2.5 nM).



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-3697

Cat. No.: HY-12301

MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-4256

Cat. No.: HY-13466

MK-4256 is a potent and selective **SSTR3** antagonist with IC_{50}s of 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-447

Cat. No.: HY-100297

MK-447 is a free radical scavenger, also a nonsteroidal antiinflammatory agent, and enhances the formation of the endoperoxide, PGH_2, and other **prostaglandins**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-7246

Cat. No.: HY-15853

MK-7246 is a potent and selective **CRTH2** antagonist with a K_i of 2.5±0.5 nM.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-7246 S enantiomer

Cat. No.: HY-15853A

MK-7246 S enantiomer is the less active enantiomer of MK-7246. MK-7246 is a potent and selective CRTH2 antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-8318

Cat. No.: HY-112604

MK-8318 is a potent and selective **CRTh2 receptor** antagonist with a K_i of 5.0 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML 145

Cat. No.: HY-107536

ML 145 is a selective and competitive human **GPR35/CXCR8** antagonist with an IC_{50}/EC_{50} of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC_{50}/EC_{50}=21.7 μM). ML 145 has no significant activity for GPR35 at either rodent ortholog.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML-00253764 hydrochloride

Cat. No.: HY-110123

ML-00253764 hydrochloride is a brain penetrant nonpeptidic **melanocortin receptor 4 (MC4R)** antagonist with a K_i and IC_{50} of 0.16 μM and 0.103 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML-109

Cat. No.: HY-114116

ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC_{50} of 40 nM.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML224

(NCGC00242364; ANTAG3)

Cat. No.: HY-12381

ML224(NCGC00242364; ANTAG3) is a selective TSHR inverse agonist; inhibits TSH-stimulated cAMP production with an IC50 = 2.3 μM.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML314

Cat. No.: HY-16639

ML314 is a potent molecule agonist of NTR1 (EC50 = 1.9 μM); showed good selectivity against NTR2 and GPR35, but did not stimulate Ca2+ mobilization.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ML604086

Cat. No.: HY-124416

ML604086 is a selective **CCR8** inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca^{2+} concentrations.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mometasone furoate

(Sch32088)

Cat. No.: HY-13693

Mometasone furoate (Sch32088) is a **glucocorticoid receptor** agonist with anti-inflammatory and anti-allergic activity.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Mometasone furoate-d3

(Sch32088-d3)

Cat. No.: HY-13693S

Mometasone furoate-d3 (Sch32088-d3) is a deuterium labeled Mometasone furoate. Mometasone furoate (Sch32088) is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Monobutyl phthalate

Cat. No.: HY-N7143

Monobutyl phthalate, a major metabolite of dibutyl phthalate (DBP), possesses antiandrogenic effects. Monobutyl phthalate is an embryotoxicant.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Monohydroxy Netupitant D6

Cat. No.: HY-G0012S

Monohydroxy Netupitant D6 is the deuterium labeled Monohydroxy Netupitant, which is a metabolite of Netupitant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Motixafortide

(BKT140 (4-fluorobenzoyl); BL-8040; TF14016)

Cat. No.: HY-P0171

Motixafortide (BKT140 4-fluorobenzoyl) is a novel **CXCR4** antagonist with an IC_{50} vakue of 1 nM.



Purity: 99.03%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 25 mg

Moxisylyte hydrochloride

(Thymoxamine hydrochloride)

Cat. No.: HY-B1435

Moxisylyte (hydrochloride) is (alpha 1-blocker) antagonist, it can vasodilates cerebral vessels without reducing blood pressure. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g

Mozavaptan

(OPC-31260)

Cat. No.: HY-18346

Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active **vasopressin V_2 receptor** antagonist with an **IC_{50}** of 14 nM.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Mozavaptan hydrochloride

(OPC-31260 hydrochloride)

Cat. No.: HY-123593

Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active **vasopressin V_2 receptor** antagonist with an **IC_{50}** of 14 nM.



Purity: 98.16%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MRE-269

(ACT-333679)

Cat. No.: HY-79593

MRE-269 is an active metabolite of selexipag, and acts as a selective **IP receptor** agonist.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MSDC 0160

(Mitoglitazone; CAY10415)

Cat. No.: HY-100550

MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating **insulin sensitizer** and a modulator of **mitochondrial pyruvate carrier (MPC)**. MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities.



Purity: 99.40%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

MSI-1436

(Trodusquemine; Aminosterol-1436)

Cat. No.: HY-12219

MSI-1436 is a selective, non-competitive inhibitor of the enzyme **protein-tyrosine phosphatase 1B (PTB1B)**, with an **IC_{50}** of appr 1 μM, 200-fold preference over TCPTP (IC_{50}, 224 μM).



Purity: ≥95.0%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 50 mg

MSI-1436 lactate

(Trodusquemine lactate; Aminosterol-1436 lactate)

Cat. No.: HY-12219A

MSI-1436 lactate is a selective, non-competitive inhibitor of the enzyme **protein-tyrosine phosphatase 1B** (**PTB1B**), with an **IC_{50}** of 1 μM, 200-fold preference over TCPTP (**IC_{50}** of 224 μM).



Purity: ≥95.0%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 50 mg

MSX-122

Cat. No.: HY-13696

MSX-122 is an orally active partial antagonist of **CXCR4**, inhibiting **CXCR4/CXCL12** actions, with an **IC_{50}** of 10 nM. MSX-122 has anti-inflammatory and anti-metastatic activity.



Purity: 98.29%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

N-Acetyl Norgestimate-d6

Cat. No.: HY-132692S



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

N-Acetylhistamine

(N-Omega-acetylhistamine)

Cat. No.: HY-112175

N-Acetylhistamine is a histamine metabolite. N-acetylhistamine can be used as a potential biomarker of histidine metabolism for anaphylactoid reactions.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

N-Acetyloxytocin

Cat. No.: HY-P3219

N-Acetyloxytocin is isolated and characterized in the neurointermediate lobe of the rat pituitary (NIL) and their presence in several brain areas of the rat.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

N-Benzyloctadecanamide

(N-Benzylstearamide) Cat. No.: HY-N4188

N-Benzyloctadecanamide (N-Benzylstearamide) is a macamide, a distinct class of secondary metabolites in Lepidium meyenii Walp. (Maca).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

N-desmethyl Netupitant D6

Cat. No.: HY-G0010S

N-desmethyl Netupitant D6 is the deuterium labeled N-desmethyl Netupitant, which is a metabolite of Netupitant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nadolol-d9

(SQ-11725-d9) Cat. No.: HY-B0804S

Nadolol D9 (SQ-11725 D9) is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active **β-adrenergic receptors** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naftopidil

(KT-611; BM-15275) Cat. No.: HY-B0391

Naftopidil (KT-611) is is a selective **alpha1-adrenoceptor** antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_{1a}-, α_{1b}- and α_{1d}-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects.



Purity: 98.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Naminterol

Cat. No.: HY-101822

Naminterol is a phenethanolamine derivative, is a **β_2 adrenoceptor** agonist with bronchodilatory properties. Naminterol is used for treatment of asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naphazoline hydrochloride

Cat. No.: HY-B0446

Naphazoline hydrochloride is an ocular vasoconstrictor and imidazoline derivative sympathomimetic amine. Target: Adrenergic Receptor Naphazoline hydrochloride is the common name for 2-(1-naphthylmethyl)-2-imidazoline hydrochloride.



Purity: 98.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Nastorazepide

(Z-360) Cat. No.: HY-17617

Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Navarixin

(SCH 527123; MK-7123) Cat. No.: HY-10198

Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both **CXCR1** and **CXCR2**, with K_d values of 41 nM for **cynomolgus CXCR1** and 0.20 nM, 0.20 nM, 0.08 nM for **mouse**, **rat** and **cynomolgus monkey CXCR2**, respectively.



Purity: 99.13%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NBI-74330

Cat. No.: HY-15320

NBI-74330 is a potent antagonist for **CXCR3**, and exhibits potent inhibition of (^{125}I)CXCL10 and (^{125}I)CXCL11 specific binding with K_i of 1.5 and 3.2 nM, respectively.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCGC00229600

Cat. No.: HY-18286

NCGC00229600 is an allosteric inverse agonist of **thyrotropin receptor (TSHR)**. NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenously expressed in Graves' disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nebivolol

(R 065824) Cat. No.: HY-B0203

Nebivolol selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM. Target: β1-adrenergic receptor Nebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent maner.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Nebivolol hydrochloride

(R 065824 hydrochloride) Cat. No.: HY-B0203A

Nebivolol hydrochloride selectively inhibits β1-adrenergic receptor with IC50 of 0.8 nM. Target: β1- adrenergic receptor Nebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent maner.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Nedocromil

(FPL 59002) Cat. No.: HY-13448

Nedocromil suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4 (LTC_4)**, and **prostaglandin D_2 (PGD_2)**.



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Nedocromil sodium

(FPL 59002KP; Nedocromil disodium salt) Cat. No.: HY-16344

Nedocromil sodium suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4 (LTC_4)**, and **prostaglandin D_2 (PGD_2)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nefazodone hydrochloride

(BMY-13754; MJ-13754-1) Cat. No.: HY-B1396

Nefazodone hydrochloride (BMY-13754) is a potent and selective **5HT2A** (K_i=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC_{50} of 290 and 300 nM, respectively).



Purity: 99.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Nemorexant

(ACT-541468) Cat. No.: HY-109095

Nemorexant (ACT-541468) is a potent **orexin receptor** antagonist extracted from patent WO2015083094A1, compound example 7, has IC_{50}s of 2 nM and 3 nM for **Ox_1 receptor** and **Ox_2 receptor**, respectively.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nesolicaftor

(PTI-428) Cat. No.: HY-111680

Nesolicaftor (PTI-428) is a specific cystic fibrosis transmembrane conductance regulator (**CFTR**) amplifier.



Purity: 99.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nestoron

(ST-1435; Elcometrine) Cat. No.: HY-13071

Nestoron (ST-1435) is a 19-norprogesterone derivative with high affinity and selectivity for **progesterone receptors**. Nestoron is a highly selective and potent progestogen that can be used as a hormonal contraceptive.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Netupitant

(CID 6451149) Cat. No.: HY-16346

Netupitant (CID-6451149) is a highly potent, selective and orally active **neurokinin-1 (NK_1)** receptor antagonist with a K_i of 0.95 nM for hNK_1 in CHO cells. Netupitant has antiemetic affect.



Purity: 99.93%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Netupitant metabolite Monohydroxy Netupitant

(Monohydroxy Netupitant) Cat. No.: HY-G0012

Monohydroxy Netupitant is the metabolite of Netupitant, which is a highly selective NK1 receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Netupitant metabolite Netupitant N-oxide

(Netupitant N-oxide) Cat. No.: HY-G0011

Netupitant N-oxide is the metabolite of Netupitant, which is a highly selective NK1 receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Netupitant N-oxide D6

Cat. No.: HY-G0011S

Netupitant N-oxide D6 is the deuterium labeled Netupitant N-oxide, which is a metabolite of Netupitant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Netupitant-d6

(CID-6451149-d6) Cat. No.: HY-16346S

Netupitant D6 is the deuterium labeled Netupitant (CID-6451149), which is a highly potent and selective, orally active neurokinin-1 (NK_1) receptor antagonist.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg

Neurokinin A

(Substance K; Neurokinin α; Neuromedin L) Cat. No.: HY-P0197

Neurokinin A (Substance K), a peptide neurotransmitter of the tachykinin family, acts via the **NK-2** receptor. Neurokinin A acts as a major mediator in human airway and gastrointestinal tissues.

HKTDSFVGLM-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Neurokinin A TFA

(Substance K TFA; Neurokinin α TFA; Neuromedin L TFA) Cat. No.: HY-P0197A

Neurokinin A TFA (Substance K TFA), a peptide neurotransmitter of the tachykinin family, acts via the **NK-2** receptor. Neurokinin A acts as a major mediator in human airway and gastrointestinal tissues.

HKTDSFVGLM-NH_2 (TFA salt)

Purity: 99.25%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Neurokinin A(4-10)

Cat. No.: HY-P0236

Neurokinin A (4-10) is a **tachykinin NK_2 receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neurokinin A(4-10) TFA

Cat. No.: HY-P0236A

Neurokinin A (4-10) TFA is a **tachykinin NK_2 receptor** agonist.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Neurokinin antagonist 1

Cat. No.: HY-U00320

Neurokinin antagonist 1 is a **Neurokinin** antagonist extracted from patent WO1998045262A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neurokinin B

Cat. No.: HY-P0242

Neurokinin B belongs to the tachykinin family of peptides. Neurokinin B binds a family of GPCRs-including neurokinin receptor 1 (NK1R), NK2R, and NK3R-to mediate their biological effect.

DMHDFFVGLM-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neurokinin B TFA

Cat. No.: HY-P0242A

Neurokinin B TFA belongs to the tachykinin family of peptides. Neurokinin B binds a family of GPCRs-including neurokinin receptor 1 (NK1R), NK2R, and NK3R-to mediate their biological effect.

DMHDFFVGLM-NH_2 (TFA salt)

Purity: 95.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Neuropeptide EI, rat

Cat. No.: HY-P1869

Neuropeptide EI, rat displays functional melanin concentrating hormone (MCH)-antagonist and melanocyte-stimulating hormone (MSH) agonist activity in different behavioral paradigms.

EIGDEENSAKFPI-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuropeptide Y (13-36), amide, human

(Neuropeptide Y (13-36), human)

Cat. No.: HY-P1480

Neuropeptide Y (13-36), amide, human is a selective **neuropeptide Y_2 receptor** agonist.

PAEDMARYYSALRHYINLITRQRY-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

Neuropeptide Y (22-36)

Cat. No.: HY-P1818

Neuropeptide Y (22-36), a 15 amino acid peptide, is a fragment of Neuropeptide Y. Neuropeptide Y (22-36) acts on Y_2 receptor and retains subnanomolar affinity for the Y_2 receptor.

SALRHYINLITRQRY-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuropeptide Y (human)

Cat. No.: HY-P0198

Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuropeptide Y (human) (TFA)

Cat. No.: HY-P0198A

Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH_2 (TFA salt)

Purity: 98.84%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuropeptide Y(29-64)

Cat. No.: HY-P1601

Neuropeptide Y(29-64) is a 36 amino acid peptide, a fragment of Neuropeptide Y.

YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY

Purity: 99.47%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neurotensin

Cat. No.: HY-P0234

Neurotensin, a gut tridecapeptide, acts as a potent cellular mitogen for various colorectal and pancreatic cancers which possess high-affinity **neurotensin receptors** (**NTR**).

Pyr-LYENKPRRPYIL

Purity: 97.40%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

NGD-4715

Cat. No.: HY-100318

NGD-4715 is a selective and orally active **melanin-concentrating hormone receptor 1 (MCHR1)** antagonist .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nicotinamide N-oxide

Cat. No.: HY-101407

Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the **CXCR2** receptor.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Niperotidine

Cat. No.: HY-15539

Niperotidine is a **histamine H2-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nizatidine

Cat. No.: HY-B0310

Nizatidine is a potent and orally active **histamine H_2 receptor** antagonist, can be used for the research of stomach and intestines ulcers.



Purity: 99.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

NK-1 Antagonist 1

Cat. No.: HY-106659

NK-1 Antagonist 1 is an antagonist of **NK-1 receptor**, used in the research of NK-1 related diseases and conditions such as cough, overactive bladder, alcohol dependency and depression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NKP608

Cat. No.: HY-18006

NKP608 is a non-peptidic derivative of 4-aminopiperidine which acts as a selective, specific and potent antagonist at the neurokinin-1 (NK-1) receptor both in vitro(IC50=2.6 nM) and in vivo.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Nomegestrol

Cat. No.: HY-105634

Nomegestrol is a potent and orally available progestin, acts as a selective full **progesterone receptor** agonist, with a K_d of 5.44 nM for rat uterine progesterone receptor, and has moderate antiandrogenic activity and strong antiestrogenic activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Nomegestrol acetate

Cat. No.: HY-105634A

Nomegestrol acetate is a potent, highly selective progestogen, which is characterized as a full agonist at the **progesterone receptor**, with no or minimal binding to other steroid receptors, including the androgen and glucocorticoid receptors.



Purity: 98.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nonapeptide-1 acetate salt

(Melanostatine-5 acetate salt)

Cat. No.: HY-P0097A

Nonapeptide-1 acetate salt, a peptide hormone, is a potent α-Melanocyte-stimulating hormone **(α-MSH)** antagonist, with an IC_{50} of 11 nM. Reduces synthesis of melanin and helps decrease skin pigmentation to a substantial degree.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Noradrenaline tartrate

(Levarterenol tartrate; L-Noradrenaline tartrate)

Cat. No.: HY-13715C

Norepinephrine tartrate (Levarterenol tartrate), a naturally occurring chemical in the body that acts as both a stress hormone and neurotransmitter, is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Norcholic acid

Cat. No.: HY-N9457

Norcholic acid is a normal minorbile C23 bile acid having four side chain and exsits in human urine and meconium. Norcholic acid can become prominent under certain pathological conditions. Norcholic acid is efficiently absorbed from intestine and quickly excreted into the bile but not into urine.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Norepinephrine

(Levarterenol; L-Noradrenaline)

Cat. No.: HY-13715

Norepinephrine (Levarterenol; L-Noradrenaline) is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.



Purity: 98.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; ...)

Cat. No.: HY-13715B

Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate) is a β_1-selective **adrenergic receptor** agonist with EC_{50} of 5.37 μM.



Purity: 99.75%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

Norepinephrine hydrochloride (Levarterenol hydrochloride; L-Noradrenaline hydrochloride)

Cat. No.: HY-13715A

Norepinephrine hydrochloride (Levarterenol hydrochloride) is a β_1-selective **adrenergic receptor** agonist with **EC_{50}** of 5.37 μM.



Purity: 98.75%
Clinical Data: Launched
Size: 500 mg

Norethindrone (Norethisterone)

Cat. No.: HY-B0554

Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea.



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Norethindrone acetate (19-Norethindrone acetate)

Cat. No.: HY-B1710

Norethindrone acetate is a female hormone used for the research of endometriosis.



Purity: 99.41%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Norethindrone acetate-D8 (19-Norethindrone acetate-D8)

Cat. No.: HY-B1710S

Norethindrone acetate-D8 (19-Norethindrone acetate-D8) is the deuterium labeled Norethindrone acetate. Norethindrone acetate is a female hormone used for the research of endometriosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Norethisterone enanthate (Norigest)

Cat. No.: HY-A0285

Norethisterone enanthate is a long-acting **parenteral progestogen**. Norethisterone enanthate is orally active.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

Norgestimate

Cat. No.: HY-W013172

Norgestimate, a synthetic progesterone analog, is an orally active **progestin** with highly selective progestational activity and minimal androgenicity. Norgestimate is used for an oral contraceptive.



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mg

Norgestimate D6

Cat. No.: HY-139244S

Norgestimate D6 is the deuterium labeled Norgestimate. Norgestimate, a synthetic progesterone analog, is an orally active **progestin** with highly selective progestational activity and minimal androgenicity. Norgestimate is used for an oral contraceptive.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NRA-0160

Cat. No.: HY-101641

NRA-0160 is a selective **dopamine D4 receptor** antagonist, with a **K_i** value of 0.48 nM and with negligible affinity for **dopamine D2 receptor** (**K_i**: >10000 nM), **D3 receptor** (**K_i**: 39 nM), rat **5-HT2A receptor** (**K_i**: 180 nM) and rat **α1 adrenoceptor** (**K_i**: 237 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-ADW742 (ADW742; GSK 552602A; ADW)

Cat. No.: HY-10252

NVP-ADW742 (ADW742) is an orally active, selective **IGF-1R tyrosine kinase** inhibitor with an **IC_{50}** of 0.17 μM. NVP-ADW742 inhibits **insulin receptor (InsR)** with an **IC_{50}** of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/**proapoptotic** biologic sequelae in tumor cells.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-AEW541 (AEW541)

Cat. No.: HY-50866

NVP-AEW541 (AEW541) is a potent inhibitor of **IGF-1R** with **IC_{50}** of 0.15 μM, also inhibits **InsR**, with **IC_{50}** of 0.14 μM.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BAW2881

(BAW2881) Cat. No.: HY-100394

NVP-BAW2881 (BAW2881) is a potent and selective **VEGFR2** inhibitor with an IC_{50} of 4 nM.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVP-TAE 226

(TAE226) Cat. No.: HY-13203

NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual **FAK** and **IGF-1R** inhibitor with IC_{50}s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits **Pyk2** and **insulin receptor (InsR)** with IC_{50}s of 3.5 nM and 44 nM, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVS-CRF38

Cat. No.: HY-12339

NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility. IC50 value: Target: CRF1 antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ocedurenone

Cat. No.: HY-132827

Ocedurenone is a **corticosteroid receptor** antagonist. Ocedurenone can be used for the research of kidney disease (WO2018054357, compound I).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Octopamine hydrochloride

((±)-p-Octopamine hydrochloride) Cat. No.: HY-B0528A

Octopamine ((±)-p-Octopamine) hydrochloride, a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Octreotide

(SMS 201-995) Cat. No.: HY-P0036

Octreotide is a somatostatin analog that binds to the **somatostatin receptor**, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.

FCFWKTCT(Disulfide bridge: Cys2-Cys7)

Purity: 98.84%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Octreotide acetate

(SMS 201-995 acetate) Cat. No.: HY-17365

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits **growth hormone**, **glucagon**, and **insulin** more potently.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Olmesartan medoxomil

(CS 866) Cat. No.: HY-17005

Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** inhibitor with IC_{50} of 66.2 μM.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Olmesartan medoxomil-d6

Cat. No.: HY-17005S

Olmesartan medoxomil-d6 (CS 866-d6) is the deuterium labeled Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** inhibitor with IC_{50} of 66.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olmesartan-d4 Medoxomil

Cat. No.: HY-17005S1

Olmesartan-d4 Medoxomil (CS 866-d4) is the deuterium labeled Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective **angiotensin AT1 receptor** inhibitor with IC_{50} of 66.2 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Olodanrigan

(EMA401; PD-126055) Cat. No.: HY-13106

Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted **angiotensin II type 2 receptor (AT2R)** antagonist. It is under development as a neuropathic pain therapeutic agent.



Purity: 99.16%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olodaterol

(BI1744) Cat. No.: HY-14301

Olodaterol (BI1744) is a selective, long acting **β_2-adrenoceptor** (β_2-AR) agonist (EC_{50}=0.1 nM and pK_i= 9.14 for human β_2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis.



Purity: 98.48%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olodaterol hydrochloride

(BI1744 hydrochloride) Cat. No.: HY-14301A

Olodaterol (BI1744) hydrochloride is a selective, long acting **β_2-adrenoceptor** (β_2-AR) agonist (EC_{50}=0.1 nM and pK_i= 9.14 for human β_2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis.



Purity: 99.70%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olopatadine hydrochloride

(ALO4943A; KW4679) Cat. No.: HY-B0426A

Olopatadine hydrochloride (ALO4943A) is a histamine blocker used to treat allergic conjunctivitis.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Olopatadine-d3 hydrochloride

Cat. No.: HY-B0426AS

Olopatadine-d3 hydrochloride (ALO4943A-d3) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A) is a histamine blocker used to treat allergic conjunctivitis.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Omidenepag

Cat. No.: HY-17642

Omidenepag,a pharmacologically active form of Omidenepag Isopropyl, is a selective, non-prostanoid **EP2** receptor agonist, with an EC_{50} of 1.1 nM. Omidenepag shows binding affinities (IC_{50}) 10 nM for h-EP2.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ONC212

Cat. No.: HY-111343

ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer agent and also a selective agonist of **GPR132**. ONC212 also induces **apoptosis**.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ONO-AE3-208

(AE 3-208) Cat. No.: HY-50901

ONO-AE3-208 is an **EP4** antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

OP-3633

Cat. No.: HY-125839

OP-3633 is a potent and selective steroidal **glucocorticoid receptor (GR)** antagonist with an IC_{50} of 29 nM, with inhibition of GR transcriptional activity. OP-3633 exhibits low progesterone receptor (PR) agonism and androgen receptor (AR) antagonism.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OPC-28326

Cat. No.: HY-101610

OPC-28326 is a selective peripheral vasodilator and an angatonist of **α2-adrenergic receptor**, with K_i of 2040, 285, and 55nM for α2A-, α2B- and α2C-adrenoceptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

opigolix

Cat. No.: HY-U00289

Opigolix is a Gonadotropin-releasing hormone (**GnRH**) receptor antagonist, used for the research of endometriosis and rheumatoid arthritis.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Orexin 2 Receptor Agonist

Cat. No.: HY-19320

Orexin 2 Receptor Agonist is a potent (EC50 on OX2R is 23 nM) and OX2R-selective (OX1R/OX2R EC50 ratio is 70) agonist. IC50 value: 23 nM (EC50)
Target: Orexin 2 Receptor Orexin 2 Receptor Agonist shows not only potent activity but also high selectivity for OX2R over OX1R.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Orexin B, human

(Human orexin B)

Cat. No.: HY-P1339

Orexin B, human is an endogenous agonist at **Orexin** receptor with K_is of 420 and 36 nM for OX1 and OX2, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Orexin B, human TFA

(Human orexin B TFA)

Cat. No.: HY-P1339A

Orexin B, human (TFA) is an endogenous agonist at **Orexin** receptor with K_is of 420 and 36 nM for OX1 and OX2, respectively.

Purity: 98.15%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

Orexin B, rat, mouse

(Rat orexin B; Orexin B (mouse))

Cat. No.: HY-P1349

Orexin B, rat, mouse is an endogenous agonist at **Orexin** receptor with K_is of 420 and 36 nM for OX1 and OX2, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

Org41841

Cat. No.: HY-100271

Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (**LHCGR**) and thyroid-stimulating hormone receptor (**TSHR**) with EC_{50}s of 0.2 and 7.7 µM, respectively.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ORIC-101

Cat. No.: HY-112710

ORIC-101 is a highly potent and selective **glucocorticoid receptor** antagonist, with an EC_{50} of 5.6 nM. Anti-cancer activity.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg

ORM-15341

Cat. No.: HY-19337

ORM-15341 is a potent and full antagonist for human AR (hAR) with IC50 values of 38 nM as shown by transactivation assays in AR-HEK293 cells stably expressing full-length hAR and an androgen-responsive luciferase reporter gene construct.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Osthole

(Osthol; NSC 31868)

Cat. No.: HY-N0054

Osthole (Osthol) is a natural antihistamine alternative. Osthole may be a potential inhibitor of **histamine H_1 receptor** activity. Osthole also suppresses the secretion of **HBV** in cells.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 1 g, 5 g

OT antagonist 1

Cat. No.: HY-103650

OT antagonist 1 (Compound 4) is a potent, selective **Oxytocin** antagonist with a K_i of 50 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OT antagonist 1 demethyl derivative

Cat. No.: HY-103651

OT antagonist 1 demethyl derivative is the demethyl derivative of OT antagonist 1. OT antagonist 1 (Compound 4) is a potent, selective **Oxytocin** antagonist with a K_i of 50 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OT antagonist 3

Cat. No.: HY-103649

OT antagonist 3 is an **oxytocin** (OT) antagonist extracted from patent WO2007017752A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OT antagonist 3 analog

Cat. No.: HY-103652

OT antagonist 3 analog is an analog of OT antagonist 3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OT-R antagonist 1

(Oxytocin receptor antagonist 1)

Cat. No.: HY-15015

OT-R antagonist 1 is a new potent and selective nonpeptide low molecular weight OT-R antagonist. OT-R antagonist 1 inhibits oxytocin-evoked intracellular Ca2+ mobilization (IC50 = 8 nM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

OT-R antagonist 2

(Oxytocin receptor antagonist 2)

Cat. No.: HY-15015A

OT-R antagonist 2 is a nonpeptide low molecular weight OT-R antagonist. OT-R antagonist 2 inhibitis IP3-Synthesis, rat OT-R (IC50 = 0.33 μM). IC50 value: 0.33μM Target: oxytocin receptor.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Oxindole

(Indolin-2-one)

Cat. No.: HY-Y0061

Oxindole (Indolin-2-one) is an aromatic heterocyclic building block. 2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Oxytocin

(α-Hypophamine; Oxytocic hormone)

Cat. No.: HY-17571

Oxytocin (α-Hypophamine; Oxytocic hormone) is a pleiotropic, **hypothalamic peptide** known for facilitating parturition, lactation, and prosocial behaviors.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg

Oxytocin acetate

(α-Hypophamine acetate; Oxytocic hormone acetate)

Cat. No.: HY-17571A

Oxytocin acetate is a pleiotropic, **hypothalamic peptide** known for facilitating parturition, lactation, and prosocial behaviors.



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Oxytocin antiparallel dimer

Cat. No.: HY-P3222

Oxytocin antiparallel dimer is the disulfide-bridged homo peptide dimer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxytocin free acid

(9-Deamidooxytocin)

Cat. No.: HY-P3216

Oxytocin free acid (9-Deamidooxytocin) is an analog of oxytocin in which the glycinamide residue at position 9 in oxytocin has been replaced by a glycine residue.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxytocin parallel dimer

Cat. No.: HY-P3215

Oxytocin parallel dimer is the disulfide-bridged homo peptide dimer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p,p'-DDE

(4,4'-DDE; p,p'-Dichlorodiphenyldichloroethylene)

Cat. No.: HY-B1986

p,p'-DDE (4,4'-DDE), a major metabolite of persistent dichlorodiphenyltrichloroethane (DDT), is a potent **androgen receptor** antagonist, with an IC_{50} of 5 μM and a K_i of 3.5 μM.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

p-Hydroxycinnamic acid

Cat. No.: HY-N2391

p-Hydroxycinnamic acid, a common dietary phenol, could **inhibit platelet** activity, with IC_{50}**s** of 371 μM, 126 μM for thromboxane B_2 production and lipopolysaccharide-induced prostaglandin E_2 generation, respectively.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

p-Hydroxyphenethyl trans-ferulate

Cat. No.: HY-N3078

p-Hydroxyphenethyl trans-ferulate has anti-hyperglycemiceyeast **α-glucosidaseIC**$_{50}$ 19.24 ± 1.73 μmol L-1, antioxidant, and anti-inflammatory activities. p-Hydroxyphenethyl trans-ferulate shows inhibiting cancer preve.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Paltusotine

(CRN00808)

Cat. No.: HY-109155

Paltusotine (CRN00808) is an orally active, nonpeptide selective **somatostatin type 2 (SST2) receptor** agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pamabrom

Cat. No.: HY-17391

Pamabron is a common over-the-counter diuretic used for relief of menstrual-associated symptoms. The active diuretic ingredient in pamabrom is 8-bromotheophylline.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Pamatolol

Cat. No.: HY-U00019

Pamatolol is a cardioselective **beta-adrenoceptor** antagonist without sympathomimetic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pancreatic Polypeptide, bovine

Cat. No.: HY-P1537

Pancreatic Polypeptide, bovine, a 36-amino acid, straight chain polypeptide derived primarily from the pancreas, inhibits secretin- and cholecystokinin-stimulated pancreatic secretion; Pancreatic Polypeptide, bovine acts as an agonist of **NPY receptor**, with high affinity at **NPYR4**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Pancreatic Polypeptide, human

(Human pancreatic polypeptide)

Cat. No.: HY-P0199

Pancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a **neuropeptide Y** (**NPY**) **Y4/Y5** receptor agonist.

Purity: 99.91%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Pancreatic Polypeptide, rat

(Rat pancreatic polypeptide)

Cat. No.: HY-P1532

Pancreatic Polypeptide, rat is an agonist of **NPY receptor**, with high affinity at **NPYR4**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Pancreatin

Cat. No.: HY-B2118

Pancreatin is the porcine pancreas extract (PPE) which contains the main pancreatic digestive enzymes.

Pancreatin

Purity: >98%
Clinical Data: Phase 4
Size: 500 mg

Parathyroid hormone (1-34) (rat)

Cat. No.: HY-P2279

Parathyroid hormone (1-34) (rat) improves both cortical and cancellous bone structure.

AVSEIQLMHNLGKHLASVERMQWLRKKLQDVHNF

Purity: 95.53%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pardoprunox

(SLV-308; DU-126891)

Cat. No.: HY-14958

Pardoprunox (SLV-308) is a partial **dopamine D2** and **D3 receptor** partial agonist and a **serotonin 5-HT1A receptor** agonist, with **pEC$_{50}$**s of 8, 9.2, and 6.3, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Pardoprunox hydrochloride

(SLV-308 hydrochloride; DU-126891 hydrochloride)

Cat. No.: HY-14958A

Pardoprunox (SLV-308) hydrochloride is a partial **dopamine D2** and **D3 receptor** partial agonist and a **serotonin 5-HT1A receptor** agonist, with **pEC$_{50}$**s of 8, 9.2, and 6.3, respectively.



Purity: 98.24%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pargolol hydrochloride

(Ko 1400 hydrochloride)

Cat. No.: HY-101658

Pargolol hydrochloride is a **β adrenergic receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Paroxypropione

(4'-Hydroxypropiophenone)

Cat. No.: HY-B1353

Paroxypropione is a manufactured, nonsteroidal estrogen which has been used medically as an antigonadotropin.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Pasireotide

(SOM230)

Cat. No.: HY-16381

Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors** (subtypes **sst1/2/3/4/5**, **pK$_i$**=8.2/9.0/9.1/<7.0/9.9, respectively).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pasireotide acetate

(SOM230 acetate)

Cat. No.: HY-16381A

Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors** (subtypes **sst1/2/3/4/5**, **pK$_i$**=8.2/9.0/9.1/<7.0/9.9, respectively).



Purity: 99.78%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Pasireotide ditrifluoroacetate

(SOM230 ditrifluoroacetate; Pasireotide TFA salt)

Cat. No.: HY-79135

Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors** (subtypes **sst1/2/3/4/5**, **pK$_i$**=8.2/9.0/9.1/<7.0/9.9, respectively).



Purity: 99.27%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Pasireotide L-aspartate salt

(SOM230 L-aspartate)

Cat. No.: HY-79136

Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors** (subtypes **sst1/2/3/4/5**, **pK$_i$**=8.2/9.0/9.1/<7.0/9.9, respectively).



Purity: 99.44%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Pasireotide pamoate

(SOM230 pamoate) Cat. No.: HY-108768

Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors** (subtypes **sst1/2/3/4/5**, **pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pavinetant

(MLE-4901; AZD2624; AZD4901) Cat. No.: HY-14432

Pavinetant (MLE-4901) is a **neurokinin-3 receptor** (**NK3R**) antagonist.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PCO371

Cat. No.: HY-100856

PCO371 is an orally active full agonist of **parathyroid hormone receptor 1 (PTHR1)**, with no effect on PTH type 2 receptor.



Purity: 98.54%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD 123319

((S)-(+)-PD 123319) Cat. No.: HY-10259

PD 123319 (ditrifluoroacetate) is a potent, selective **AT2 angiotensin II receptor** antagonist with **IC_{50}** of 34 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD 123319 ditrifluoroacetate

Cat. No.: HY-10259A

PD 123319 (ditrifluoroacetate) is a potent, selective **AT2 angiotensin II receptor** antagonist with **IC_{50}** of 34 nM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PD-159020

Cat. No.: HY-101598

PD-159020 is a non-selective **ETA/ETB** antagonist, with **IC_{50}**s of 30 and 50 nM for hETA and hETB, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pedalitin

Cat. No.: HY-N3101

Pedalitin is a inhibitor of tyrosinase**IC_{50}**=0.28 mM and α-glucosidase**IC_{50}**=0.29 mM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Pemirolast potassium

(TWT-8152; BMY 26517) Cat. No.: HY-B0538A

Pemirolast potassium (TWT-8152) is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Penbutolol sulfate

((-)-Terbuclomine) Cat. No.: HY-B1154

Penbutolol sulfate is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker. Penbutolol is a sympathomimetic drugused in the treatment of high blood pressure.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Pentagastrin

(ICI-50123) Cat. No.: HY-A0261

Pentagastrin (ICI-50123) is a selective agonist of **Cholecystokinin B (CCK_B) receptor** with an **IC_{50}** of 11 nM. Pentagastrin enhances gastric mucosal defence mechanisms against acid and protects the gastric mucosa from experimental injury.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Peptide 401

Cat. No.: HY-12537

Peptide 401, a potent mast cell degranulating factor from bee venom, suppresses the increased vascular permeability due to intradermal injection of various smooth muscle spasmogens (**histamine**, and **5-HT**).

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Peptide YY (PYY), human

Cat. No.: HY-P1514

Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the **Neuropeptide Y receptors**.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg

Peroxidase

Cat. No.: HY-125859

Peroxidase actively involves in oxidizing reactive oxygen species, innate immunity, hormone biosynthesis and pathogenesis of several diseases.

Peroxidase

Purity: >98%
Clinical Data: No Development Reported
Size: 15 KU

Perphenazine

Cat. No.: HY-A0077

Perphenazine is a typical antipsychotic drug, inhibits **5-HT$_{2A}$receptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor**, and **Histamine H1 receptor**, with K_i values of 5.6, 10, 0.765/0.13, 3.4, and 8 nM, respectively.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Perphenazine D8 Dihydrochloride

Cat. No.: HY-A0077AS

Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pexacerfont

(BMS-562086)

Cat. No.: HY-12127

Pexacerfont is a selective corticotropin-releasing factor (**CRF$_1$**) receptor antagonist with **IC$_{50}$** of 6.1±0.6 nM for human CRF$_1$ receptor.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PF-00446687

Cat. No.: HY-10622

PF-00446687 is a potent, selective **melanocortin-4 receptor** (**MC4R**) agonist with **EC50** of 12±1 nM. Pf-446687 is brain penetrant.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-02413873

(PF-2413873)

Cat. No.: HY-11028

PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal **progesterone receptor (PR)** antagonist, with a K_i of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PF-03654746

Cat. No.: HY-11045

PF-03654746 is a potent and selective **histamine H3 receptor** antagonist with high brain penetration. PF-03654746 reduces allergen-induced nasal symptoms, might be a novel therapeutic strategy to further explore allergic rhinitis.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

PF-03654746 Tosylate

Cat. No.: HY-11044

PF-03654746 Tosylate is a potent and selective **histamine H3 receptor** antagonist with high brain penetration. PF-03654746 Tosylate reduces allergen-induced nasal symptoms.



Purity: 99.65%
Clinical Data: Phase 2
Size: 1 mg

PF-04418948

Cat. No.: HY-18966

PF-04418948 is an orally active, potent and selective **prostaglandin EP2 receptor** antagonist with an IC_{50} of 16 nM.



Purity: 99.22%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-4136309

(INCB8761)

Cat. No.: HY-13245

PF-4136309 is a potent, selective, and orally bioavailable **CCR2** antagonist, with IC_{50}s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.



Purity: 99.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-5190457

(PF-05190457)

Cat. No.: HY-12584

PF-5190457 (PF-05190457) is a potent and selective **ghrelin receptor** inverse agonist with a pK_i of 8.36.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-998425

Cat. No.: HY-14250

PF-998425 is a potent, selective nonsteroidal **androgen receptor (AR)** antagonist with an IC_{50} of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg

PG01

Cat. No.: HY-103369

PG01 is a potent **CFTR** Cl^- channel potentiator. PG01 can correct gating defects of **CFTR** mutants, is effective on b>E193K, **G970R** and **G551D** (CFTR mutants) with K_d values of 0.22 μM, 0.45 μM and 1.94 μM, respectively. PG01 is also effective on **ΔF508** (K_a of 0.3 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

PGlu-3-methyl-His-Pro-NH2 TFA

(A-42872 TFA)

Cat. No.: HY-107380A

PGlu-3-methyl-His-Pro-NH2 TFA (A-42872 TFA), the modified thyrotropin-releasing hormone (TRH) peptide, enhances binding to pituitary TRH receptors and increases stimulation of thyroid-stimulating hormone (TSH) release from the pituitary.



Purity: 96.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Pheniramine Maleate

Cat. No.: HY-B0971

Pheniramine Maleate ia an antihistamine and vasoconstrictor.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Phenoxybenzamine hydrochloride

Cat. No.: HY-B0431A

Phenoxybenzamine hydrochloride is a selective antagonist of both **α-adrenoceptor** and **calmodulin** that is commonly used for the treatment of hypertension, specifically caused by pheochromocytoma.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g

Phentolamine Analogue 1

Cat. No.: HY-U00404

Phentolamine Analogue 1 is an analogue of phentolamine. Phentolamine is a nonselective **alpha-adrenergic** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phentolamine mesylate

(Phentolamine methanesulfonate)

Cat. No.: HY-B0362A

Phentolamine mesylate (Phentolamine methanesulfonate) is a reversible, non-selective, and orally active blocker of **α1** and **α2** **adrenergic receptor** that expands blood vessels to reduce peripheral vascular resistance.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Phentolamine-d4 hydrochloride

Cat. No.: HY-12717AS

Phentolamine-d4 (Phentolamine-d4) hydrochloride is the deuterium labeled Phentolamine hydrochloride.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Phenylephrine

((R)-(-)-Phenylephrine; L-Phenylephrine) Cat. No.: HY-B0769

(R)-(-)-Phenylephrine is a selective **α_1-adrenoceptor** agonist primarily used as a decongestant.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Phenylephrine hydrochloride ((R)-(-)-Phenylephrine hydrochloride; L-Phenylephrine hydrochloride)

Cat. No.: HY-B0471

(R)-(-)-Phenylephrine hydrochloride is a selective **α_1-adrenoceptor** agonist with **pK_is** of 5.86, 4.87 and 4.70 for α_{1D}, α_{1B} and α_{1A} receptors respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Phosphatidylcholines,soya

(Soybean phosphatidylcholine) Cat. No.: HY-125853

Phosphatidylcholines,soya is a phosphatidylcholine from soybean used in the preparation of liposomes. Phosphatidylcholines,soya can be used as a vehicle in animal drug administration.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Phosphorylase Kinase β-Subunit Fragment (420-436)

Cat. No.: HY-P1873

Phosphorylase Kinase β-Subunit Fragment (420-436) is the β-Subunit fragment (peptide 430-436) of phosphorylase kinase. Phosphorylase kinase is a serine/threonine-specific protein kinase which activates glycogen phosphorylase to release glucose-1-phosphate from glycogen.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Physalaemin

Cat. No.: HY-P0255

Physalaemin, a non-mammalian tachykinin, binds selectively to **neurokinin-1** (**NK1**) **receptor** with high affinity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Picropodophyllin

(AXL1717; Picropodophyllin; PPP) Cat. No.: HY-15494

Picropodophyllin (AXL1717) is a selective **insulin-like growth factor-1 receptor (IGF-1R)** inhibitor with an **IC_{50}** of 1 nM.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pimethixene

(Pimetixene) Cat. No.: HY-B1101

Pimethixene is antihistamine and antiserotonergic compound, acts as an antimigraine agent.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pimethixene maleate

(Pimetixene maleate) Cat. No.: HY-B1101A

Pimethixene maleate is antihistamine and antiserotonergic compound, acts as an antimigraine agent.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Pimozide

(R6238) Cat. No.: HY-12987

Pimozide is a **dopamine receptor** antagonist, with **K_i**s of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at **α1-adrenoceptor**, with a **K_i** of 39 nM; Pimozide also inhibits **STAT3** and **STAT5**.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Pimozide-d4

(R6238-d4) Cat. No.: HY-12987S

Pimozide D4 (R6238 D4) is a deuterium labeled Pimozide.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Pindolol

(LB-46) Cat. No.: HY-B0982

Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (Ki=33nM).



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Pindolol-d7

Cat. No.: HY-B0982S

Pindolol-d7 (LB-46-d7) is the deuterium labeled Pindolol. Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (K_i=33 nM).



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg, 10 mg, 25 mg

Piperoxan hydrochloride

(Benodaine hydrochloride) Cat. No.: HY-100850

Piperoxan (Benodaine) hydrochloride is an α_2 adrenoceptor antagonist. Piperoxan hydrochloride is the first-generation antihistamine.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Piribedil

Cat. No.: HY-12707

Piribedil is a **dopamine D_2 receptor** (D_2R) agonist which also displays antagonist property at **hα_{1A}-adrenoceptor** (hα_{1A}-AR).



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Piribedil D8

(ET-495 D8) Cat. No.: HY-12707S

Piribedil D8 (ET-495 D8) is the deuterium labeled Piribedil, which is an antiparkinsonian agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pirolate

(CP-32387) Cat. No.: HY-100280

Pirolate is a **histamine H1** receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pitolisant

(Tiprolisant) Cat. No.: HY-12199

Pitolisant is a potent and selective nonimidazole inverse agonist at the recombinant human **histamine H3 receptor** (K_i=0.16 nM).



Purity: 97.22%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pitolisant hydrochloride

(Ciproxidine; BF 2649) Cat. No.: HY-12199B

Pitolisant hydrochloride is a potent and selective nonimidazole inverse agonist at the recombinant human **histamine H3 receptor** (K_i=0.16 nM).



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pitolisant oxalate

(Tiprolisant oxalate) Cat. No.: HY-12199A

Pitolisant oxalate is a potent and selective nonimidazole inverse agonist at the recombinant human **histamine H3 receptor** (K_i=0.16 nM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Plasma kallikrein-IN-1

Cat. No.: HY-139888

Plasma kallikrein-IN-1 is a **PKK** inhibitor with an IC_{50} value of 0.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Plerixafor

(AMD 3100; JM3100; SID791)

Cat. No.: HY-10046

Plerixafor (AMD 3100) is a selective **CXCR4** antagonist with an IC_{50} of 44 nM. Plerixafor, an immunostimulant and a **hematopoietic stem cell (HSC)** mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits **HIV-1** and **HIV-2** replication with an EC_{50} of 1-10 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Plerixafor octahydrochloride (AMD3100 octahydrochloride; JM3100 octahydrochloride; SID791 octahydrochloride)

Cat. No.: HY-50912

Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective **CXCR4** antagonist with an IC_{50} of 44 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pratosartan

(FW 7203; KD 3-671; KT 3671)

Cat. No.: HY-101574

Pratosartan is a selective **angiotensin II receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prazosin

Cat. No.: HY-B0193

Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Prazosin hydrochloride

Cat. No.: HY-B0193A

Prazosin hydrochloride is a well-tolerated, CNS-active **α1-adrenergic receptor** antagonist for the research of high blood pressure and alcohol use disorders.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Prednisolone

Cat. No.: HY-17463

Prednisolone is a potent, orally active corticosteroid and a glucocorticoid. Prednisolone possesses about four times the anti-inflammatory activity of hydrocortisone while causing less salt and water retention. Prednisolone can be used for ocular, anti-inflammatory research.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Prednisolone disodium phosphate

(Prednisolone 21-phosphate disodium)

Cat. No.: HY-B0645

Prednisolone disodium phosphate is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Prednisolone Tebutate

Cat. No.: HY-U00098

Prednisolone tebutate is a synthetic glucocorticoid used as an antiinflammatory and immunosuppressant.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Prednisone

(Dehydrocortisone)

Cat. No.: HY-B0214

Prednisone (Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound. Target: Others Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Prednisone acetate

(Prednisone 21-acetate)

Cat. No.: HY-B1832

Prednisone acetate (Prednisone 21-acetate), the acetate salt form of prednisolone, is a **glucocorticoid receptor** agonist with anti-inflammatory and immunomodulating properties.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Proglumide

Cat. No.: HY-B1330

Proglumide is a nonpeptide and orally active **cholecystokinin (CCK)-A/B receptors** antagonist. Proglumide selective blocks **CCK**'s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Proglumide hemicalcium

Cat. No.: HY-103354A

Proglumide hemicalcium is a nonpeptide and orally active **cholecystokinin (CCK)-A/B receptors** antagonist. Proglumide hemicalcium selective blocks **CCK**'s effects in the central nervous system (CNS).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Proglumide sodium

Cat. No.: HY-103354

Proglumide sodium is a nonpeptide and orally active **cholecystokinin (CCK)-A/B receptors** antagonist. Proglumide sodium selective blocks **CCK**'s effects in the central nervous system (CNS).



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Promegestone

(R-5020; Surgestone)

Cat. No.: HY-119384

Promegestone (R-5020), a progestin, is a potent **progesterone receptor (PR)** agonist. Promegestone has the potential for endocrine regulation and cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Promestriene

Cat. No.: HY-108293

Promestriene is a synthetic diethyl-ether of estradiol and a locally effective estrogen. Promestriene has an efficient action on vaginal atrophy while it is minimally absorbed.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Promestriene-d3

Cat. No.: HY-108293S

Promestriene-d3 is the deuterium labeled Promestriene. Promestriene is a synthetic diethyl-ether of estradiol and a locally effective estrogen. Promestriene has an efficient action on vaginal atrophy while it is minimally absorbed.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

Promethazine hydrochloride

Cat. No.: HY-B0781

Promethazine hydrochloride is the first-generation antihistamine; strong antagonist of the H1 receptor and moderate mACh receptor antagonist, moderate affinity for 5-HT2A, 5-HT2C, D2 and α1-adrenergic receptors.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

Propranolol

Cat. No.: HY-B0573B

Propranolol is a nonselective **β-adrenergic receptor (βAR)** antagonist, has high affinity for the β1AR and β2AR with K_i values of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [^{3}H]-DHA binding to rat brain membrane preparation with an IC_{50} of 12 nM.



Purity: 99.87%
Clinical Data: Launched
Size: 100 mg

Propranolol hydrochloride

Cat. No.: HY-B0573

Propranolol hydrochloride is a nonselective **β-adrenergic receptor (βAR)** antagonist, has high affinity for the β1AR and β2AR with K_i values of 1.8 nM and 0.8 nM, respectively.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Propranolol-d7 hydrochloride

Cat. No.: HY-B0573S

Propranolol D7 hydrochloride is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective **β-adrenergic receptor (βAR)** antagonist, has high affinity for the β1AR and β2AR with K_i values of 1.8 nM and 0.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propylthiouracil

(6-n-Propylthiouracil; 6-Propyl-2-thiouracil; PTU)

Cat. No.: HY-B0346

Propylthiouracil(6-Propyl-2-thiouracil) is a thyroperoxidase and 5'-deiodinase inhibitor.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Prostaglandin E1

(Alprostadil; PGE1)

Cat. No.: HY-B0131

Prostaglandin E1 (Alprostadil) is a **prostanoid receptor** ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for **mouse EP3**, **EP4**, **EP2**, **IP** and **EP1**, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation.



Purity: 98.03%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg

Prostaglandin E1-d4

Cat. No.: HY-B0131S

Prostaglandin E1-d4 (Alprostadil-d4) is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a **prostanoid receptor** ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for **mouse EP3**, **EP4**, **EP2**, **IP** and **EP1**, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Prostaglandin E2

(PGE2; Dinoprostone)

Cat. No.: HY-101952

Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.



Purity: 98.36%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Protein Kinase C Peptide Substrate

(PKCε; PRKCE ; Peptide Epsilon)

Cat. No.: HY-P1803

Protein Kinase C Peptide Substrate is targeted to a specific cellular compartment in a manner dependent on second messengers and on specific adapter proteins in response to extracellular signals that activate G-protein-coupled receptors, tyrosine kinase receptors, or...

ERMRPRKRQGSVRRRV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protirelin

(Thyrotropin-releasing-hormone; TRH)

Cat. No.: HY-P0002

Protirelin is a highly conserved neuropeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulatory functions.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Protirelin acetate

(Thyrotropin-releasing-hormone acetate; TRH acetate)

Cat. No.: HY-P0002A

Protirelin Acetate is a highly conserved neuropeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulatory functions.



1.5 CH_3COOH

Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pseudolaric acid A-O-β-D-glucopyranoside

Cat. No.: HY-N4088

Pseudolaric acid A-O-β-D-glucopyranoside, isolated from Cortex Pseudolaricis, demonstrates antifungal and antifertility activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSN 375963

Cat. No.: HY-108258

PSN 375963 is a potent **GPR119** agonist, with EC_{50}s of 8.4 and 7.9 μM for human and mouse GPR119, respectively. PSN 375963 shows similar potency to the endogenous agonist oleoylethanolamide (OEA).



Purity: 98.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PSN 375963 hydrochloride

Cat. No.: HY-108258A

PSN 375963 hydrochloride is a potent **GPR119** agonist, with EC_{50}s of 8.4 and 7.9 μM for human and mouse GPR119, respectively. PSN 375963 hydrochloride shows similar potency to the endogenous agonist oleoylethanolamide (OEA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

QF0301B

Cat. No.: HY-101690

QF0301B is an **α1 adrenergic receptor** antagonist and a low α2 adrenoceptor, 5-HT2A, and histamine H1 receptor blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quassin

(Nigakilactone D)

Cat. No.: HY-N1581

Quassin (Nigakilactone D) is a bioactive triterpenoid from stem bark extract of Quassia amara. Quassin inhibits **P. falciparum** with an IC_{50} of 0.15 μM. Quassin possesses reversible antifertility, anti-estrogenic and anti-plasmodial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Quinestrol

(W-3566)

Cat. No.: HY-B1012

Quinestrol is a synthetic estrogen, used in hormone replacement therapy, and occasionally to treat breast cancer and prostate cancer.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Quinotolast sodium

(FR71021)

Cat. No.: HY-U00027

Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits **histamine**, LTC_4 and PGD_2 release in a concentration-dependent manner.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

R121919

(NBI30775)

Cat. No.: HY-14127

R121919 (NBI30775) is a potent small-molecule **CRF1** receptor antagonist with a K_i of 2 to 5 nM for the CRF1 receptor and over 1000-fold weaker activity at the CRF2 receptor, CRF-binding protein, or 70 other receptor types.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Ralinepag

(APD811)

Cat. No.: HY-16751

Ralinepag is a potent, orally bioavailable and non-prostanoid **prostacyclin (IP) receptor** agonist, with EC_{50}s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Raloxifene 4'-glucuronide

Cat. No.: HY-135582

Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to **estrogen receptor** with an IC_{50} of 370 μM. .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Raloxifene 6-glucuronide

Cat. No.: HY-135581

Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to **estrogen receptor** with an IC_{50} of 290 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Raloxifene Bismethyl Ether

Cat. No.: HY-135580

Raloxifene Bismethyl Ether is a metabolite of Raloxifene and an estrogen receptor inactive compound on which both hydroxyl groups are absent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Raloxifene Bismethyl Ether hydrochloride

Cat. No.: HY-135580A

Raloxifene Bismethyl Ether hydrochloride is a metabolite of Raloxifene and an estrogen receptor inactive compound on which both hydroxyl groups are absent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Raloxifene hydrochloride (Keoxifene hydrochloride; LY156758; LY139481 hydrochloride)

Cat. No.: HY-13738A

Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active **estrogen receptor** modulator.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Ramatroban

(BAY u3405)

Cat. No.: HY-B0745

Ramatroban is a selective **thromboxane A_2** (**TxA_2**, **IC_{50}**=14 nM) antagonist, which also antagonizes **CRTH2** (**IC_{50}**=113 nM) by inhibiting **PGD_2** binding.



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ramelteon

(TAK-375)

Cat. No.: HY-A0014

Ramelteon is a highly potent and selective **melatonin** receptor agonist with **K_i** values of 14 and 112 pM for human melatonin1 and melatonin2.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

Ramelteon metabolite M-II

Cat. No.: HY-103005

Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC_{50}s of 208 pM, 1470 pM for human melatonin receptors (MT_1 or MT_2). Ramelteon is a selective melatonin agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ranitidine

Cat. No.: HY-B0693

Ranitidine is a potent, selective and orally active **histamine H2-receptor** antagonist with an **IC_{50}** of 3.3 μM that inhibits gastric secretion. Ranitidine is a weak inhibitor of **CYP2C19** and **CYP2C9**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ranitidine hydrochloride

Cat. No.: HY-B0281A

Ranitidine hydrochloride is a potent, selective and orally active **histamine H2-receptor** antagonist with an **IC_{50}** of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of **CYP2C19** and **CYP2C9**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Rauwolscine hydrochloride (α-Yohimbine hydrochloride; Corynanthidine hydrochloride; Isoyohimbine hydrochloride)

Cat. No.: HY-12710A

Rauwolscine hydrochloride is a potent and specific **α2 adrenergic** receptor antagonist with a **K_i** of 12 nM.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Relugolix

(TAK-385)

Cat. No.: HY-16474

Relugolix (TAK-385) is a potent, orally active, nonpeptidic **gonadotropin-releasing hormone (GnRH)** antagonist.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ReN-1869 hydrochloride

(NNC-05-1869 hydrochloride)

Cat. No.: HY-101724

ReN 1869 hydrochloride is a novel, selective **histamine H_1 receptor** antagonist, which demonstrates affinity to the histamine H_1 receptor (guinea pig brain) with K_i of 0.19±0.04 μM and the non-selective σ site (guinea pig brain) with K_i of 0.45 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reparixin

(Repertaxin; DF 1681Y) Cat. No.: HY-15251

Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors **CXCR1** and **CXCR2** activation with IC_{50}s of 1 and 100 nM, respectively.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Reparixin L-lysine salt

(Repertaxin L-lysine salt) Cat. No.: HY-15252

Reparixin L-lysine salt is an allosteric inhibitor of **chemokine receptor 1/2 (CXCR1/2)** activation.



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Resmetirom

(MGL-3196; VIA-3196) Cat. No.: HY-12216

Resmetirom (MGL-3196) is a highly selective thyroid hormone receptor β (**THR-β**) agonist with an EC_{50} value of 0.21 μM.



Purity: 99.71%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Retosiban

(GSK 221149; GSK 221149A) Cat. No.: HY-14778

Retosiban (GSK221149A) is a potent and selective oxytocin antagonist with a K_i of 0.65 nM.



Purity: 98.97%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Retrobradykinin

Cat. No.: HY-P2039

Retrobradykinin has the reverse sequence of Bradykinin (HY-P0206). Retrobradykinin exhibits no kinin activity and can be used as a negative control for Bradykinin.

RFPSFGPPR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

RF9

Cat. No.: HY-107382

RF9 is a potent and selective **Neuropeptide FF receptor** antagonist, with K_i values of 58 and 75 nM for **hNPFF1R** and **hNPFF2R**, respectively.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

RF9 hydrochloride

Cat. No.: HY-107382A

RF9 hydrochloride is a potent and selective **Neuropeptide FF receptor** antagonist, with K_i values of 58 and 75 nM for **hNPFF1R** and **hNPFF2R**, respectively.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RFRP-1(human)

Cat. No.: HY-P1428

RFRP-1(human) is a gonadotropin-inhibitory hormone (GnIH) homolog. RFRP-1(human) targets human gonadotropin-releasing hormone (GnRH) neurons and gonadotropes and potently inhibits **gonadotropin**.

MPHSFANLPLRF-NH_2

Purity: 99.32%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

RG7713

(RO5028442) Cat. No.: HY-12981

RG7713 (RO5028442) is a highly potent and selective **Brain-Penetrant Vasopressin 1a** (**V1a**) receptor antagonist with K_is of 1 nM (**hV1a**) and 39 nM (**mV1a**).



Purity: 99.79%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Rhoifolin

Cat. No.: HY-N0755

Rhoifolin is a flavone glycoside isolated from Citrus grandis (L.) Osbeck leaves. Rhoifolin is beneficial for diabetic complications through enhanced adiponectin secretion, tyrosine phosphorylation of **insulin receptor-β** and **glucose transporter 4 (GLUT 4)** translocation.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Ritodrine hydrochloride

(DU21220 hydrochloride) Cat. No.: HY-B0452

Ritodrine hydrochloride (DU21220 hydrochloride) is a β-2 adrenergic receptor agonist. Target: β-2 Adrenergic Receptor Ritodrine is a tocolytic drug, used to stop premature labor.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

RJW100

Cat. No.: HY-131445

RJW100 is a potent **liver receptor homolog 1 (LRH-1, NR5A2)** and **steroidogenic factor-1 (SF-1, NR5A1)** agonist with **pEC_{50}**s of 6.6 and 7.5, respectively. RJW100 also causes strong activation of the **miR-200c (miRNA-200c, microRNA-200c) promoter**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro 46-2005

Cat. No.: HY-19529

Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RO1138452

(CAY10441) Cat. No.: HY-108912

RO1138452 is a potent and selective **IP (prostacyclin) receptor** antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, **pK_i** is 9.3±0.1; in a recombinant IP receptor system, **pK_i** is 8.7±0.06.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rolapitant

(SCH619734) Cat. No.: HY-14751

Rolapitant (SCH619734) is a potent, selective and orally active **neurokinin** NK1 receptor antagonist with a **K_i** of 0.66 nM.



Purity: 98.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rotigotine

(N-0437; N-0923) Cat. No.: HY-75502

Rotigotine (N-0437; N-0923) is a full agonist of **dopamine receptor**, a partial agonist of the **5-HT1A receptor**, and an antagonist of the **α2B-adrenergic receptor**, with **K_i**s of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine...



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

RS 17053 hydrochloride

(RS-17053) Cat. No.: HY-101336

RS 17053 hydrochloride is a potent and selective **$α1_A$ adrenoceptor** antagonist, with a **pK_i** value of 9.1 in native cell membrane and a **pA_2** value of 9.8 in functional assays.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RS 504393

Cat. No.: HY-15418

RS 504393 is a selective **CCR2** chemokine receptor antagonist (**IC_{50}** values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RS-601

Cat. No.: HY-U00072

RS-601 is a novel **leukotriene D4 (LTD4)/thromboxane A2 (TxA2)** dual receptor antagonist, with antiasthmatic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RS102895

Cat. No.: HY-18611A

RS102895 is a potent **CCR2** antagonist, with an **IC_{50}** of 360 nM, and shows no effect on CCR1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RS102895 hydrochloride

Cat. No.: HY-18611

RS102895 hydrochloride is a potent **CCR2** antagonist, with an **IC_{50}** of 360 nM, and shows no effect on CCR1.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

RU 58841

(PSK-3841; HMR-3841)

Cat. No.: HY-10561

RU 58841 (PSK-3841) is a specific androgen receptor antagonist or anti-androgen. RU 58841 (PSK-3841) has a dramatic effect on hair regrowth.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

S 38093

Cat. No.: HY-104003

S 38093 is a brain-penetrant, orally active antagonist of **H3 receptor**, with **K_i**s of 8.8, 1.44 and 1.2 μM for rat, mouse and human H3 receptors, respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

S-Dihydrodaidzein

Cat. No.: HY-N4200

S-Dihydrodaidzein is the (S)-enantiomer of dihydrodaidzein which is one of the most prominent dietary phytoestrogens.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sacubitril/Valsartan

(LCZ696)

Cat. No.: HY-18204A

Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting **angiotensin receptor-neprilysin (ARN)** inhibitor for hypertension and heart failure.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Salbutamol

(Albuterol; AH-3365)

Cat. No.: HY-B1037

Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Salbutamol hemisulfate

(Albuterol hemisulfate; AH-3365 hemisulfate)

Cat. No.: HY-B0436

Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting β2 adrenergic receptor agonist Target: β2 Adrenergic Receptor Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and...



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Salmeterol

(GR33343X)

Cat. No.: HY-14302

Salmeterol (GR33343X) is a potent and selective human **β2 adrenoceptor** agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human **β2, β1 and β3 adrenoceptors** with **pEC_{50}**s of 9.6, 6.1, and 5.9, respectively.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Salmeterol xinafoate

(GR 33343X xinafoate)

Cat. No.: HY-17453

Salmeterol (GR 33343X) xinafoate is a potent and selective human **β2 adrenoceptor** agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human **β2, β1 and β3 adrenoceptors** with **pEC_{50}**s of 9.6, 6.1, and 5.9, respectively.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Salmeterol-D3

Cat. No.: HY-135119

Salmeterol-D3 is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human **β2 adrenoceptor** agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human **β2, β1 and β3 adrenoceptors** with **pEC_{50}**s of 9.6, 6.1, and 5.9, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Saredutant

(SR 48968; SR 48968C)

Cat. No.: HY-106910

Saredutant is a selective **NK2 receptor** antagonist.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sauvagine

Cat. No.: HY-P1298

Sauvagine, a 40-amino-acid neuropeptide from the skin of the frog, is a **mammalian CRF** agonist. Sauvagine is effective at releasing ACTH from rat pituitary cells. Sauvagine possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sauvagine TFA

Cat. No.: HY-P1298A

Sauvagine TFA, a 40-amino-acid neuropeptide from the skin of the frog, is a **mammalian CRF** agonist. Sauvagine TFA is effective at releasing ACTH from rat pituitary cells.

Purity: 95.17%
Clinical Data: No Development Reported
Size: 5 mg

SB-222200

Cat. No.: HY-15722

SB-222200 is a potent, selective, orally active and blood-brain barrier (BBB) penetrant **NK-3 receptor** antagonist. SB-222200 is developed for central nervous system (CNS) disorders.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SB-334867

(SB 334867A)

Cat. No.: HY-10895

SB-334867 (SB 334867A) is an excellent,selective and blood–brain barrier permeable **orexin-1 (OX1) receptor** antagonist, shows selectivity over **OX2** (pK_b=7.4), 100-fold over 5-HT_{2B}, 5-HT_{2C} with pK_i values of 5.4 and 5.3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-334867 free base

(SB334867A free base)

Cat. No.: HY-10895A

SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable **orexin-1 (OX1) receptor** antagonist, shows selectivity over **OX2** (pK_b=7.4), 100-fold over 5-HT_{2B}, 5-HT_{2C} with pK_i values of 5.4 and 5.3, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SB-408124

Cat. No.: HY-70068

SB-408124 is a non-peptide **OX1 receptor** antagonist with K_is of 57 nM and 27 nM in whole cell and membrane, respectively. SB-408124 exhibits 50-fold selectivity over OX2 receptor.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 100 mg

SB-408124 Hydrochloride

Cat. No.: HY-76612

SB-408124 Hydrochloride is a selective non-peptide **orexin receptor 1 (OX1) receptor** antagonist with K_is of 57 nM and 27 nM in whole cell and membrane, respectively. SB-408124 Hydrochloride exhibits 50-fold selectivity over OX2 receptor.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SB-568849

Cat. No.: HY-100308

SB-568849 is a **melanin-concentrating hormone receptor 1** (**MCH R1**) antagonist with a pK_i of 7.7.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-649868

(GSK649868)

Cat. No.: HY-10806

SB-649868 is a potent and selective orally active **orexin** (**OX**) **1** and OX_2 receptor antagonist (pK_i =9.4 and 9.5 at the OX_1 and OX_2 receptor, respectively).



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-674042

Cat. No.: HY-10898

SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd = 3.76 nM); exhibits 100-fold selectivity for OX1 over OX2 receptors.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SB225002

Cat. No.: HY-16711

SB225002, a potent, selective and non-peptide **CXCR2** antagonist, inhibits ^{125}I-IL-8 binding to CXCR2 with an **IC_{50}** of 22 nM.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SB297006

Cat. No.: HY-103361

SB297006 is a **CCR3** antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SBI-553

Cat. No.: HY-125880

SBI-553 is a potent and brain penetrant **NTR1** allosteric modulator, with an **EC_{50}** of 0.34 μM.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SCH 546738

Cat. No.: HY-10017

SCH 546738 is a potent, orally active and non-competitive **CXCR3** antagonist, the affinity constant (K_i) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SCH 563705

Cat. No.: HY-10011

SCH 563705 is a potent and orally available **CXCR2** and **CXCR1** antagonist, with **IC_{50}**s of 1.3 nM, 7.3 nM and **K_i**s of 1 and 3 nM, respectively.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SCH28080

Cat. No.: HY-103261

SCH28080 is a reversible, K^+-competitive inhibitor of the **gastric H,K-ATPase**, with a **K_i** of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Scopine

(6,7-Epoxytropine)

Cat. No.: HY-B0459

Scopine is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Scopine hydrochloride

(6,7-Epoxytropine hydrochloride)

Cat. No.: HY-B0459A

Scopine hydrochloride (6,7-Epoxytropine hydrochloride) is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Scyliorhinin II

Cat. No.: HY-P1588

Scyliorhinin II is a selective **neurokinin-3 receptor** agonist, with a **K_i** of 2.5 nM for neurokinin-3 receptor in rat cerebral cortex.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

SecinH3

Cat. No.: HY-100559

SecinH3 is an antagonist of **cytohesins** with IC_{50}s of 5.4 μM, 2.4 μM, 5.4 μM, 5.6 μM, 5.6 μM and 65 μM for **hCyh1**, **hCyh2**, **mCyh3**, **hCyh3**, **drosophila steppke** and **yGea2-S7**, respectively.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Secretin, canine

Cat. No.: HY-P1784

Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Selexipag

(NS-304; ACT-293987)

Cat. No.: HY-14870

Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (**PGI_2**) receptor (IP receptor).



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Selexipag-d8

Cat. No.: HY-14870S

Selexipag-d8 (NS-304-d8) is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (**PGI_2**) receptor (IP receptor).



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Seltorexant

(JNJ-42847922)

Cat. No.: HY-109012

Seltorexant (JNJ-42847922) is an orally active, high-affinity, and selective **orexin-2 receptor (OX2R)** antagonist (**pK_i** values of 8.0 and 8.1 for human and rat OX2R). Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain.



Purity: 99.62%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Seltorexant hydrochloride

(JNJ-42847922 hydrochloride)

Cat. No.: HY-109012A

Seltorexant hydrochloride (JNJ-42847922 hydrochloride) is an orally active, high-affinity, and selective **OX2R** antagonist (**pK_i** values of 8.0 and 8.1 for human and rat OX2R).



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

Senktide

Cat. No.: HY-P0187

Senktide is a tachykinin **NK_3 receptor** agonist.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Seratrodast

(AA 2414)

Cat. No.: HY-B0774

Seratrodast(AA 2414) is an anti-asthmatic agent and a potent and selective thromboxane A2 receptor (TP) antagonist.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Serlopitant

(VPD-737; MK-0594)

Cat. No.: HY-12114

Serlopitant is a selective **Neurokinin-1 (NK-1)** receptor antagonist.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Setipiprant

(ACT-129968; KYTH-105)

Cat. No.: HY-16635

Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2.



Purity: 98.70%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Sevelamer

Cat. No.: HY-13995

Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

SHR1653

Cat. No.: HY-128351

SHR1653 is a highly potent, selective and brain penetrated **oxytocin receptor (OTR)** antagonist, with an **IC_{50}** of 15 nM for hOTR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SID 7969543

Cat. No.: HY-107404

SID 7969543 is a selective **SF-1** (steroidogenic factor 1, NR5A1) inhibitor with an **IC_{50}** of 760 nM. SID 7969543 inhibits SF-1-triggered luciferase expression with IC_{50} of 30 nM. SF-1 is a transcription factor belonging to the nuclear receptor superfamily.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Silodosin

(KAD 3213; KMD 3213)

Cat. No.: HY-10122

Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active **α1A-adrenergic receptor (α1A-AR)** blocker.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Silodosin-d4

Cat. No.: HY-10122S

Silodosin-d4 (KAD 3213-d4) is the deuterium labeled Silodosin. Silodosin (KAD 3213) is a potent, selective and orally active **α1A-adrenergic receptor (α1A-AR)** blocker.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Silychristin

Cat. No.: HY-N0647

Silychristin is an abundant flavonolignan present in the fruits of Silybum marianum, with antioxidant properties. Silychristin is a potent inhibitor of the thyroid hormone transporter **MCT8**, and elicits a strong inhibition of T3 uptake with an IC_{50} of 110 nM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sitaxsentan

(IPI 1040; TBC-11251)

Cat. No.: HY-76520

Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure. IC50 value: Target: ETA receptor.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Sitaxsentan sodium

(IPI 1040 sodium; TBC11251 sodium)

Cat. No.: HY-11103

Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of **endothelin A receptors**.



Purity: 99.03%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SL910102

Cat. No.: HY-100292

SL910102 is a nonpeptide **angiotensin AT_1 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNAP 94847

Cat. No.: HY-107625

SNAP 94847 is a novel, high affinity selective **melanin-concentrating hormonereceptor1 (MCHR1)** antagonist with (K_i= 2.2 nM, K_d=530 pM), it displays >80-fold and >500-fold selectivity over **MCHα1A** and **MCHD2** receptors respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNT-207707

Cat. No.: HY-11029

SNT-207707 is a selective, potent and orally active **melanocortin MC-4** receptor antagonist with an IC_{50} of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SNT-207858

Cat. No.: HY-11030

SNT207858 is a selective, blood brain barrier penetrating, potent and orally active **melanocortin-4** (**MC-4**) **receptor** antagonist. SNT207858 has an IC_{50} of 22 nM (binding) and 11 nM (function) on the MC-4 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNT-207858 free base

Cat. No.: HY-11030A

SNT207858 free base is a selective, blood brain barrier penetrating, potent and orally active **melanocortin-4** (**MC-4**) **receptor** antagonist. SNT207858 free base has an IC_{50} of 22 nM (binding) and 11 nM (function) on the MC-4 receptor.



Purity: 98.06%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sobetirome

(GC-1; QRX-431)

Cat. No.: HY-14823

Sobetirome (GC-1) is a thyroid hormone receptor β (**TRβ**)-specific agonist which bind selectively to **TRβ-1** with an EC_{50} of 0.16 μM.



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Sodium tauroglycocholate

(Tauroglycocholic acid sodium salt)

Cat. No.: HY-B2119

Sodium tauroglycocholate is an inhibitor of the biliary acid transporting system of the hepatocyte and also a surfactant used as a chemical permeation enhancer.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Sograzepide

(Netazepide; YF 476; YM-220)

Cat. No.: HY-14850

Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent , highly selective and orally active **Gastrin/CCK-B** antagonist with an IC_{50} value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC_{50} of 502...



Purity: 98.51%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Solabegron

(GW 427353)

Cat. No.: HY-19436

Solabegron (GW 427353) is a selective **β_3-adrenergic receptor** agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β_3-AR, with an EC_{50} value of 22 nM.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Somatostatin

Cat. No.: HY-P0015

Somatostatin is a tetradecapeptide which can suppress the growth hormone (GH) secretion and control the pituitary hormone secretion in human CNS.

Purity: 99.41%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Soyasaponin Bb

Cat. No.: HY-N0310

soyasaponin Bb is a soyasaponin isolated from Phaseolus vulgaris, acting as an **aldose reductase differential inhibitor (ARDI)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Sparsentan

(RE-021; DARA-a)

Cat. No.: HY-17621

Sparsentan (RE-021) is a highly potent dual **angiotensin II** and **endothelin A** receptor antagonist with K_is of 0.8 and 9.3 nM, respectively.



Purity: 99.08%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sphingosine-1-phosphate

(S1P)

Cat. No.: HY-108496

Sphingosine-1-phosphate (S1P) is an agonist of **$S1P_{1-5}$ receptors** and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca^{2+} as an extracellular ligand for G protein-coupled receptors.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Spirendolol

(Li 32-468; S 32-468; Substance 32468)

Cat. No.: HY-101817

Spirendolol is a **β adrenergic receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR 146131

Cat. No.: HY-11077

SR 146131 is a potent, orally available, and selective nonpeptide (**cholecystokinin 1**) receptor agonist.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

SRT3109

Cat. No.: HY-15462

SRT3109 is an antagonist of **CXCR2**, with a **pIC_{50}** of 8.2, and used in the research of chemokine mediated diseases.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SRT3190

Cat. No.: HY-13021

SRT3190 is an antagonist of **CXCR2**, used in the research of chemokine mediated diseases.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SSR-241586

Cat. No.: HY-19456

SSR-241586 is an antagonist of **neurokinin receptors**. SSR-241586 is shown to be active in the treatment of depression, schizophrenia, urinary trouble, emesis, and irritable bowel syndrome (IBS).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSR240612

Cat. No.: HY-15039

SSR240612 is a potent, and orally active specific non-peptide **bradykinin B1 receptor** antagonist, with K_is of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes...



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

SSTR5 antagonist 1

Cat. No.: HY-102037

SSTR5 antagonist 1 is a potent, selective, and orally available somatostatin receptor subtype 5 (**SSTR5**) antagonist with **IC_{50}**s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively. (Compound 25a).



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SSTR5 antagonist 2

Cat. No.: HY-114191

SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and **selective somatostatin (receptor) subtype 5 (SSTR5)** antagonist and has potential to treat type 2 diabetes mellitus (T2DM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSTR5 antagonist 2 TFA

Cat. No.: HY-114191A

SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and **selective somatostatin (receptor) subtype 5 (SSTR5)** antagonist and has potential to treat type 2 diabetes mellitus (T2DM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Stanolone benzoate (Androstanolone benzoate; Dihydrotestosterone benzoate; DHTB)

Cat. No.: HY-128698

Stanolone benzoate (Androstanolone benzoate) is a synthetic androgen and anabolic steroid.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Statine

((3S,4S)-Statine; (S,S)-Statine)

Cat. No.: HY-101877

Statine is an unusual amino acid that occurs twice in the sequence of pepstatin, a protease inhibitor that is active against **pepsin** and other **acid proteases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Substance P

(Neurokinin P)

Cat. No.: HY-P0201

Substance P (Neurokinin P) is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is **neurokinin 1 receptor** (**NK1-receptor**, **NK1R**).

Purity: 99.60%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 25 mg

Substance P (7-11)

Cat. No.: HY-P1492

Substance P (7-11) is a C-terminal fragment of Substance P which can cause an increase in the intracellular calcium concentration.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Substance P TFA

(Neurokinin P TFA)

Cat. No.: HY-P0201A

Substance P TFA (Neurokinin P TFA) is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is **neurokinin 1 receptor** (**NK1-receptor**, **NK1R**).

Purity: 99.60%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Substance P(1-7)

Cat. No.: HY-P1485

Substance P(1-7) is a fragment of the neuropeptide, substance P (SP). Substance P(1-7) gives depressor and bradycardic effects when applied to the nucleus tractus solitarius.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Substance P(1-7) TFA

Cat. No.: HY-P1485A

Substance P(1-7) TFA is a fragment of the neuropeptide, substance P (SP). Substance P(1-7) TFA gives depressor and bradycardic effects when applied to the nucleus tractus solitarius.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Substituted piperidines-1

Cat. No.: HY-100305

Substituted piperidines-1 is a compound that can promote the release of growth hormone in humans and animals.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sufugolix

(TAK-013)

Cat. No.: HY-100209

Sufugolix (TAK-013) is a highly potent and orally available luteinizing hormone-releasing hormone (**LHRH**) receptor antagonist with an IC_{50} of 0.1 nM.



Purity: 95.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sulfisoxazole

(Sulfafurazole)

Cat. No.: HY-B0323

Sulfisoxazole (Sulfafurazole), an endothelin receptor antagonist, is a sulfonamide antibacterial with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

SUN 1334H

Cat. No.: HY-U00084

SUN 1334H is a potent, orally active, highly selective **H1 receptor** antagonist, with K_i of 9.7 nM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg

SX-682

Cat. No.: HY-119339

SX-682 is an orally bioavailable, potent allosteric inhibitor of **CXCR1** and **CXCR2**. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.



Purity: 98.52%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Synephrine

(Oxedrine)

Cat. No.: HY-N0132

Synephrine (Oxedrine), an alkaloid, is an **α-adrenergic** and **β-adrenergic** agonist derived from the Citrus aurantium. Synephrine is a sympathomimetic compound and can be used for weight loss.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 5 mg

Synephrine hydrochloride

(Oxedrine hydrochloride)

Cat. No.: HY-N0132A

Synephrine (Oxedrine) hydrochloride, an alkaloid, is an **α-adrenergic** and **β-adrenergic** agonist derived from the Citrus aurantium. Synephrine hydrochloride is a sympathomimetic compound and can be used for weight loss.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

T3-ATA (S-isomer)

Cat. No.: HY-114271A

T3-ATA S-isomer is the S-isomer of T3-ATA, which is the active form of the thyroid hormone.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

T4-ATA (S-isomer)

Cat. No.: HY-114272A

T4-ATA S-isomer is the S-isomer of T4-ATA, which is the active form of the thyroid hormone.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Tachykinin angatonist 1

Cat. No.: HY-U00392

Tachykinin angatonist 1 is a **neurokinin receptor** antagonist extracted from patent US5968923, compound example 32.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-220

Cat. No.: HY-19974

TAK-220 is a selective and orally bioavailable **CCR5** antagonist, with IC_{50}s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits **HIV-1**,...



Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TAK-779

(Takeda 779)

Cat. No.: HY-13406

TAK-779 is a potent and selective nonpeptide antagonist of **CCR5** and **CXCR3**, with a K_i of 1.1 nM for CCR5, and effectively and selectively inhibits **R5 HIV-1**, with EC_{50} and EC_{90} of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Talipexole dihydrochloride

(B-HT 920 dihydrochloride)

Cat. No.: HY-A0008

Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Talnetant
(SB 223412) Cat. No.: HY-14552

Talnetant (SB 223412) is a potent and selective NK3 receptor antagonist (ki=1.4 nM, hNK-3-CHO); 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 uM.



Purity: 99.43%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

Talnetant hydrochloride
(SB 223412 hydrochloride; SB 223412-A) Cat. No.: HY-14552A

Talnetant Hcl(SB 223412 Hcl) is a potent and selective NK3 receptor antagonist(ki=1.4 nM, hNK-3-CHO); 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 uM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Taltirelin
(TA-0910) Cat. No.: HY-B0596

Taltirelin (TA0910) is a superagonist at **thyrotropin-releasing hormone receptor (TRH-R)** with an IC_{50} of 910 nM and EC_{50} of 36 nM for stimulating an increase in cytosolic Ca^{2+} concentration (Ca^{2+} release).



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Taltirelin acetate
(TA-0910 acetate) Cat. No.: HY-B0596A

Taltirelin acetate (TA-0910 acetate) is a superagonist at **thyrotropin-releasing hormone receptor (TRH-R)** with an IC_{50} of 910 nM and EC_{50} of 36 nM for stimulating an increase in cytosolic Ca^{2+} concentration (Ca^{2+} release).



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tamsulosin
((R)-(-)-YM12617 free base; LY253351 free base) Cat. No.: HY-B0661

Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of **α_1-adrenergic receptor**. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tamsulosin hydrochloride
((R)-(-)-YM12617; LY253351) Cat. No.: HY-B0661A

Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of **α_1-adrenergic receptor**. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tanaproget
(NSP-989) Cat. No.: HY-15606

Tanaproget (NSP-989) is a novel nonsteroidal progesterone receptor agonist which can bind to the PR from various species with a higher relative affinity than reference steroidal progestins.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Taprenepag
(CP-544326) Cat. No.: HY-14899

Taprenepag (CP-544326) is a potent and selective **prostaglandin EP(2)** agonist with IC_{50}s of 10 and 15 nM for human and rat EP2, respectively. Taprenepag shows selectivity for EP2 over other EP receptors (IC50s>3200 nM for EP1, EP3, and EP4) and a panel of 37 G protein-coupled receptors.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Taprenepag isopropyl
(PF-04217329) Cat. No.: HY-19998

Taprenepag isopropyl is a highly selective **EP_2 receptor** agonist.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tarazepide
Cat. No.: HY-U00062

Tarazepide is a potent and specific **CCK-A** receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tasimelteon

(BMS-214778; VEC-162) Cat. No.: HY-14803

Tasimelteon (BMS-214778) is an orally active and selective **dual melatonin receptor agonist (DMRA)**. Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor.



Purity: 99.16%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tasosartan

(WAY-ANA 756) Cat. No.: HY-A0250

Tasosartan is a long-acting **angiotensin II** (**AngII**) **receptor** antagonist.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

TBC3711

Cat. No.: HY-106182

TBC3711 is a **endothelin receptor** modulator, used for the research of endothelin-mediated disorders.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TC-G-1008

(GPR39-C3) Cat. No.: HY-103007

TC-G-1008 (GPR39-C3) is a potent and orally available **GPR39** agonist with EC_{50} values of 0.4 and 0.8 nM for rat and human receptors respectively.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TCS 1102

Cat. No.: HY-10900

TCS 1102 is a potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively). IC50 value: 0.2 nM (Ki, OX2 receptor); 3 nM (Ki, OX1 receptor) Target: OX2 and OX1 receptor TCS-1102 (10 and 20 mg/kg, i.p.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TCS-OX2-29

Cat. No.: HY-100452

TCS-OX2-29 is a potent, high affinities and selective **orexin-2 receptor** (OX_2R) antagonist with an IC_{50} value of 40 nM and a pK_i value of 7.5. TCS-OX2-29 displays ~250-fold selectivity for OX_2 over OX_1.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TD-0212

Cat. No.: HY-114412

TD-0212 (compound 35) is an orally active dual pharmacology **angiotensin II type 1 receptor** (AT_1) antagonist and **neprilysin (NEP)** inhibitor, with a pK_i of 8.9 for AT_1 and a pIC_{50} of 9.2 for NEP.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TD-5471 hydrochloride

Cat. No.: HY-19942A

TD-5471 hydrochloride is a potent and selective full agonist of the human β_2-**adrenoceptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tedatioxetine hydrobromide

(Lu AA24530 hydrobromide) Cat. No.: HY-101755

Tedatioxetine (Lu AA24530) hydrobromide acts as a serotonin and norepinephrine (NE)-preferring triple reuptake inhibitor (TRI) and **5-HT_{2A}**, **5-HT_{2C}**, **5-HT_3** and **α_{1A}-adrenergic receptor** antagonist
. ,.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Telmisartan

(BIBR 277) Cat. No.: HY-13955

Telmisartan is a potent, long lasting antagonist of **angiotensin II type 1 receptor (AT1)**, selectively inhibiting the binding of ^{125}I-AngII to AT1 receptors with IC_{50} of 9.2 nM.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Teoprolol

Cat. No.: HY-U00016

Teoprolol is a **β-adrenergic receptor** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Terazosin

Cat. No.: HY-B0371

Terazosin is a quinazoline derivative and a competitive and orally active **α1-adrenoceptor** antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Terazosin hydrochloride

Cat. No.: HY-B0371F

Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active **α1-adrenoceptor** antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Terazosin hydrochloride dihydrate

Cat. No.: HY-B0371A

Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active **α1-adrenoceptor** antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Terbogrel

(BIBV 308SE)

Cat. No.: HY-19189

Terbogrel is an orally available **thromboxane A2 receptor** antagonist and a **thromboxane A2 synthase** inhibitor, with both IC_{50}s of about 10 nM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Terbutaline sulfate

(Terbutaline hemisulfate)

Cat. No.: HY-B0802

Terbutaline sulfate is a β2-adrenergic receptor agonist; a fast-acting bronchodilator and a tocolytic to delay premature labor.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Terfenadine

((±)-Terfenadine; MDL-991)

Cat. No.: HY-B1193

Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of **hERG** with an IC_{50} of 204 nM. Terfenadine, an **H1 histamine receptor** antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca^{2+} homeostasis.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Terfenadine-d3

Cat. No.: HY-B1193S

Terfenadine-d3 ((±)-Terfenadine-d3) is the deuterium labeled Terfenadine. Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of **hERG** with an IC_{50} of 204 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 2000 μg, 5 mg, 10 mg, 25 mg

Terlipressin

Cat. No.: HY-12554

Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective **vasopressin V1 receptor** agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Terlipressin acetate

Cat. No.: HY-12554A

Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective **vasopressin V1 receptor** agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding.



Purity: 99.76%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tertatolol

((±)-Tertatolol; Racemic Tertatolol; dl-Tertatolol) Cat. No.: HY-U00356

Tertatolol is a potent antagonist of **beta-adrenoceptor** and **5-HT receptor**, with unique renal vasodilatatory effects.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Terutroban

(S-18886) Cat. No.: HY-16991

Terutroban is a **thromboxane-prostaglandin receptor** antagonist.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tetrahydroalstonine

Cat. No.: HY-N1163

Tetrahydroalstonine, a indole alkaloid isolated from the fruits of Rhazya stricta, is a selective **alpha 2-adrenoceptor** antagonist.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Tetrahydrozoline hydrochloride

(Tetryzoline hydrochloride) Cat. No.: HY-B0556A

Tetrahydrozoline hydrochloride (Tetryzoline hydrochloride), a derivative of imidazoline, is an **α-adrenergic** agonist that causes vasoconstriction. Tetrahydrozoline hydrochloride is widely used for the research of nasal congestion and conjunctival congestion.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Tezosentan

(RO 610612) Cat. No.: HY-17351

Tezosentan (RO 610612) is an **endothelin (ET)** receptor antagonist, with **pA_2s** of 9.5, 7.7 for ET_A and ET_B receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tezosentan-d4

Cat. No.: HY-17351S

Tezosentan-d4 (RO 610612-d4) is the deuterium labeled Tezosentan. Tezosentan (RO 610612) is an **endothelin (ET)** receptor antagonist, with **pA_2s** of 9.5, 7.7 for ET_A and ET_B receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

TG4-155

Cat. No.: HY-18971

TG4-155 is a potent, brain-permeant and selective **EP2 receptor** antagonist with a **K_i** of 9.9 nM. TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TG6-10-1

Cat. No.: HY-16978

TG6-10-1 is an **EP2** antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Thioquinapiperifil

(KF31327 free base) Cat. No.: HY-119611

Thioquinapiperifil (KF31327 free base), a potent, selective and non-competitive **phosphodiesterase-5 (PDE-5, IC_{50}** of 0.074 nM) inhibitor, is used for sexual enhancement study.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thioquinapiperifil dihydrochloride

(KF31327) Cat. No.: HY-119611A

Thioquinapiperifil dihydrochloride (KF31327), a potent, selective and non-competitive **phosphodiesterase-5 (PDE-5, IC_{50}** of 0.074 nM) inhibitor, is used for sexual enhancement study.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Thyroxine sulfate

(T4 Sulfate) Cat. No.: HY-101406

Thyroxine sulfate is a thyroid hormone metabolite.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tiaprost

(Iliren) Cat. No.: HY-111478

Tiaprost is a prostaglandin $F_{2\alpha}$ (**$PGF_{2\alpha}$**) analogue.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Timapiprant

(OC000459) Cat. No.: HY-15342

Timapiprant (OC000459) is a potent, selective, and orally active D prostanoid receptor 2 (**DP_2**, also known as **CRTH2**) antagonist.



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Timapiprant sodium

(OC000459 sodium) Cat. No.: HY-15342A

Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (**DP_2**, also known as **CRTH2**) antagonist.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tiodazosin

(BL-5111) Cat. No.: HY-100255

Tiodazosin is a potent competitive postsynaptic **alpha adrenergic receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tiratricol

(3,3',5-Triiodothyroacetic acid) Cat. No.: HY-B1201

Tiratricol is a thyroid hormone analog with hepatic, has been used to suppress pituitary TSH secretion, with attenuation of extrapituitary thyromimetic effects.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Tizanidine

Cat. No.: HY-B0194

Tizanidine is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons. Target: α2-adrenergic receptor Tizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tizanidine hydrochloride

Cat. No.: HY-B0194A

Tizanidine hydrochloride is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons. Target: α2-adrenergic receptor Tizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tizanidine-d4

Cat. No.: HY-B0194S

Tizanidine-d4 is the deuterium labeled Tizanidine. Tizanidine is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

TLQP-21

Cat. No.: HY-P1345

TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent **G-protein-coupled receptor complement-3a receptor 1 (C3aR1)** agonist (**EC_{50}**: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TLQP-21 TFA

Cat. No.: HY-P1345A

TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent **G-protein-coupled receptor complement-3a receptor1 (C3aR1)** agonist (EC_{50}: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM).

Purity: 99.66%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

TM-N1324

Cat. No.: HY-108699

TM-N1324 is an agonist of G-Protein-Coupled Receptor 39 (**GPR39**) with EC_{50}s of 9 nM/5 nM in the presence of Zn^{2+}, and 280 nM/180 nM in the absence of Zn^{2+} for **human/murine GPR39**.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Todralazine

(Ecarazine)

Cat. No.: HY-B1001

Todralazine (Ecarazine) is an anti-hypertensive agent, acts as a **β_2AR** blocker, with antioxidant and free radical scavenging activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Todralazine hydrochloride

(Ecarazine hydrochloride)

Cat. No.: HY-B1001A

Todralazine hydrochloride (Ecarazine hydrochloride) is an anti-hypertensive agent, acts as a **β_2AR** blocker, with antioxidant and free radical scavenging activity.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tolazamide

(U-17835)

Cat. No.: HY-B0920

Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tolazoline

(Imidaline; NSC35110)

Cat. No.: HY-A0066

Tolazoline(Imidaline) is a non-selective competitive α-adrenergic receptor antagonist.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Tolazoline hydrochloride

(Imidaline hydrochloride; NSC35110 hydrochloride)

Cat. No.: HY-A0066A

Tolazoline (hydrochloride)(Imidaline (hydrochloride)) Hcl is a non-selective competitive α-adrenergic receptor antagonist.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Tolvaptan

(OPC-41061)

Cat. No.: HY-17000

Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tolvaptan-D7

Cat. No.: HY-17000S

Tolvaptan-D7 (OPC-41061-D7) is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC_{50} of 1.28μM for the inhibition of AVP-induced platelet aggregation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Torcetrapib

(CP-529414)

Cat. No.: HY-12089

Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (**CETP**) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM.



Purity: 99.39%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Toreforant

(JNJ-38518168)

Cat. No.: HY-16756

Toreforant is a potent and selective histamine H_4 receptor (**H4R**) antagonist, with a K_i at the human receptor of 8.4 nM.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TR antagonist 1

Cat. No.: HY-111443

TR antagonist 1 is a high-affinity **thyroid hormone receptor (TR)** antagonist with IC_{50}s of 36 and 22 nM for TRα and TRβ, respectively.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tradipitant

(VLY-686; LY686017)

Cat. No.: HY-16732

Tradipitant (VLY-686) is a **neurokinin-1** (**NK-1**) antagonist.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tranilast

(MK-341; SB 252218)

Cat. No.: HY-B0195

Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of **prostaglandin D2** (**PGD2**, IC_{50}= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tranilast sodium

(MK-341 sodium; SB 252218 sodium)

Cat. No.: HY-B0195A

Tranilast sodium (MK-341 sodium) acts as an anti-atopic agent. Tranilast suppresses production of **prostaglandin D2** (**PGD2**, IC_{50}= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg

Trans-Anethole

((E)-Anethole)

Cat. No.: HY-N0367

Trans-Anethole ((E)-Anethole), a phenylpropene derivative isolated from Pimpinella, shows estrogenic activity at lower concentrations and cytotoxic at higher concentrations in cancer cell lines.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

trans-Tranilast

(trans-MK-341; trans-SB 252218)

Cat. No.: HY-18706

trans-Tranilast (trans-MK-341) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Travoprost

(Fluprostenol isopropyl ester; AL6221; Flu-Ipr)

Cat. No.: HY-B0584

Travoprost (Fluprostenol isopropyl ester), an isopropyl ester prodrug, is a high affinity, selective **FP** prostaglandin full receptor agonist. Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Treprostinil

(UT-15)

Cat. No.: HY-100441

Treprostinil (UT-15) is a potent **DP1** and **EP2** agonist with EC_{50} values of 0.6±0.1 and 6.2±1.2 nM, respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Treprostinil palmitil

(INS-1009)

Cat. No.: HY-109163

Treprostinil palmitil (TP) is the prodrug of **DP1** and **EP2** agonist, Treprostinil (UT-15), whose EC_{50} values were 0.6 and 6.2 nM, respectively. Treprostinil palmitil is a pure prodrug and possesses no inherent binding to G-protein coupled receptors including prostanoid receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Treprostinil sodium

(UT-15 sodium)

Cat. No.: HY-16504

Treprostinil (UT-15) sodium is a potent **DP1** and **EP2** agonist with EC_{50} values of 0.6±0.1 and 6.2±1.2 nM, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Triamcinolone

Cat. No.: HY-B0328

Triamcinolone is a long-acting synthetic corticosteroid. Triamcinolone is a **corticosteroid hormone receptor** agonist and an anti-inflammatory agent. Target: Glucocorticoid Receptor Dimethyl fumarate is an anti-inflammatory.



Purity: 99.15%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Triamcinolone acetonide

Cat. No.: HY-B0636

Triamcinolone acetonide is a more potent type of triamcinolone, being about 8 times as effective as prednisone.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Triamcinolone Benetonide

Cat. No.: HY-U00043

Triamcinolone benetonide is a synthetic glucocorticoid corticosteroid with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trilostane

(Win 24540)

Cat. No.: HY-14281

Trilostane(Win 24540; Modrastane) is an inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Trinexapac-ethyl

Cat. No.: HY-W022973

Trinexapac-ethyl (TE) is well-known as an anti-gibberellin plant growth regulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tripelennamine hydrochloride

Cat. No.: HY-17428

Tripelennamine hydrochloride, a H1-receptor antagonist, is a psychoactive drug and member of the pyridine andethylenediamine classes that is used as an antipruritic and first-generation antihistamine.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Tropodifene

(Tropaphen)

Cat. No.: HY-U00313

Tropodifene (Tropaphen) is an **α-Adrenergic receptor** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TSHR antagonist S37a

Cat. No.: HY-129995A

TSHR antagonist S37a is a highly selective **thyrotropin receptor (TSHR)** antagonist, with potential for the treatment of Graves' orbitopathy.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TSHR antagonist S37b

Cat. No.: HY-129995

TSHR antagonist S37b is the less effective enantiomer of TSHR antagonist S37a (HY-129995A). TSHR antagonist S37b shows only a minor effect for **thyrotropin receptor (TSHR)** inhibition. TSHR antagonist S37b can be used for the research of thyroid function.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tulobuterol

(C-78 free base) Cat. No.: HY-B1810

Tulobuterol (C-78 free base) is a long-acting **β_2-adrenoceptor** agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.



Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg

Tulobuterol hydrochloride

(C-78) Cat. No.: HY-W011733

Tulobuterol hydrochloride (C-78) is a long-acting **β_2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.**.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Tulobuterol-D9 hydrochloride

(C-78-D9) Cat. No.: HY-B1810S

Tulobuterol-D9 hydrochloride (C-78-D9) is the deuterium labeled Tulobuterol. Tulobuterol (C-78 free base) is a long-acting **β_2-adrenoceptor** agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Udenafil

(DA8159) Cat. No.: HY-18253

Udenafil (DA8159) is a potent, selective and orally active **phosphodiesterase type 5 (PDE5)** inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ulipristal

(CDB-3236; Deacetyl CDB-2914) Cat. No.: HY-14959

Ulipristal (CDB 3236) is a selective **progesterone receptor** modulator (SPRM). Ulipristal binds to the progesteron receptor, thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system.



Purity: ≥98.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ulipristal acetate

(CDB-2914) Cat. No.: HY-16508

Ulipristal acetate (CDB-2914) is an orally active, selective **progesterone receptor** modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNBS5162

Cat. No.: HY-16509

UNBS5162 is a pan-antagonist of **CXCL chemokine** expression, with anti-tumor activity.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Urapidil

Cat. No.: HY-B0716

Urapidil is an **α1 adrenoreceptor** antagonist and a **5-HT_{1A} receptor** agonist.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Urapidil D6

Cat. No.: HY-B0716S

Urapidil D6 is a deuterium labeled Urapidil. Urapidil is an **α1-adrenoreceptor** antagonist and a **5-HT_{1A} receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urapidil hydrochloride

Cat. No.: HY-B0354A

Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist.



Purity: ≥99.0%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Urapidil-d4 hydrochloride

Cat. No.: HY-B0354AS

Urapidil-d4 hydrochloride is the deuterium labeled Urapidil hydrochloride. Urapidil hydrochloride is an α1-adrenoceptor antagonist and 5-HT_{1A} receptor agonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Urocortin II, human

Cat. No.: HY-P1752

Urocortin II (human) is a selective endogenous peptide agonist of **type-2 corticotropin-releasing factor (CRF2) receptor**. For investigating the role of the CRF (2) receptor in ingestive behavior.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urocortin II, human TFA

Cat. No.: HY-P1752A

Urocortin II, human (TFA) is a selective endogenous peptide agonist of **type-2 corticotropin-releasing factor (CRF2) receptor**. For investigating the role of the CRF (2) receptor in ingestive behavior.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urocortin III, mouse

Cat. No.: HY-P1858

Urocortin III, mouse is a corticotropin-releasing factor (**CRF**)-related peptide. Urocortin III preferentially binds and activates **CRF-R2**. Urocortin III (Ucn3) is a known component of the behavioral stress response system.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urocortin III, mouse TFA

Cat. No.: HY-P1858A

Urocortin III, mouse TFA is a corticotropin-releasing factor (**CRF**)-related peptide. Urocortin III preferentially binds and activates **CRF-R2**. Urocortin III (Ucn3) is a known component of the behavioral stress response system.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Urocortin, human (Urocortin (human); Human urocortin; Human urocortin 1; Human urocortin I)

Cat. No.: HY-P1295

Urocortin, human, a 40-aa neuropeptide, acts as a selective agonist of endogenous **CRF_2 receptor**, with **K_i**s of 0.4, 0.3, and 0.5 nM for $hCRF_1$, $rCRF_{2\alpha}$ and $mCRF_{2\beta}$, respectively.

Purity: 98.43%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Urocortin, rat (Urocortin (Rattus norvegicus); Rat urocortin;)

Cat. No.: HY-P1296

Urocortin, rat (Urocortin (Rattus norvegicus)) is a neuropeptide and a potent endogenous **CRFR** agonist with **K_i**s of 13 nM, 1.5 nM, and 0.97 nM for **human CRF_1**, **rat $CRF_{2\alpha}$** and **mouse $CRF_{2\beta}$**, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Urocortin, rat TFA (Urocortin (Rattus norvegicus) (TFA); Rat urocortin TFA)

Cat. No.: HY-P1296A

Urocortin, rat TFA (Urocortin (Rattus norvegicus) TFA) is a neuropeptide and a potent endogenous **CRFR** agonist with **K_i**s of 13 nM, 1.5 nM, and 0.97 nM for **human CRF_1**, **rat $CRF_{2\alpha}$** and **mouse $CRF_{2\beta}$**, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urotensin I (Catostomus urotensin I)

Cat. No.: HY-P1542

Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of **CRF receptor** with **pEC_{50}**s of 11.46, 9.36 and 9.85 for human CRF_1, human CRF_2 and rat $CRF_{2\alpha}$ receptors in CHO cells, and **K_i**s of 0.4, 1.8, and 5.7 nM for $hCRF_1$, $rCRF_{2\alpha}$ and $mCRF_{2\beta}$ receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Urotensin I TFA (Catostomus urotensin I TFA)

Cat. No.: HY-P1542B

Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of **CRF receptor** with **pEC_{50}**s of 11.46, 9.36 and 9.85 for human CRF_1, human CRF_2 and rat $CRF_{2\alpha}$ receptors in CHO cells, and **K_i**s of 0.4, 1.8, and 5.7 nM for $hCRF_1$, $rCRF_{2\alpha}$ and...

Purity: 98.29%
Clinical Data: No Development Reported
Size: 500 μg

USL311

Cat. No.: HY-114244

USL311 is a selective **CXCR4** antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UT-34

Cat. No.: HY-136242

UT-34 is a potent, selective and orally active second-generation pan-**androgen receptor (AR)** antagonist and degrader with IC_{50}s of 211.7 nM, 262.4 nM and 215.7 nM for **wild-type**, **F876L** and **W741L AR**, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Valsartan

(CGP 48933)

Cat. No.: HY-18204

Valsartan (CGP 48933) is an **angiotensin II** receptor antagonist and has the potential for high blood pressure and heart failure research.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Valsartan-d9

(CGP 48933-d9)

Cat. No.: HY-18204S

Valsartan D9 (CGP-48933 D9) is deuterium labeled valsartan. Valsartan is an angiotensin Ⅱ receptor antagonist and has the potential for high blood pressure and heart failure research.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Vanilpyruvic acid

(Vanylpyruvic acid)

Cat. No.: HY-101416

Vanilpyruvic acid is a catecholamine metabolite and precursor to vanillactic acid.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Vanitiolide

(Vanitiolid)

Cat. No.: HY-B1034

Vanitiolide is a choleretics.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vardenafil

Cat. No.: HY-B0442

Vardenafil is a selective, orally active, potent inhibitor of **phosphodiesterase-5 (PDE5)**, with an IC_{50} of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Vatinoxan hydrochloride

(MK-467 hydrochloride; L-659066 hydrochloride)

Cat. No.: HY-19057A

Vatinoxan hydrochloride (MK-467 hydrochloride;L-659066 hydrochloride) is a peripheral **α2 adrenergic receptor** antagonist.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Velneperit

(S2367)

Cat. No.: HY-14423

Velneperit (S-2367) is a novel neuropeptide Y (NPY) Y5 receptor antagonist. Target: neuropeptide Y receptor Velneperit (S-2367) is a once-daily, oral, centrally acting, small molecule neuropeptide Y (NPY) Y5 receptor antagonist.



Purity: 99.50%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Velsecorat

(AZD7594; AZ13189620)

Cat. No.: HY-111453

AZD7594 is a potent selective nonsteroidal **glucocorticoid receptor** modulator, with an IC_{50} of 0.9 nM.



Purity: 99.60%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vercirnon

(GSK-1605786; CCX282-B; Traficet-EN) Cat. No.: HY-15724

Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of **CCR9**. Vercirnon inhibits CCR9-mediated Ca^{2+} mobilization and chemotaxis on Molt-4 cells with **IC_{50}** values of 5.4 and 3.4 nM, respectively.



Purity: 98.19%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vercirnon sodium

(GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium) Cat. No.: HY-15724A

Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of **CCR9**. Vercirnon sodium inhibits CCR9-mediated Ca^{2+} mobilization and chemotaxis on Molt-4 cells with **IC_{50}** values of 5.4 and 3.4 nM, respectively.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Verucerfont

(GSK561679) Cat. No.: HY-14875

Verucerfont is a **corticotropin-releasing factor receptor 1** (**CRF1**) antagonist with **IC_{50}**s of ~6.1, >1000 and >1000nM for CRF1, CRF2, and CRF-BP, respectively.



Purity: 98.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vicriviroc maleate

(SCH-417690 maleate; SCH-D maleate) Cat. No.: HY-17377

Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of **CCR5**, with a **K_i** of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with **IC_{90}**s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU570).



Purity: 99.91%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vilanterol

(GW642444) Cat. No.: HY-14300

Vilanterol (GW642444) is a long-acting **β_2-adrenoceptor** (β_2-AR) agonist with 24 h activity. The **pEC_{50}**s for β_2-AR,β_1-AR and β_3-AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.



Purity: 96.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vilanterol trifenatate

(GW642444 trifenatate) Cat. No.: HY-14300A

Vilanterol trifenatate (GW642444 trifenatate) is a long-acting **β_2-adrenoceptor** (β_2-AR) agonist with inherent 24-hour activity. The **pEC_{50}**s for β_2-AR, β_1-AR and β_3-AR are 10.37, 6.98 and 7.36, respectively.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vofopitant

(GR 205171) Cat. No.: HY-12142

Vofopitant is potent **tachykinin NK_1 receptor** antagonist, with **pK_i**s of 10.6, 9.5, and 9.8 for human, rat and ferret NK_1 receptor, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vofopitant dihydrochloride

(GR 205171A) Cat. No.: HY-12143

Vofopitant dihydrochloride (GR 205171A) is a potent, selective and orally available tachykinin neurokinin 1(NK1) receptor antagonist, inhibits [^{3}H]SP binding to the NK1 receptor with **pK_i** values of 9.5 and 10.6 in rat and human membranes respectively, acts as a potential...



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vonoprazan

(TAK-438 free base) Cat. No.: HY-100007

Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active **potassium-competitive acid blocker (P-CAB)**, with antisecretory activity.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 250 mg

Vosilasarm

(RAD140) Cat. No.: HY-14383

Vosilasarm (RAD140) is a potent, orally active, nonsteroidal selective **androgen receptor** modulator (SARM) with a **K_i** of 7 nM. Vosilasarm shows good selectivity over other steroid hormone nuclear receptors.



Purity: 99.45%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VUF10460

Cat. No.: HY-101420

VUF10460 is a non-imidazole histamine **H4** receptor agonist; binds to rat H4 receptor with a **pK_i** of 7.46.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WAY-151932

(VNA-932; WAY-VNA 932)

Cat. No.: HY-19381

WAY-151932 is a **vasopressin V_2-receptor** agonist with **IC_{50}** of 80.3 nM and 778 nM in human-V_2 binding and V_{1a} binding assay.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Win 18446

Cat. No.: HY-W011094

Win 18446 is an orally active **testes-specific enzyme ALDH1a2** inhibitor, with an **IC_{50}** of 0.3 μM. Win 18446 reversibly inhibits spermatogenesis in many species and inhibits Retinoic acid (HY-14649) biosynthesis from Retinol (HY-B1342) within the testes.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Wy 49051

Cat. No.: HY-101830

Wy 49051 is a potent, orally active **H1 receptor** antagonist, with **IC_{50}** of 44 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WZ811

Cat. No.: HY-15478

WZ811 is an orally active, highly potent competitive antagonist of **CXCR4**. WZ811 efficiently inhibits CXCR4/SDF-1 (or CXCL12)-mediated modulation of cAMP levels (EC_{50}=1.2 nM) and SDF-1 induced Matrigel invasion in cells (EC_{50}=5.2 nM).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with **IC_{50}**s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Xylometazoline hydrochloride

Cat. No.: HY-B0475

Xylometazoline hydrochloride is an α-adrenoceptor agonist commonly used as nasal decongestant.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Y1 receptor antagonist 1

(H 409-22 isomer)

Cat. No.: HY-101704

Y1 receptor antagonist 1 (H 409-22 isomer) is a **neuropeptide Y1 receptor** antagonist.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 1 mg

YM-46303

Cat. No.: HY-U00104

YM-46303 is an **mAChR** antagonist which exhibits the highest affinities for M1 and M3 receptors, and selectivity for M3 over M2 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM158 free base

(YM-57158)

Cat. No.: HY-U00355

YM158 free base is a potent and selective **LTD_4** and **TXA_2 receptor** antagonist with **pA_2** values of about 8.87 and 8.81, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Yohimbine

Cat. No.: HY-12715

Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC50 of 0.6 μM.



Purity: 98.10%
Clinical Data: Launched
Size: 500 mg

Yohimbine Hydrochloride

Cat. No.: HY-N0127

Yohimbine Hydrochloride is an alpha 2-adrenoreceptor antagonist, blocking the pre- and postsynaptic alpha-2 adrenoreceptors and causing an increased release of noradrenaline and dopamine.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

YS-49

Cat. No.: HY-15477

YS-49 is a **PI3K/Akt** (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits **angiotensin II (Ang II)**-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

YS-49 monohydrate

Cat. No.: HY-15477A

YS-49 (monohydrate) is a **PI3K/Akt** (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits **angiotensin II (Ang II)**-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Zaltidine

(CP-57361)

Cat. No.: HY-15541

Zaltidine(CP-57361) is a H2-receptor antagonist, which has the antisecretory action.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Zaprinast

(M&B 22948)

Cat. No.: HY-B1816

Zaprinast (M&B 22948) is an inhibitor of cGMP-selective **Phosphodiesterases(PDEs)**. Zaprinast is a **G protein-coupled receptor (GPR) 35** agonist which activates rat GPR35 strongly and activates human GPR35 moderately.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

ZD 7155(hydrochloride)

Cat. No.: HY-102093

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (**AT1 receptor**) antagonist.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZD-1611

Cat. No.: HY-19274

ZD-1611 is a potent, orally active, selective **ETA receptor** antagonist, used for the research of ischemic stroke.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zearalanone

Cat. No.: HY-N6678

Zearalenone is a nonsteroidal estrogenic mycotoxin produced by Fusarium species, which colonizes several grains. Zearalenone has low acute toxicity and carcinogenicity.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Zibotentan

(ZD4054)

Cat. No.: HY-10088

Zibotentan (ZD4054) is a potent, selective and orally active **endothelin A (ET_A) receptor** antagonist with a K_i of 13 nM. Zibotentan has no inhibitory effect on ETB.



Purity: 99.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Zilpaterol-d7

Cat. No.: HY-A0072S

Zilpaterol-d7 is a deuterium labeled Zilpaterol.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK 216348

((+)-ZK 216348)

Cat. No.: HY-123352

ZK 216348 ((+)-ZK 216348) is a nonsteroidal selective **glucocorticoid receptor** agonist with an IC_{50} of 20.3 nM. ZK 216348 also binds to Progesterone and mineralocorticoid receptors with IC_{50}s of 20.4 nM and 79.9 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK-90055 hydrochloride

Cat. No.: HY-U00293

ZK-90055 hydrochloride is a **β2 adrenergic receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK159222

Cat. No.: HY-12397

ZK159222, a 25-carboxylic ester analogue of 1α,25-(OH)2D3, is a potent **1α,25-(OH)2D3 receptor (VDR)** antagonist. The mechanism of ZK159222 antagonistic action is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 1 mg

ZK756326 dihydrochloride

Cat. No.: HY-101038A

ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor **CCR8**.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zuclomiphene citrate

Cat. No.: HY-B1617A

Zuclomiphene citrate is a cis isomer of Clomiphene citrate. Zuclomiphene citrate has an antiestrogenic effect and can inhibit the secretion of luteinizing hormone (LH) more than the trans isomer. Zuclomiphene citrate is also an orally active hypocholesterolemic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Zuclomiphene D4 citrate

Cat. No.: HY-B1617AS

Zuclomiphene D4 citrate is a deuterium labeled Zuclomiphene citrate. Zuclomiphene citrate has an antiestrogenic effect and can inhibit the secretion of luteinizing hormone (LH) more than the trans isomer. Zuclomiphene citrate is also an orally active hypocholesterolemic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

[Ala1,3,11,15]-Endothelin (53-63) (TFA)

Cat. No.: HY-P1019A

[Ala1,3,11,15]-Endothelin (53-63) (TFA), a linear peptide analog of endothelin (ET)-1, is a highly selective **endothelin B (ETB)** receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

[Asp5]-Oxytocin

Cat. No.: HY-P3217

[Asp5]-Oxytocin is the first 5-position neurohypophyseal hormone analogue possessing significant biological activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[bAla8]-Neurokinin A(4-10)

(MEN 10210)

Cat. No.: HY-P1031

[bAla8]-Neurokinin A(4-10) is a **neurokinin 2 (NK2) receptor** agonist.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

[D-Asn5]-Oxytocin

Cat. No.: HY-P3220

[D-Asn5]-Oxytocin possesses very low specific oxytocic and vasodepressor activities. By cumulative dose-response studies for oxytocic activity, [D-Asn5]-Oxytocin has similar intrinsic activity to oxytocin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[D-Trp7,9,10]-Substance P

Cat. No.: HY-P1375

[D-Trp7,9,10]-Substance P is a substance P analogue. Substance P stimulates substance P receptors but also inhibits ion conductance through nicotinic acetylcholine receptors.

RPKPQQWFWWM-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[D-Trp7,9,10]-Substance P TFA

Cat. No.: HY-P1375A

[D-Trp7,9,10]-Substance P TFA is a substance P analogue. Substance P stimulates substance P receptors but also inhibits ion conductance through nicotinic acetylcholine receptors.

RPKPQQWFWWM-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Des-Arg9]-Bradykinin

Cat. No.: HY-P0298

[Des-Arg9]-Bradykinin is a **Bradykinin** (B_1) receptor agonist that displays selectivity for B_1 over B_2 receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Des-Arg9]-Bradykinin acetate

Cat. No.: HY-P0298A

[Des-Arg9]-Bradykinin acetate is a **Bradykinin B_1 receptor** agonist that displays selectivity for B_1 over B_2 receptors.



Purity: 96.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

[Gln8]-C517 (LH-RH), chicken

Cat. No.: HY-P1905

[Gln8]-C517 (LH-RH), chicken is an avian hypothalamic peptide, which stimulates release of gonadotropins from anterior pituitary, thus regulating reproductive functions.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

[Glu4]-Oxytocin

Cat. No.: HY-P3218

[Glu4]-Oxytocin is an appropriate derivative of oxytocin for conducting a comprehensive investigation by a variety of methods of the conformation of "oxytocin-like" molecules in aqueous solution.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Hyp3]-Bradykinin

Cat. No.: HY-P3061

[Hyp3]-Bradykinin, naturally occurring peptide hormone, is a bradykinin receptor agonist. [Hyp3]-Bradykinin interacts with B2-bradykinin receptors and stimulates inositol phosphate production in cultured human fibroblasts.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

[Leu3]-Oxytocin

Cat. No.: HY-P3221

[Leu3]-Oxytocin, an oxytocin analogue, is derived by structural variation in sequence position 3 replaced by leucine (Leu).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Nle11]-Substance P

Cat. No.: HY-P1506

[Nle11]-Substance P is a substance P analog that avoids methionine oxidation problems.

RPKPQQFFGL-Nle-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

[Sar1, Ile8]-Angiotensin II

Cat. No.: HY-P1564

[Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

[Sar9,Met(O2)11]-Substance P

Cat. No.: HY-P1012

[Sar9,Met(O2)11]-Substance P is a **tachykinin NK_1 receptor** selective agonist.

RPKPQQFF-{Sar}-LM[O_2]-NH_2

Purity: 98.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

[Sar9,Met(O2)11]-Substance P TFA

Cat. No.: HY-P1012A

[Sar9,Met(O2)11]-Substance P TFA is a **tachykinin NK_1 receptor** selective agonist.

RPKPQQFF-{Sar}-LM[O_2]-NH_2 (TFA salt)

Purity: 99.68%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

[Sar9] Substance P

Cat. No.: HY-P1738

[Sar9] Substance P is a potent and selective **neurokinin (NK)-1 receptor** agonist.

RPKPQQFF-{SAR}-LM-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Tyr1]-Somatostatin-14

Cat. No.: HY-P2545

[Tyr1]-Somatostatin-14 could binds to **SSTR2**.

YGCKNFFWKTFTSC (Disulfide bridge: Cys3-Cys14)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Factor Mating Pheromone, yeast

(Mating Factor α)

Cat. No.: HY-P1482

α-Factor Mating Pheromone, yeast is a tridecapeptide secreted by S. cerevisiae α cells via **Ste2p** receptor.

WHWLQLKPGQPMY

Purity: 99.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Muricholic acid

Cat. No.: HY-115433

α-Muricholic acid is the most abundant primary bile acid in rodents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α1 adrenoceptor-MO-1

Cat. No.: HY-U00333

α1 adrenoceptor-MO-1, an S enantiomer, has affinity at **alpha 1 adrenergic receptor**, shows alphalytic activity, and possesses analgesic action; more active than R enantiomer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Amyrin palmitate

Cat. No.: HY-N2924

β-Amyrin palmitate shows HMG-CoA reductase inhibition. And β-Amyrin palmitate has anti-diabetes mellitus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-D-Glucopyranosyl abscisate

(ABA-GE; (S)-cis,trans-Abscisic acid glucosyl ester)

Cat. No.: HY-111974

β-D-Glucopyranosyl abscisate (ABA-GE) is a hydrolyzable abscisic acid (ABA) conjugate that accumulates in the vacuole and presumably also in the endoplasmic reticulum.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Estradiol 17-acetate

(1,3,5(10)-Estratriene-3,17β-diol 17-acetate) **Cat. No.:** HY-B0708

β-Estradiol 17-acetate is a metabolite of estradiol. Target: Others β-Estradiol 17-acetate is a metabolite of estradiol.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

β-Melanocyte Stimulating Hormone (MSH), human

(Beta-MSH (1-22) (human)) **Cat. No.:** HY-P1504

β-Melanocyte Stimulating Hormone (MSH), human, a 22-residue peptide, acts as an endogenous **melanocortin-4 receptor** (**MC4-R**) agonist.

AEKKDEGPYRMEHFRWGSPPKD

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Melanocyte Stimulating Hormone (MSH), human TFA

(Beta-MSH (1-22) (human) TFA) **Cat. No.:** HY-P1504A

β-Melanocyte Stimulating Hormone (MSH), human TFA, a 22-residue peptide, acts as an endogenous **melanocortin-4 receptor** (**MC4-R**) agonist.

AEKKDEGPYRMEHFRWGSPPKD (TFA salt)

Purity: 99.84%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

β-Zearalenol

Cat. No.: HY-N6741

β-Zearalenol is a non-steroidal estrogenic mycotoxin synthesized by Fusarium species. β-Zearalenol potentially influences transcription and effects gene expression on translational level.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

β3-AR agonist 1

Cat. No.: HY-101514

β3-AR agonist 1 (compound 15) is a highly potent, selective, and orally available **β3-adrenergic receptor (β3-AR)** agonist (EC_{50}=18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β3-AR agonist 2

Cat. No.: HY-U00391

$β_3$-AR agonist 2 is a potent and selective **$β_3$-adrenergic receptor** ($β_3$-**AR**) agonist with an EC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

γ-1-Melanocyte Stimulating Hormone (MSH), amide

Cat. No.: HY-P1531

γ-1-Melanocyte Stimulating Hormone (MSH), amide is a 11-amino acid peptide. γ-1-Melanocyte Stimulating Hormone (MSH) regulates sodium (Na^+) balance and blood pressure through activation of the **melanocortin receptor 3** (**MC3-R**).

YVMGHFRWDRF-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

γ-2-MSH (41-58), amide

Cat. No.: HY-P1922

γ-2-MSH (41-58), amide is derived from γ-2-MSH. γ-2-MSH is a twelve amino acid peptide that is derived from the N-terminal fragment of proopiomelanocortin (POMC) and contains the His-Phe-Arg-Trp motif common to all melanocortin endogenous agonist ligands.

YVMGHFRWDRFG-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

λ-Cyhalothrin

Cat. No.: HY-B0836

λ-Cyhalothrin is a high efficiency, broad-spectrum type II synthetic pyrethroid insecticide containing α-cyano group. λ-Cyhalothrin is used to control a wide range of **pests** in a variety of applications.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 100 mg